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Abstract
Astrocytic gliomas are the most common tumours arising in the central nervous 
system. This thesis focuses on examining genetic changes in high-grade astrocytic 
gliomas. It describes the development of an analytical tool to facilitate systematic 
analysis of array comparative genomic hybridisation (CGH) results and catalogues copy 
number changes in high-grade astrocytic glioma cell lines and patient samples. Molecular 
cytogenetic analysis of chromosome 6 was used to explore the relationship between copy 
number changes and positional aberrations. Three regions of copy number associated 
with translocation breakpoints are described. The first translocation associated with a 
copy number change was in the cell line U87, loss of 6pter to 6p21 arises from an 
unbalanced translocation between chromosomes 6 and 7, with the breakpoint at 6p21 
being close to the POLH and GTPBP2 genes. The second is a discrete deletion in 6q23- 
24 in U87 is associated with a translocation between chromosomes 6 and 12, and 
involves several genes including MAP3K5 and MAP7. The third is a discrete deletion of 
6q26-27 in cell lines CRL2020 and CRL1620 involving IGF2R, PARK2, PACRG and 
QKI is associated chromosome translocations. Inactivation of a tumour suppressor gene 
near the breakpoint may be a primary consequence of certain translocations in solid 
tumours, in contrast to the oncogenic gene fusions present in haematological and 
mesenchymal malignancies.
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Chapter One 
Introduction
1.1 Overview
This thesis examines the genetics of the most common histological group of 
primary brain cancer, astrocytic glioma. In particular, it focuses on the high-grade 
tumours, astrocytic glioma grade III and grade IV. These tumours have complex genetic 
aberrations that are poorly understood. Although the prevalence of these tumours is 
relatively low, accounting for one to two percent of primary adult malignancy, 
conventional treatments, namely surgery, radiotherapy and chemotherapy have had only a 
marginal impact on survival, and the tumours are invariably fatal. Therefore, it is 
necessary to explore the potential of different approaches in the treatment of these 
tumours. One approach that has had some success for other tumour types is the use of 
therapies that are rationally designed to reverse the effect of specific molecular 
aberrations. These have been termed molecularly targeted agents. Presently, the poor 
understanding of the genetic aberrations in astrocytic gliomas is a limiting factor in the 
use of molecularly targeted agents. However, recent developments of the human genome 
project provide an opportunity to gain a greater understanding of these tumours.
Currently, the human genome project has yielded a draft of the entire DNA 
sequence (Lander et a l, 2001; Venter et a l , 2001), and complete sequences for 
chromosomes 5 (Schmutz et al., 2004), 6 (Mungall et a l , 2003), 7 (Hillier et a l , 2003), 9 
(Humphray et a l , 2004), 10 (Deloukas et a l , 2004), 13 (Dunham et a l , 2004), 14 (Heilig 
et a l , 2003), 19 (Grimwood et a l, 2004), 20 (Deloukas et a l, 2001), 21 (Hattori et a l,
18
2000), 22 (Dunham et a l, 1999) and X (Ross et al., 2005). In parallel to this advance, 
developments in computation and microengineering have produced micro-array 
technology. Several applications of this technology facilitate the study of genetics, 
including array comparative genomic hybridisation (CGH) and expression arrays. Array 
CGH is an immensely powerful emerging method that facilitates the assessment of DNA 
copy number across the genome in one experiment (Kraus et al., 1997; Pinkel et a l, 
1998; Solinas-Toldo et a l, 1997). Expression arrays give a genome-wide assessment of 
gene expression (Schena et al., 1995). The utilisation of array technology offers great 
potential in elucidating the relationship between genetics and disease. In respect of cancer 
management, a better understanding of genetics can improve diagnostic capability, 
identify therapeutic targets, and can help in predicting and assessing response to 
treatments. The aim of the research described in this thesis is to explore the utilisation of 
array CGH in order to identify copy number changes present in high-grade astrocytic 
gliomas accurately.
1.2 Cancer Genetics
Normal human cells can be grown in culture but they can only replicate a limited 
number of times. After a number of generations, typically forty, the cell enters a ‘crisis’ 
phase when it dies (Hayflick and Moorhead, 1961). Normal cells in culture display the 
characteristics of controlled growth: anchorage dependence, dependence on serum 
growth factors, and density-dependent inhibition. However, some cells, at a low 
frequency, can become transformed, so that they become independent of growth controls 
and develop limitless replication potential. Cancer is a term that describes a group of
19
diseases that are characterised by cell transformation. Cancer has a variety of aetiological 
factors, but a common feature of how these may cause cancer is through their influence 
on the genome. The genome can be altered in various ways to cause cancer, but at the 
most fundamental level, alterations in two broad categories of genes, tumour suppressor 
genes and oncogenes, are critical. A loss of function mutation in a tumour suppressor 
gene confers an increased susceptibility to tumour formation. An activating mutation in 
an oncogene has a dominant transforming effect on the cell.
Solid tumours arise from the accumulation of multiple genetic changes, and 
models of carcinogenesis have been described for most major forms of cancer based on 
this hypothesis. The earliest model of the multi-step process of carcinogenesis was 
proposed for colorectal cancer. Here, each stage of tumour development is associated 
with aberrations in particular genes (Ashley, 1969; Fearon and Vogelstein, 1990; 
Moolgavkar and Knudson, 1981). The multi-step theory has been developed further to 
give an integrated view of the cellular physiology for all tumours. It is suggested that the 
cancer cell requires six essential alterations in cellular physiology namely: “self- 
sufficiency in growth signals, insensitivity to growth inhibitory (antigrowth) signals, 
evasion of programmed cell death, limitless replicative potential, sustained angiogenesis, 
and tissue invasion and metastasis” (Hanahan and Weinberg, 2000).
Cells containing mutations of key genes that give an increased growth potential 
will have a selective advantage in the population. There is interplay between the 
generation of mutations and selection of cells that determines how a tumour develops;
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however the relative importance of each is debatable (Loeb, 2001; Tomlinson et a l ,
1996). An additional classification of genes in cancer has been proposed, which places 
them into two groups, gatekeeper genes and caretaker genes (Kinzler and Vogelstein,
1997). Genes that directly regulate tumour growth by inhibiting growth or by promoting 
cell death are classed as gatekeeper genes. The second group are caretaker genes. 
Caretaker genes are involved in maintaining the integrity of the genome. Inactivated 
caretaker genes do not directly promote tumours. Instead their inactivation results in 
genetic instability, which causes an increased mutation rate affecting all genes. This 
increase in mutation rate will affect the gatekeeper genes, which do directly regulate 
tumour growth. The breast cancer susceptibility gene (BRCA1) is an example of a 
caretaker gene.
1.2.1 Cell cycle control and apoptosis
The cell cycle describes the sequence of events required to replicate the cells 
genetic material and separate the two copies into daughter cells. The cell cycle is divided 
into G1 phase, S phase, G2 phase and M phase. G1 is a gap phase, DNA replication 
occurs during S phase. G2 is the second gap phase where the DNA content of the cell is 
4n. M phase or mitosis follows G2, when there is division of the DNA into two daughter 
cells. The cell cycle is a regulated process that ensures the ordered replication and 
division of genetic material. There are two key control points, the first in G1 when the 
cell becomes committed to start replication and at G2/M, just prior to cell division. 
Regulation of the cell cycle occurs through a series of signalling molecules, whose 
activity is controlled by phosphorylation and dephosphorylation (Lewin, 2004).
21
Apoptosis is the process of programmed cell death. It is triggered by a variety of factors 
including agents that damage DNA such as irradiation and chemotherapy, activation of 
certain receptors such as Fas receptor, cytotoxic T cells, glucocorticoids and withdrawal 
of growth factors (Lewin, 2004). The cell cycle and apoptosis are intimately related as 
they share key molecules in their control pathways, as shown in Figure 1.1.
Mitogenic
signalling
-► Myc \
Ras Cyclin D 
Cdk
T
pi 6 IN K 4A
S phase
RB-E2F E2F f  Cntfy
CDKN2A
1
Cell
cycle
arrest
>  MDM2
i103 x
Apoptosis
Figure 1.1 Diagram showing the relationship between mitogenic signalling, Ras, p53 
and RB in controlling the cell cycle (Sherr and McCormick, 2002).
Oncogenes are typically genes that are involved in cell cycle control and 
apoptosis, and encode growth factors and their receptors, tyrosine kinases, serine 
threonine kinases, RAS proteins, transcription factors and other regulatory proteins. Key 
tumour suppressor genes shown in the diagram are RB, p53 and p i6. The gain of 
function of oncognes and loss of function of tumour suppressor genes are discussed 
throughout this thesis.
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1.2.2 Oncogenes
Oncogenes were first identified as genes in retroviruses that can transform cells. 
Oncogenes can acquire gain of function through mutation, gene amplification and/ or 
chromosome re-arrangement.
1.2.2.1 Tumour viruses and oncogenes
Tumour viruses can be classified as DNA viruses or RNA viruses. DNA viruses 
cause transformation of a cell by integrating into the host genome and encoding proteins 
that interfere with the function of tumour suppressor genes in the host cell. Table 1.1 
shows the oncogenes encoded by polyomaviruses, human papilloma viruses (HPV) and 
adenoviruses. Transforming retroviruses are divided into two categories based on the 
mechanism of cellular transformation, non-defective viruses and acute transforming 
viruses. Non-defective viruses transform the cell by integrating near to, and activating a 
cellular proto-oncogene. Acute transforming viruses incorporate cellular proto­
oncogenes, into their genomes, which then become viral oncogenes by the acquisition of 
mutations. Following transfection, the acute transforming virus integrates into the target 
cell genome and transforms the cell.
Virus Genome Size Oncogenes Origin of oncogene
Polyoma dsDNA 5-6 kb T antigens Early viral gene
HPV dsDNA 8 kb E6 and E7 Early viral gene
Adenovirus dsDNA 37 kb E1A and ElB Early viral gene
Retrovirus ssRNA 6-9 kb Individual Cellular
Table 1.1 Oncogenic viruses (Lewin, 2004).
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Oncogenes were first identified through the transforming retrovirus, Rous 
sarcoma virus (RSV). Rous demonstrated that a transmissible agent was able to induce 
cancer in chickens (Rous, 1911). Stehelin et al demonstrated that the transmissible agent 
in Rous sarcoma virus contained novel nucleotide sequences not present in related 
retroviruses but related to normal nucleotide sequences in chicken DNA (Stehelin et al., 
1976). The transforming gene, v-src> is a homologue of the normal cellular gene, SRC, 
which is involved in control of cell growth.
1.2.2.2 Point mutation and oncogene activation
Ras are guanosine 5’-triphosphate (GTP)-binding proteins that are involved in 
transmitting signals from cell surface receptors to the nucleus. There are three different 
Ras proteins H-Ras, N-Ras and K-Ras. Ras proteins switch between an active state when 
GTP is bound and an inactive state when guanosine 5’-diphosphate (GDP) is bound 
(Alberts et al., 2002). Point mutations in Ras resulting in a single amino acid change have 
been identified which reduce hydrolysis of bound GTP and give constitutive activity to 
the Ras protein (Lewin, 2004). Mutant Ras is found in up to a quarter of all human 
cancers (Alberts et al., 2002).
1.2.2.3 DNA amplification and oncogenes
DNA amplification describes the selective increase in copy number of a region of 
DNA and generally there is a target gene or genes being amplified (Schwab, 1999). Gene
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amplification tends to result in increased gene expression. DNA amplification is found in 
two situations in humans, firstly in drug resistance and secondly in cancer.
Amplification of certain genes has been found to be associated with resistance of 
a tumour to chemotherapy. For example, amplification of 18p 11.32, containing the 
Thymidylate Synthase gene (TYMS) was found in colorectal metastases to the liver in 
patients being treated with 5-fluorouracil (5-FU) (Wang et al., 2004). TYMS is a 
downstream target of 5-FU. Amplification of 18pl 1.32 was found to be associated with a 
shorter survival in these patients. The Multi-Drug Resistance gene MDR1 (7q21.1) is 
associated with resistance to a variety of chemotherapeutic agents and amplification of 
the Dihydrofolate Reductase gene (DHFR) (5ql4.1) in methotrexate resistance (Pastan 
and Gottesman, 1987). This has led to the hypothesis that tumours evolve to develop 
chemo-resistance through amplification of certain genes.
More commonly DNA amplification is found in cancer prior to treatment. In 
tumours, regions of amplified DNA contain oncogenes. These oncogenes become over- 
active by the amplification, and this contributes to the growth and survival of the tumour 
cell. Amplification of the Avian Myelocytomatosis Viral-Related Oncogene 
Neuroblastoma-Derived (MYCN) (2p24.1) was first found in neuroblastoma (Schwab et 
al., 1983). It is associated with an aggressive phenotype and the patients with MYCN 
amplification have a poorer prognosis than those without MYCN amplification (Seeger et 
al., 1985). Many oncogenes are amplified in cancer, and a summary is given in Table 
1.2.
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Gene Cytogenetic
location
Tumour
AKT 19ql3 Ovarian cancer
CYCUN 
D1 
HST-1 
GST 
SEA
llq l3 Breast, oesophageal carcinoma and many other solid tumours
CCNE 19ql2 Gastric cancer
GU
SAS
CDK-4
MDM2
12ql3 Soft tissue sarcoma and Glioma
EGFR 7pl2 Glioblastoma, Head and Neck cancer
ERBB2 17qll Breast, Ovarian cancer
FGFR1 8pl2 Breast cancer
FGFR2 10q25 Breast cancer
HRAS llp l5 Colorectal cancer, Bladder carcinoma
KRAS 12pl3 Colorectal, Gastric cancer
MDM2 12ql4 Sarcoma, Neuroblastoma, Glioblastoma
MYB 6q23 Colorectal cancer
MYC 8q22 Ovarian, Breast, Head and Neck, Oesophageal, Cervical, Small 
cell lung cancer
MYCN 2p24 Neuroblastoma, Retinoblastoma, Small Cell Lung Carcinoma
MYCL lp32 Small cell lung carcinoma
PDGFRA 4ql2 Glioblastoma
PDGFRB 5q33-35 Glioblastoma
Table 1.2 Examples of oncogenes amplified in human cancers (Sheer and Shipley, 
2005; Vogelstein and Kinzler, 1998). Table shows the normal cytogenetic location of the 
gene.
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1.2.2.4 Translocations and oncogene activation
A chromosome translocation involves a double strand break, and joining of the 
chromosome fragment to either a different place on the same chromosome or to a 
different chromosome. There are two main mechanisms of oncogene activation through 
chromosome translocation. The first involves translocation breakpoints between two 
genes and re-joining to create a tumour-specific oncogenic chimeric protein. This has 
been observed primarily in leukaemias, lymphomas and sarcomas (Tables 1.3 and 1.4). 
For example, the Philadelphia chromosome t(9;22)(q34;qll) generates a fusion between 
two genes, Breakpoint Cluster Region (BCR) and Abelson (ABL). The normal function of 
BCR is not known; ABL is a tyrosine kinase-signalling molecule. The translocation 
generates a fusion protein giving constitutive kinase activity to the ABL kinase. The 
Philadelphia chromosome is present in the majority of cases of chronic myeloid 
leukaemia (CML) and in a significant minority of those with acute lymphocytic 
leukaemia (ALL). Translocations characteristic to specific tumours can be used in 
diagnosis and in some cases in predicting prognosis (Table 1.5). For example, alveolar 
rhabdomyosarcoma can be difficult to distinguish histologically from embryonal 
tumours. However, t(2;13)(q25-37;ql4) which occurs in the majority of alveolar 
rhabdomyosarcoma or t(l;13)(p36;ql4), a variant translocation, can be used in diagnosis.
The second mechanism described for oncogene activation occurs in B and T 
lymphocyte malignancies. This involves translocation of the oncogene to the regulatory 
elements of immunoglobulin or T cell receptor genes. Burkitt’s lymphoma is an example 
of the mechanism. The oncogene involved in the translocation is MYC (8q24) and is most
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commonly translocated near to the Immunoglobulin Heavy chain gene on chromosome 
14 in the t(8;14)(q24;q32), or to the Immunoglobulin Light chain genes (IgL), IgLk in the 
t(2;8)(pl2;q24) or IgLX in the t(8;22)(q24;qll).
Malignancy Chromosome Aberration Affected Genes
CML «9;22)(q34;qll) ABL, BCR
CML blast crisis (9;22)(q34;qll), +8, 
+Ph, +19, or i(17q)
ABL, BCR, 
p53
AML-M2 K8;21)(q22;q22) ETO , AML1
APL-M3, M3V t(15;17)(q22;ql 1.2) PM L, RARA
AMMoL-M4Eo inv(16)(pl3q22) 
or t(16;16)(pl3;q22)
MYH11, CBFB
AMMoL-M4/M5 «4;ll)(q21;q23)
tCll;19>(q23;pl3)
AF4, MLL 
ENL, MLL
AML-M7 (infants) t(l;22)(pl3;ql3) OTT, MAL
AML t(6;9)(p23;q34) 
t(3;21)(q26;q22) 
-5 or del(5q)
7 or del(7q)
+8
t(12p) or del(12p)
DEK, CAN
EAP/EVU/MDS1,
AML1
Therapy-related AML -5 or del(5q)
-7 or del(7q)
t(3;21)(q26;q22)
K9;ll)(p22;q23)
EAP/EVI1/MDS1,
AML1
AF9, MLL
pre-B ALL t(l;19)(q23;pl3.3) PBX1, E2A
pro-B ALL t(17;19)(q22;pl3.3) HLF, E2A
ALL «9;22)(q34;qll)
t(l;ll)(p32;q23)
t(4;ll)(q21;q23)
«ll;19)(q23;pl3)
del(9p)
del (6q), del(l lq),del(12p)
ABL, BCR 
epsl5, MLL 
AF4, MLL 
ENL, MLL 
CDKN2A/B
CLL +12
Table 1.3 Examples of recurrent chromosome aberrations in myeloid and lymphoid 
malignancies (Sheer and Shipley, 2005).
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Tumour Chromosome
Aberration
Affected Genes
Ewing's sarcoma and pPNET t(ll;22)(q24;ql2) 
t(2 ;22)(q3 3 ;q 12) 
t(7;22)(p22;ql2) 
t(17;22)(q21;ql2) 
t(21;22)(q22;ql2)
FLl-1, EWS 
FEV, EWS 
ETV1, EWS 
ETV4, EWS 
ERG, EWS
Ewing's sarcoma t( 1; 16)(q 11 -25 ;q 11 -24)
Clear cell sarcoma t(12;22)(ql3;ql2) ATF1, EWS
Intra-abdominal small cell sarcoma t(ll;22)(pl3;ql2) WT1,EWS
Extraskeletal myxoid chondrosarcoma t(9;22)(q22;ql2) DDTT3, EWS
Alveolar rhabdomyosarcoma t(2;13)(q35-37;ql4) PAX3, FKHR
Synovial sarcoma t(X;18)(pll.2;qll.2) SSX1/SSX2/SSX4, SYT
Myxoid liposarcoma t(12;16)(ql3;pll) CHOP, TLS/FUS
Dematofibrosarcoma protruberans t(17;22)(q22;ql3) COL1A, PDGFB
Congenital fibrosarcoma t(2;15)(pl3;q25) ETV6, NTRK3
Alveolar soft part sarcoma t(X;17)(pll.2;q25) ASPL, TFE3
Table 1.4 Examples of recurrent chromosome aberrations in sarcomas (Sheer and 
Shipley, 2005).
Malignancy PROGNOSIS
Good Intermediate Poor
CML blast crisis 
AML t(8;21)
t(15;17)
inv(16)
del(7q) 
del(9q) 
abn llq23 
+22
Other structural & numerical 
abnormalities 
No abnormality
+Ph,+8, i(17q)or +19 
abn 3q 
-5 or del(5q)
-7
complex karyotypes 
+8
+11
+13
+21
ALL >50 chromosomes
t(12;21)
t(10;14)
+4, +10
47-50 chromosomes <47 chromosomes 
-96 chromosomes 
t(9;22) 
t(8;14)
Kl;19)
K4;ll)fKll;19)
Table 1.5 Examples of prognostic associations in myeloid and lymphoid 
malignancies (Sheer and Shipley, 2005).
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While chromosome translocations are recognised as an important mechanism for 
oncogene activation in haematological malignancies and sarcomas, there are only a few 
examples where this process is described in epithelial tumours (Table 1.6). A 
t(15;19)(qll;pl3) in association with an increased expression of NOTCH3 gene was 
found in a lung carcinoma (Dang et a l , 2000). Tognon et al demonstrated a translocation, 
t(12;15), leading to fusion of the ETS variant 6 (ETV6) and Neurotrophic Tyrosine 
Kinase Receptor type 3 (NTRK3) genes in secretory breast carcinoma (Tognon et a l , 
2002). The fusion transcript was found in 12 out of 13 secretory breast carcinomas. 
Barlund et al found over-expression of the Breast Carcinoma Amplified Sequence 3 
(BCAS3), in 9 out of 13 breast cancer cell lines, but in cell line MCF7 they identified a 
fusion protein derived from BCAS3 and BCAS4 (Barlund et a l , 2002). Strictly speaking, 
a translocation was not described, although a rearrangement was suggested from two 
colour FISH, which showed colocalisation of the probes representing the two genomic 
regions. Adelaide et al studied translocations involving 8 p ll in 9 pancreatic, and 34 
breast cancer cell lines. Seven breakpoints involving Neuregulin 1 (NGR1) were 
identified (Adelaide et a l , 2003). The significance of this breakpoint cluster in these 
tumours has yet to be identified.
Model system Affected genes
Secretory breast carcinoma ETV6 (12pl3.2), NTRK3 (15q25.3)
MCF breast cancer cell line BCAS3 (17q23), BCAS4 (20ql3)
Lung cancer NOTCH3 (19pl3)
Table 1.6 Oncogenes activated by translocation in epithelial tumours (Barlund et a l , 
2002; Dang et a l , 2000; Tognon et al., 2002).
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1.2.3 Tumour suppressor genes
Knudson first proposed the concept of a tumour suppressor gene after studying 
retinoblastoma (Knudson, 1971). Retinoblastoma is a tumour that arises in the retina of 
children. Sixty percent of cases of retinoblastoma cases are hereditary and of these, 80% 
arise in both eyes. The non-hereditary cases are always unilateral, that is they only arise 
in one eye. Knudson’s ‘two hit’ model recognised that the transformation of a normal cell 
to a tumour cell requires inactivating mutations in each allele of a tumour suppressor 
gene. Knudson proposed that patients with hereditary retinoblastomas have one mutant 
allele present in the germ-line, and the addition of a second mutation in the remaining 
normal allele gives rise to retinoblastoma. In the non-hereditary patients both mutations 
are spontaneous and must occur in the same cell, hence the lower frequency of non- 
hereditary retinoblstoma. Subsequently, retinoblastoma has been found to be associated 
with mutation of both alleles of a gene termed retinoblastoma (RB), present on 13ql4, 
thus supporting Knudson’s hypothesis (Friend et al., 1986). Knudson’s ‘two hit’ 
hypothesis has been broadly supported by the identification of other tumour suppressor 
genes where both alleles are abrogated before tumour suppressor activity is lost.
p53 was first identified as a tumour suppressor gene in colorectal cancer. Analysis 
of chromosome 17p in colorectal carcinomas with microsatellite markers found a 
minimum region of loss from 17pl2 to 17pl3, containing p53 (Baker et al., 1989). It was 
known at this time that p53 was involved in SV40 transformation of cells (Lane and 
Crawford, 1979; Linzer and Levine, 1979), and hence its coding sequence was analysed. 
Mutations were found in p53 in two colorectal carcinomas with loss of heterozygosity
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(LOH) at 17pl3.1. Subsequently, the same group found mutations in p53 in other 
common human tumours, including astrocytic glioma grade IV, breast and lung cancer 
(Nigro et a/., 1989). p53 plays a pivotal role in integrating cell responses and influencing 
the balance of apoptosis and cell growth. Loss of function of p53 leads to genomic 
instability, which is a common feature of cancer (Bogler et al., 1995a; Bogler et a l , 
1995b). Indeed, p53 is mutated in half of human cancers and is the most frequently 
mutated tumour suppressor gene in cancer (Lane, 1992). The complexity of cancer 
genetics is exemplified with p53. Normal p53 is a tumour suppressor gene. However, 
while the mutated gene loses tumour suppressor function, it also develops tumour- 
enhancing capabilities and hence can also be classified as an oncogene. Two independent 
studies reached this conclusion using mouse models (Lang et a l , 2004; Olive et a l , 
2004). It was found that mice, which bear the mutant p53 had a different tumour 
spectrum from p53 null mice.
1.2.3.1 Family cancer syndromes
Certain families have a history of cancer, for example five percent of breast 
cancer cases have a strong family history of breast cancer. Tumour suppressor genes, 
including BRCA1, have been detected in linkage studies in family cancer syndromes 
(Hall et a l , 1990). Sporadic tumours may also have mutations of the same tumour 
suppressor genes but be a different tumour type to those found in familial cases (Table 
1.7).
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Gene Genomic
Location
Family cancer 
Syndrome
Sporadic cancer
APC 5q21 Adenomatous polyposis coli and 
Turcot syndrome
Colon and brain cancers
BRCA1 17q21 Breast/ovarian cancer Breast, ovary and prostate
BRCA2 13q 12-13 Breast cancer Breast, ovarian and pancreatic
NF1 17ql 1.2 Neurofibromatosis type I Neurofibromatosis, colon and brain
NF2 22ql2.2 Neurofibromatosis type II Vestibular schwannoma, meningioma and 
ependymoma
CDKN2A 9p21 Melanoma-astrocytoma Melanoma, astrocytic glioma, pancreatic, 
breast and other cancers
p53 17pl3 Li-Fraumeni syndrome Many including brain, breast, lung, colon, 
bladder, ovarian and prostate
RBI 13ql4.3 Retinoblastoma Retinoblastoma, osteosarcoma, bladder, 
breast and lung cancer
SMAD4 18q21 Juvenile polyposis Pancreatic, colon and lung cancer
PTEN 10q24-25 Cowden disease Brain, breast and prostate cancer
VHL 3p25-26 Von Hippel-Lindau syndrome Renal cell and pheochromocytoma
WT1 llp!3-15 Wilm Tumour Nephroblastoma
Table 1.7 Tumour suppressor genes involved in familial cancer syndromes and 
associated sporadic tumours (Thiagalingam et a l , 2002).
1.2.3.2 Deletions and tumour suppressor gene inactivation
The other method of identifying tumour suppressor genes has been the detection 
of regions of homozygous deletion or minimal regions of copy number loss with a 
mutation in a tumour suppressor gene on the remaining allele. Examples of genes 
identified by homozygous deletion are CDKN2A, CDKN2A, DCC and PTEN (Fearon et 
al., 1990; Hahn et al., 1996; Kamb et al., 1994; Steck et al., 1997). In each of these 
examples, cases were also identified where loss of functional gene product was achieved
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through LOH and mutation in the remaining allele (Fearon et a l ,  1990; Hahn et a l ,  1996; 
Kamb et a l ,  1994; Li et a l ,  1997; Rhei et a l ,  1997; Steck et a l ,  1997). Hence, tumour 
suppressor gene function can be lost by homozygous deletion and by loss of 
heterozygosity with mutation of the remaining allele, but at the chromosome level this 
can present as a number of different scenarios (Figure 1.2).
Localized deletion 
Gene conversion 
Double mitotic recombination
or
or
Chromosome breakage 
and loss
Chromosome loss 
and duplication
Figure 1.2 Genetic changes accompanying tumour suppressor gene inactivation 
(Thiagalingam et a l ,  2002). The loss of heterozygosity by a chromosomal rearrangement 
accompanied by a point mutation in the remaining allele will lead to loss of tumour 
suppressor gene function.
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1.2.4 Aneuploidy theory of tumorigenesis
Solid tumours commonly have abnormal numbers of chromosomes, termed 
aneuploidy. Aneuploidy is often accompanied by rearrangements of chromosomes, such 
as translocations. Aneuploidy can arise from a number of different proposed routes. The 
main proposed mechanisms start from either the diploid karyotype or the tetraploid 
karyotype (Storchova and Pellman, 2004). Whilst it is clear that aberrant gene function is 
involved in carcinogenesis, it has been debated whether aneuploidy is an underlying 
cause of cancer or a secondary effect (Marx, 2002; Nigg, 2002).
Mosaic variegated aneuploidy (MVA) is an inherited condition associated with 
the clinical findings of intra-uterine growth retardation, microcephaly (small head) and 
mental retardation. These patients have aneuploid karyotypes and have an increased risk 
of developing cancer including leukaemia, rhabdosarcoma and Wilms tumour. These 
patients have been found to have truncating or missense mutations in BUB1B. This gene 
encodes the protein BUBR1, a mitotic checkpoint protein (Hanks et a l , 2004). This 
genetic condition supports the theory that aneuploidy per se can lead to cancer. However, 
it should be considered that while aneuploidy may lead to some tumours, it might not be 
a strong feature in others. For example, in colorectal cancer some tumours have marked 
chromosomal abnormalities while a subgroup with microsatellite instability have few 
chromosome changes (Abdel-Rahman et al., 2001; Douglas et al., 2004; Jones et a l , 
2005; Schlegel etal., 1995).
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Centrosome abnormalities are also associated with aneuploidy. The centrosome is 
also known as the microtubule organising centre. It is duplicated only once during the 
cell cycle. Abnormal number and structure of the centrosome is associated with 
aneuploidy arising from chromosome mis-segregation (Steams, 2001). This occurs 
because during mitosis the genetic material is segregated by the two centrosomes, if there 
are more than two centrosomes there will be abnormal segregation of DNA. 
Overexpression of the gene Serine/threonine kinase 15 (STK15) (20ql3.2) induces 
centrosome amplification and aneuploidy (Zhou et al., 1998).
1.2.5 Mechanisms of genetic change
Amplified DNA in tumours can be found as double minutes (dmin) or 
incorporated in DNA as homogeneously staining regions (HSRs) (Schwab, 1999). The 
mechanism of amplification is not fully understood, but an impression of possible 
mechanisms can be made from examining the arrangement of the genes within the 
amplified DNA. The amplicon at l l q l3  (Table 1.2) shows tandem duplication, which 
could have resulted from inter-chromosomal recombination and by unequal sister 
chromatid exchange (Roelofs et a l , 1993). Examination of the arrangement of MYCN 
copies in amplified DNA in neuroblastoma revealed that the gene was arranged in a 
tandem, head-to-tail order (Amler and Schwab, 1992; Amler et a l , 1992). Inverted 
repeats could result from a breakage-fusion-bridge (BFB) cycle. In this model, if there is 
a double strand break telomeric to an oncogene, this may result in fusion of sister 
chromatids. Following fusion of the sister chromatids the two copies of the oncogene are 
arranged in head-to-tail order. At anaphase the centrosomes are drawn apart, an anaphase
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bridge is formed, and this results in another double strand break. If there is unequal 
distribution of DNA and selection for an oncogene, then on subsequent BFB cycles there 
is ladder amplification of the oncogene. BFB in a fragile site, FRA7G has been suggested 
as a mechanism of amplification of the MET oncogene in human gastric carcinoma 
(Heilman et al., 2002).
1.2.6 DNA repair
DNA mutations can arise through internal cellular factors, such as errors during 
replication, and by external environmental factors, such as damage by radiation. Whilst 
there are mechanisms to detect and repair these genetic changes, the genes involved in 
these mechanisms are themselves prone to mutation and failure of function. There are 
two classes of DNA repair, excision and recombination. Excision repair is possible when 
the damage is limited to one strand of the double helix. It involves the removal (excision) 
of the damaged nucleotide(s) and its replacement by DNA polymerase using the 
complementary undamaged strand as a template. There are two types of excision repair: 
base excision - the replacement of a single nucleotide, and nucleotide excision, which 
involves the replacement of a longer stretch of nucleotides containing the DNA lesion. 
Recombination repair is used when both strands of a double helix are damaged. Where 
possible, the cell repairs these double strand breaks by homologous recombination with 
sequence from the sister chromatid. If a double-strand break is detected in a cell prior to 
S-phase (before the replication of chromosomes to give sister chromatids), the cell has no 
template for homologous recombination, and instead repairs the lesion by simply 
rejoining the broken DNA ends. This is called non-homologous end-joining (NHEJ).
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Importantly, this type of repair can lead to sequence deletion. If deletion involves non­
coding sequence it may be of no consequence, however at times it may interfere with 
gene function and be tumorigenic. Another mechanism of DNA repair that is sometimes 
used during replication occurs when the cell encounters a lesion that has not been 
repaired by other means and is called trans-lesion synthesis (TLS). This mechanism 
involves the synthesis of random sequence across a DNA lesion. This process is clearly 
error prone, however it does allow the cell to complete the process of chromosome 
replication (Hoeijmakers, 2001; Jackson, 2002). Table 1.8 gives examples of human 
syndromes where affected individuals have defects in DNA repair mechanisms. Table 1.9 
shows possible chromosome rearrangements following double strand breaks and 
recombination.
Syndrome Affected
maintenance
mechanism
Type of genome 
instability
Cancer
predisposition
Xeroderma pigmentosum NER Point mutations Skin cancer
Ataxia telangiectasia DSB Chromosome aberrations Lymphomas
Nijmegan breakage syndrome DSB Chromosome aberrations Lymphomas
BRCA1/BRCA2 HR Chromosome aberrations Breast (ovarian) 
cancer
Werner’s syndrome HR7/TLS Chromosome aberrations Various cancers
Bloom syndrome HR? Chromosome aberrations Leukaemia, 
lymphoma and 
others
Rothmund-Thompson syndrome HR? Chromosome aberrations Osteosarcoma
HNPCC MMR Point mutations Colorectal cancer
Table 1.8 Human syndromes with defects in DNA repair (Hoeijmakers, 2001).
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One chromosome involved Two chromosomes involved
One break Terminal deletion -
Two breaks Interstitial deletion 
Inversion 
Ring chromosome
Duplication/ deletion by sister chromatid 
exchange
Reciprocal translocation 
Robertsonian translocation 
Duplication or deletion by unequal 
recombination
Three breaks Various rearrangements Inter-chromosomal insertion
Table 1.9 Possible rearrangements following double strand chromosome breaks 
(Strachan and Read, 1999).
Genetic rearrangements also arise through loss of telomeres. Telomeres are 
repetitive sequences that cap the ends of chromosomes. The telomeres are synthesised 
and maintained by a mechanism involving the enzyme telomerase. This mechanism is 
functional in germ line cells and stem cells. All other cells, which do not have this 
maintenance mechanism, lose some telomere sequence after they divide. Eventually the 
telomeres become very short and the cell cycle is arrested. However, in a cancer cell 
there is aberrant cell cycle control and the cell cycle may not be arrested by short 
telomeres. In this instance, the ends of the chromosomes that do not have the protective 
cap of the telomere are seen as double strand breaks and this leads to fusion with other 
chromosome ends or double strand breaks.
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The mechanism of aneuploidy may lead to random copy number changes. 
However, if the change gives a survival advantage to the cell then the copy number 
change will be selected and become more prevalent in the cell population. The process of 
changing the selective pressures on a cell and clonal evolution of cells with genomic 
instability is demonstrated in two independent studies (Gorre et a l , 2001; Sawyers, 2001; 
Wang et a l , 2004). Gorre et al studied patients with chronic myeloid leukaemia in blast 
crisis whose cancer had become resistant to treatment with Gleevec. Gleevec is a receptor 
tyrosine kinase inhibitor that suppresses BCR-ABL fusion protein signal transduction. 
Patients with resistance to Gleevec had point mutations in the BCR-ABL and also 
chromosome duplications and amplifications (Gorre et a l , 2001). Similarly, Wang et al 
showed that aneuploid tumours resistant to the anti-cancer drug 5-fluorouracil (5-FXJ) had 
amplification of thymidylate synthase (Wang et a l , 2004). 5-FU inhibits Thymidylate 
Synthase in tumours. In both of these instances, the anti-cancer agent is believed to 
become ineffective by genomic instability giving rise to these cells with a growth 
advantage and these clones replacing the cells without the growth advantage.
1.2.7 Genome-wide methods of analysis of genetic change
Our understanding of cancer genetics is evolving and is largely dependent on the 
sensitivity and specificity of the method of analysis. Karyotyping was the main method 
used to analyse genetic changes in tumours until the 1980s, when restriction fragment 
length polymorphism (RFLP) was developed (Botstein et a l , 1980; Kan and Dozy, 
1978). RFLP uses restriction enzymes to cut DNA to obtain DNA fragments, and if a 
polymorphism (DNA sequence change that does not alter gene function) is present at a
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restriction site the enzyme may not cut the DNA. The presence of these polymorphisms 
generates different sized fragments that can be used to distinguish between DNA in 
linkage studies. The 1990s witnessed further technical advances, with the extensive use 
of LOH analysis to determine loss of an allele. Polymorphic alleles of the gene of interest 
are distinguished with polymerase chain reaction (PCR) based methods.
Fluorescence in situ hybridisation (FISH) is a molecular genetic technique where 
labelled DNA is hybridised to target DNA to obtain information about the target DNA 
(Pinkel et al., 1986). FISH is used to gives positional information as well as copy number 
information. FISH has been modified in Multiplex-Fluorescence In situ Hybridisation 
(M-FISH) and Comparative Genomic Hybridisation (CGH). M-FISH was first reported 
in 1996 (Speicher et a l , 1996). This technique distinguishes between different 
chromosomes (or regions of chromosomes) using differentially labelled DNA probes that 
are hybridised simultaneously. Its power lies in the breadth of information it provides. 
CGH was developed in the early 1990s and is a method for screening the entire genome 
for copy number gains and losses (Kallioniemi et a l , 1992). This assay is based on the 
competitive hybridisation of fluorescently labelled test (tumour) and reference (normal) 
DNA on human metaphase spreads and the subsequent measurement of the fluorescent 
signals along each chromosome. The relative values for normal and tumour DNA show 
the positions of copy number changes representing regions of genomic loss and gain. The 
first report of metaphase CGH demonstrated that the method could detect changes in 
DNA copy number using fibroblast cell lines that had one to five copies of the X 
chromosome. Normal female DNA labelled fluorescent red and test DNA labelled
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fluorescent green were co-hybridised to metaphase spreads. The fluorescence ratio of the 
green and red fluorescence on the X chromosome was shown to be proportional to X 
chromosome copy number (r=0.978) (Kallioniemi et a l , 1992). The main limitation of 
conventional CGH is the resolution of detection. For amplifications it is possible to detect 
regions as small as 2 Mega base-pairs (Mb) but for deletions it is 5-10 Mb. Array CGH is 
a refinement of metaphase CGH where the target metaphase is replaced with mapped 
fragments of DNA sequence immobilised on a glass slide (Pinkel et al., 1998; Solinas- 
Toldo et a l , 1997). This important advance will be described in more detail below, but it 
facilitates significantly improved resolution of detection and more accurate identification 
of genetic changes.
42
1.3 Astrocytic gliomas
1.3.1 Description of astrocytic gliomas
Two main cell types in the brain arise from the neural crest, the neural cells and 
the glial cells. Three types of glial cell are present: astrocytes, which supply nutritional 
support to neurons, oligodendrocytes, which provide the axonal myelin sheath of 
neurones, and ependymal cells, which form the lining of the cerebrospinal fluid 
ventricular system. Unlike neurones, which only have a limited potential to replicate 
when developed, glial cells retain their proliferative potential (Zhu and Parada, 2002). 
Glioma is a term used to describe a number of tumour types that appear to have followed 
distinct lines of differentiation, and include astrocytic gliomas, oligodendrogliomas and 
ependymal tumours. Although the cell of origin of gliomas is not clearly established, 
histological analysis suggests that they arise from glial cells, with astrocytes giving rise to 
astrocytic gliomas, oligodendrocytes to oligodendrogliomas and ependymal cells to 
ependymal tumours (Table 1.10).
Astrocytic gliomas are divided into four grades, designated I-IV, with grade IV 
being the most aggressive. The grade of tumour is based on the mitotic index, cellularity, 
nuclear pleomorphism, nuclear atypia, vascular proliferation and necrosis. This is also 
supported by immunocytochemistry. Grade I tumours, which are also called pilocytic 
astrocytomas, have a variable appearance and can be difficult to diagnose histologically. 
Grade II tumours are identified by a mild increase in cellularity with astrocytes having 
nuclei with abnormal morphology, being irregular and larger than normal (Figure 1.3 a). 
Grade III tumours have an increased cellularity and pleomorphism compared to grade II
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astrocytic gliomas, but they lack the necrosis and vascular proliferation of the grade IV 
tumours. The histological hallmarks of grade IV tumours are dense cellularity, necrosis 
and vascular proliferation (Figure 1.3 b). There are a number of variants of astrocytic 
glioma grade IV, such as gliosarcoma, which is characterised by sarcomatous 
differentiation in the tumour vasculature. High-grade astrocytic gliomas are 
heterogeneous tumours, and each tumour may consist of different histological grades. 
Therefore a single biopsy may not give an accurate reflection of the tumour.
Suggested cell of origin Glioma sub-type
Astrocytes Astrocytic tumours
Grade I (Pilocytic astrocytoma)
Grade II (Astrocytoma)
Grade III (malignant astrocytoma) (Anaplastic) 
Grade IV (Glioblastoma) (Glioblastoma multiforme)
Oligodendrocytes Oligodendroglial tumours
Oligodendroglioma
Anaplastic malignant oligodendroglioma
Ependymal cells Ependymal tumours
Ependymoma
Anaplastic (malignant) ependymoma 
Choroid plexus tumours 
Choroid plexus papilloma 
Choroid plexus carcinoma
Table 1.10 Modified WHO classification of gliomas showing the suggested cell of 
origin (Kleihues etal., 2002).
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Figure 1.3 a Haematoxylin & Eosin (H&E) section of an astrocytic glioma grade II 
(xl25). There is an increase in cellularity compared to normal brain, and the nuclei are 
irregular in shape and size.
Figure 1.3 b H&E section of astrocytic glioma grade IV (xl25). The hallmarks of this 
grade are dense cellularity and vascular proliferation.
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Brain tumours are deeply destructive as, along with physical and psychological 
disturbance, they also cause impairment in higher cognitive function (Figure 1.4). 
Astrocytic gliomas are a significant cause of morbidity and mortality affecting all age 
groups including young adults, being the third most common cause of death from cancer 
in the age group 18-35 years (Steck et al., 1997). Astrocytic gliomas, grade I, occur in 
children and the patients have a relatively good prognosis, tending not to progress to 
higher-grade tumours. Grade II tumours follow a relatively benign course. However, 70% 
progress to a grade IV tumour within 5-10 years (Kleihues et al., 2002). Patients with 
grade III tumours can survive two to three years, but the majority of patients with 
astrocytic glioma grade IV die within a year, with only 10% surviving two years 
(Bleehen and Stenning, 1991).
Surgery, radiotherapy and chemotherapy are the main treatment modalities used 
in astrocytic gliomas. Astrocytic gliomas diffusely infiltrate normal brain tissue, hence 
complete surgical resection is not possible. Surgery may be used to reduce the size of the 
tumour (debulking surgery) to alleviate the patient’s symptoms. To minimise 
neurological deficit, surgery is largely confined to patients with tumours in the frontal 
and temporal lobes. However, surgical biopsy remains useful for diagnostic purposes. 
Grade II tumours can be slow growing and clinical presentation depends on the 
anatomical location. If the tumour is slow growing and is having no impact on the 
patient, a policy of ‘watch and wait’ may be undertaken. If the patient becomes 
symptomatic, surgical intervention and radiotherapy are considered. Grade III tumours
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are more aggressive and if possible, are treated with debulking surgery followed by 
radiotherapy. Chemotherapy can be considered either concurrently with radiotherapy or 
on relapse. Grade IV tumours are treated if possible, with debulking surgery followed by 
radiotherapy with or without concurrent chemotherapy. Palliative chemotherapy is 
beneficial to some patients (Table 1.11).
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Figure 1.4 MRI scan of a patient with astrocytic glioma.
This patient had multiple astrocytic gliomas of different grades. One of the 
tumours is demonstrated in this MRI slice. The tumour (marked with red arrow) is 
enhanced by contrast and has a heterogenous appearance. This tumour is in the region of 
the right basal ganglia and is an astrocytic glioma grade II (shown in Figure 1.3 a).
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Agent Therapeutic action Side-effect profile
Nitrosoureas Alkylating agent Myelosuppression, nausea
Temozolomide Alkylating agent Myelosuppression nausea
Irinotecan Topoisomerase I inhibitor Myelosuppression, diarrhoea, nausea
Thalidomide TNFa inhibition, 
Anti-angiogenic
Peripheral sensory neuropathy, sedation
Carboplatin DNA cross-links Myelosuppression nausea, peripheral sensory 
neuropathy
Tamoxifen Selective oestrogen 
receptor modulator
Nausea, peripheral oedema
Table 1.11 Conventional chemotherapeutic agents used in high-grade gliomas
1.3.2 Genetic aberrations in astrocytic gliomas
A few genes and biochemical pathways have been identified as being involved in 
astrocytic gliomas, and in particular p53, RB and growth factor receptor tyrosine kinases. 
This section reviews the genetic aberrations that have been identified from analysis of 
family syndromes and loss of heterozygosity studies.
1.3.2.1 Family syndromes
Identification of the genetic defect in hereditary cancer syndromes can give an 
insight into the genetic aetiology of sporadic tumours. Astrocytic gliomas are usually 
sporadic, but certain syndromes have germ-line mutations that confer an increased risk of 
developing these tumours (Table 1.12). However, they are not a direct parallel as the 
presence of a genetic defect in a family syndrome, which is associated with an astrocytic 
glioma, does not necessarily indicate that the same genetic defect will be present in a 
sporadic tumour. Patients with the Li Fraumeni syndrome have genetic defects in p53,
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and this predisposes to many tumour types including astrocytic gliomas (Li et al., 1995). 
Neurofibromatosis types 1 and 2 both predispose to astrocytic glioma (Listemick et a l , 
1999). Turcot’s syndrome B is associated with colorectal cancer (tumours are typical of 
hereditary non-polyposis colorectal cancer (HNPCC) with defects in mis-match repair 
machinery) and astrocytic glioma (Hamilton et a l , 1995).
Genetic condition Gene Location Involved in sporadic tumour
Li Fraumeni p53 17pl3.1 Yes
Melanoma-astrocytoma syndrome CDKN2A 9p21 Yes
Neurofibromatosis 1 NF1 17ql 1.2 No
Neurofibromatosis 2 NF2 22ql2.2 No
Tuberous sclerosis TS1 9q34 No
TS2 16pl3.3 No
Turcot’s syndrome B MLH1 3p21.3 No
- PMS2 7p22 No
Table 1.12 Summary of genetic predisposition syndromes associated with astrocytic 
gliomas. The aberrant genes in Li Fraumeni and melanoma-astrocytoma syndrome (p53 
and CDKN2A respectively) are also mutated in sporadic tumours. However, this is not the 
case in Neurofibromatosis, Tuberous sclerosis and Turcot’s syndrome B.
1.3.2.2 Studies examining genetic changes in astrocytic gliomas
A number of studies have examined copy number changes in astrocytic gliomas 
using a range of analytical tools including karyotyping (Olopade et a l , 1992; Thiel et al., 
1992), RFLP (Fults et a l , 1990; Liang et a l , 1994; Ransom et a l , 1992), microsatellite 
markers (MSM) for LOH (Balesaria et a l , 1999; Miyakawa et a l , 2000; Ransom et al., 
1992; Saitoh et al., 1998), conventional CGH (Brunner et a l , 2000; Mohapatra et a l , 
1998), and low resolution array CGH (Hui et a l, 2001).
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1.3.2.2.1 Regions of LOH or copy number loss
While a large number of genetic changes have been described in high-grade 
astrocytic gliomas, some consistent findings have emerged, including loss of 6q (Table 
1.13) (Liang et al., 1994; Miyakawa et a l, 2000; Mohapatra et a l , 1998; Saitoh et a l , 
1998; Thiel et a l, 1992).
Chromosome breakpoints or allele loss have been detected in high-grade 
astrocytic gliomas involving 9p (Olopade et al., 1992; Ransom et a l , 1992; Thiel et al., 
1992) (Mohapatra et a l , 1998) and chromosome 10 (Balesaria et a l , 1999; Brunner et 
al., 2000; Fults et al., 1990; Mohapatra et a l , 1998; Ransom et a l, 1992; Thiel et a l, 
1992). Several tumour suppressor genes have been identified as a result of these studies, 
in particular CDKN2A and PTEN, on chromosomes 9 and 10 respectively (Table 1.14). 
No tumour suppressor gene has been identified on 6q in astrocytic gliomas.
Chromosome MSM flanking loss Position (Mb)
6ql6.1-6ql6.3 D6S275-D6S434 93.01-102.3
6q22.1-6q22.31 D6S1563-D6S407 105.5-128.47
6q24.1-6q24.2 D6S292-D6S441 135.93-153.37
6q25.2-6q25.3 D6S441-D6S437 153.37-158.2
6q26-6q27 D6S1599-D6S297 162.2-166.59
Table 1.13 Regions of LOH on chromosome 6 in astrocytic gliomas. The location 
refers to the nucleotide position of the gene locus in Mega base pairs (Mb), where the 
nucleotides are listed in order from the distal end of the short arm to the distal end of the 
long arm (Miyakawa et a l, 2000).
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Gene symbol Gene name Cytogenetic
location
Location
(Mb)
p53 Tumour protein p53 17pl3 7.5
CDKN2A Cyclin dependent kinase inhibitor 2A 9p21 22
RB Retinoblastoma 13ql4.1-ql4.2 47.8
PTEN Phosphatase and tensin homologue 10q23-24 89.6
DMBT1 Deleted in malignant brain tumours 1 10q26.13 124.3
MDM2 Mouse double minute homologue 2 12ql5 67.5
Table 1.14 Tumour suppressor genes identified in astrocytic gliomas.
1.3.2.2.2 Regions of genetic gain
Gains of chromosome arm 7p (Brunner et al., 2000; Mohapatra et a l , 1998; Thiel 
et a l , 1992) and chromosome 20 (Brunner et a l , 2000; Mohapatra et a l , 1998) have 
been noted in astrocytic glioma grade IV. EGFR has been identified as an oncogene on 
7p but no target gene has been identified on chromosome 20 (Table 1.15).
Gene symbol Gene name Cytogenetic
location
Location
(Mb)
EGFR Epidermal growth factor receptor 7pl 1.2 54.9
ROS1 V-ROS avian UR2 sarcoma virus oncogene 
homologue 1
6q22.1 117.7
PDGFR Platelet derived growth factor receptor 4ql2 54.9
VEGFR Vascular endothelial growth factor receptor 4ql2 54.9
CDK4 Cyclin dependent kinase 4 12ql4.1 56.4
Table 1.15 Oncogenes identified in astrocytic gliomas.
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1.3.2.2.3 Translocations
It has been suggested that critical genes at translocation breakpoints may be 
involved in development of astrocytic gliomas (Chernova et al., 2001; Chernova et al., 
1998; Krex et al., 2002). In one case report, three short-term cultures were derived from 
three tumours isolated from a patient with multifocal astrocytic glioma grade IV (Krex et 
al., 2002). Molecular genetic analysis revealed a consistent translocation 
t(l;15)(p3?6;q2?5) in all three cell cultures. Chernova et al described a translocation, 
t(10;19)(q25-26;13) in cell line CRL1620 (A172) (Chernova et al., 1998). This 
translocation involved two genes, WDR11 located at 10q25-26 and ZNF320 at 19ql3, and 
generated a transcript that encodes a truncated WDR11 (Chernova et al., 2001).
1.3.2.3 Molecular pathways
The aberrations detected in astrocytic gliomas have been diverse and seemingly 
inconsistent. However, when genetic aberrations are placed into molecular pathways, it 
can be seen that key molecular pathways controlling cell growth and apoptosis are 
involved in these tumours but may be abrogated at different steps. Key pathways found to 
be involved in astrocytic gliomas include receptor tyrosine kinase signalling pathways, 
especially the EGFR, and the p53 or Rb pathways.
Tyrosine kinases are signalling molecules within the cell, which act by 
phosphorylating tyrosine residues on proteins. There are approximately ninety tyrosine 
kinases, of which 58 are receptor tyrosine kinases, which have 20 sub-families, and 32
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are non-receptor tyrosine kinases (Robinson et a l , 2000). Receptor tyrosine kinase genes 
that have been implicated in gliomas include EGFR, PDGFR, ROS1 and VEGFR.
EGFR is a transmembrane receptor tyrosine kinase that is activated by binding of 
ligands including transforming growth factor alpha and epidermal growth factor. EGFR, 
located at 7pl 1-12, is amplified in 40% of astrocytic glioma grade IV tumours and is 
overexpressed in 80-90 percent of gliomas (von Deimling et al., 1992b). EGFR can 
acquire gain of function through DNA amplification and/or DNA mutation. 
Approximately half of the cases with EGFR amplification have a mutation. These 
mutations encode a truncated receptor, which has lost some of its extracellular domain 
(Figure 1.5). The mutated receptor is not able to bind its ligand but is constitutively active 
(Ekstrand et a l , 1994; Ekstrand et a l , 1992; Nishikawa et a l, 1994; Wong et a l, 1987). 
Ekstrand et al found deletions in the ligand-binding domain and within the Ca2+ 
regulatory/ internalisation domain and inhibitory domain (Ekstrand et a l, 1992). This 
group found no mutations in the EGFR receptors that were not amplified. Bigner et al 
found that EGFR amplification is associated with increased RNA expression (Bigner et 
a l, 1987).
Receptor tyrosine kinases signal through PI3K to phosphorylate PIP2 to PIP3 
(Figure 1.6). The balance between PIP2 and PIP3 is maintained by PI3K and PTEN 
(Ramaswamy et a l, 1999). PIP3 signals through AKT/PKB pathway to phosphorylate 
Forkhead in Rhabdomyosarcoma-like 1 (FKHRL1) (6q21, 108.9Mb) at Ser256. 
Phosphorylated FKHRL1 promotes cell survival and dephosphorylated FKHRL1
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promotes apoptosis through a Fas ligand. Loss of functional PTEN leads to increased 
activity of AKT/PKB. Many astrocytic glioma grade IV have no wild-type PTEN or they 
have aberrations involving other components of the AKT signal transduction pathway 
(Knobbe and Reifenberger, 2003). Wang et al found that of 15/34 (44%) astrocytic 
gliomas grade IV examined had a mutation in the sequence of PTEN (Wang et al., 1997). 
Fan et al detected PTEN mutations in 6/22 (27%) (2 homozygous deletions and 4 point 
mutations) astrocytic gliomas grade IV (Fan etal., 2002).
Signal peptide
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Ca2+ regulatory/ internalisation domain 
Inhibitory domain
Figure 1.5 Functional domains of EGFR protein (Ekstrand etal., 1992).
Other tyrosine kinases involved in astrocytic glioma include vascular endothelial 
growth factor (VEGF) and its receptor VEGFR and platelet derived growth factor 
(PDGF-B) and its receptors (Carmeliet and Jain, 2000; Ferrara, 2002). A relationship 
between VEGF, EGFR and PTEN has been established in high-grade astrocytic glioma
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cell lines (Figure 1.6). Maity et al showed that inhibition of EGFR signalling by a 
truncated protein causes a decrease in VEGF mRNA levels (Maity et al., 2000). Pore et 
al showed this was a PI3K pathway dependent effect, by transfecting wild-type PTEN 
into cell lines with mutant PTEN (U87 and U251), which caused a decrease in VEGF 
mRNA and an increase in phosphorylated AKT (Pore et al., 2003). They proposed that 
EGFR activation and PTEN mutation co-operate through the PI3K pathway to increase 
VEGF mRNA levels. VEGF promoter activity was decreased by a PI3K inhibitor or by 
transfection with wild-type PTEN. In addition, this group showed that inhibiting EGFR 
and introducting wild-type PTEN together increased the expression of VEGF more than 
each on their own.
EGFR
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PI3K PTEN
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Figure 1.6 EGFR signalling pathway through PI3K. PI3K phosphorylates PIP2 to the 
active PIP3, while PTEN dephosphorylates PIP3. PIP3 promotes cell survival through the 
AKT pathway.
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The majority of astrocytic glioma grade IV tumours show disruption of the p53 
and retinoblastoma (RB) pathways arising from aberrations of genes such as p53, mouse 
double minute homologue 2 (MDM2), RB, cyclin dependent kinase 4 (CDK4), or cyclin 
dependent kinase inhibitor 2A (CDKN2A/INK4A) (Ichimura et a l, 1996). Each tumour 
generally has only one aberration from within each of the p53 or RB pathways (Ichimura 
et a l, 2000) (Collins, 2002). Loss of chromosome arm 17p was found in 40% of 
astrocytic gliomas grade II and III (von Deimling et a l, 1992a). This is associated with 
mutation in the remaining allele of p53. Loss of functional p53 within tumours can occur 
through p53 mutation, or the cell may have a molecular defect that limit activation of p53 
or reduce response to p53 (Vousden, 2000). p53 can be down-regulated in tumours 
through increased MDM2 (Chene, 2001; Chene, 2003; Chene, 2004). Small molecule 
antagonists of MDM2 have been shown to activate the p53 pathway in human tumour 
xenografts in nude mice (Vassilev et a l,  2004). MDM2 interacts with the ribososmal 
protein, L ll ,  to stabilise p53, and expression of L l l  induces a p53 response (Lohrum et 
a l, 2003).
CDKN2A encodes two proteins p l6INK4A encoded by transcript CDKN2Aa and 
p l4ARF encoded by transcripts CDKN2Af3, exons 2 and 3 are common to both genes 
(Stone et a l, 1995; Stott et a l, 1998). CDKN2A is a negative regulator of the cell cycle, 
p l6 INK4A inhibits Rb through inhibition of CDK4 and p l4MF activates p53 through 
MDM2 inhibition. Changes can occur in any of the components of the 
p l4ARF/MDM2/p53 pathway (Ichimura et a l,  2000). CDKN2B encodes pl5 and this does 
not appear to be mutated in glioma (Schmidt et a l, 1997).
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1.3.2.4 Genetic aberrations in different grades of astrocytic glioma
It is not possible to distinguish between astrocytic glioma grade IV tumours by 
histopathology. However, it is emerging that these tumours may be sub-classified using 
certain clinical features and genetic aberrations present in the tumour (Maher et al., 2001) 
(Figure 1.7). Some astrocytic gliomas grade IV appear to arise de novo, while others 
appear to arise by progression from lower grade astrocytic gliomas (Kleihues and 
Ohgaki, 1999). Patients with de novo astrocytic glioma grade IV have a mean age of 55 
years while secondary astrocytic glioma grade IV tends to occur in patients less than 
forty-five years old (Kleihues and Cavenee, 2000). However, while both forms have 
aberrations of both the p53 and the RB pathways, they differ in the targeted genes that 
code for the components of these pathways (Biemat et a l , 1995; Watanabe et al., 1996). 
Primary astrocytic glioma grade IV tumours arise de novo and tend to have EGFR 
amplification and no p53 mutation (Maher et al., 2001; Watanabe et a l , 1997). 
Astrocytic glioma grade IV tumours arising through progression from lower grades also 
have a lower incidence of PTEN mutation and amplification of EGFR (Tohma et a l , 
1998), and have higher expression of PDGFRA (Hermanson et a l, 1992).
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Figure 1.7 Proposed paths to the development of astrocytic glioma grade IV. 
Astrocytic glioma grade IV has been sub-classified into two groups, primary and 
secondary astrocytic glioma grade IV.
Distinctive genetic aberrations have been described in the different grades of adult 
astrocytic gliomas (Collins, 1999). Grade I tumours have had no consistent genetic 
abnormality identified (Bigner et al ,  1997; James et a l ,  1990). One study examined 
grade II tumours and the corresponding higher-grade tumour on tumour recurrence in 15 
patients (Weber et a l ,  1996). Five of the patients had an oligodendroglioma, 10 of them 
were astrocytic glioma grade II, 5 developed into astrocytic glioma grade III and 5 
developed into astrocytic glioma grade IV. Changes found in the astrocytic glioma grade
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II included loss of Xp and 5p and gain of 8q, 19p and 12p. Progression associated 
changes included losses on 4q, 9p, lOq, lip , 13q and gains on lq, 6p, 20q, 12pl3,13q32- 
q34, 7q31-qter, 12q22-qter and 18p. Other less frequent changes in astrocytic glioma 
grade II are LOH from chromosomes 6q, lOp, 13, 17p, and 22 (Hartmann et a l, 2004; 
Ichimura et al., 1996; Ichimura et a l , 1998; Miyakawa et al., 2000; Rasheed et al., 2002). 
The platelet derived growth factor (PDGF) and platelet derived growth factor receptor A 
(PDGFRA) genes are often over-expressed, but not amplified, in low-grade astrocytic 
gliomas (Hermanson et a l, 1992).
Astrocytic glioma grade III has the same pattern of changes as astrocytic glioma 
grade II, occurring at similar or higher frequencies, as well as loss of heterozygosity on 
19q, and lOq, or mutation of the PTEN gene (Ichimura et a l, 1998; Rasheed et a l,  2002; 
von Deimling et a l, 1994). More than 90% of astrocytic gliomas grade IV have LOH of 
chromosome 10, including PTEN (Ichimura et a l, 1998; Schmidt e ta l,  1999).
1.3.2.5 Genetic changes and prognosis
Several reports have suggested that particular genetic changes in high-grade 
astocytic gliomas are associated with a poorer prognosis (loss of 6q, lOq, and gain of 
19q) or with better survival (loss of 19q) (Balesaria et a l, 1999; Burton et a l, 2002). 
Abnormalities of the genes coding for proteins in the retinoblastoma pathway (CDKN2A, 
CDKN2B, CDK4 and RB) in combination with loss of both wild-type PTEN alleles are 
associated with shorter patient survival (Backlund et a l, 2003).
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1.4 Aims of this research
The aim of this research is to define the key genetic changes that are pertinent to 
the development and survival of astrocytic gliomas. The approach taken is to utilise array 
CGH to identify copy number changes in high-grade astrocytic gliomas. However, as 
array CGH is a new analytical tool, further consideration of its advantages and limitations 
is necessary. Hence, three key aims are studied in this thesis:
I The development of a comprehensive assessment tool for high-resolution array
CGH (Chapter 3).
II The analysis of high-grade astrocytic glioma cell lines and patient samples in
order to identify DNA copy number changes (Chapter 4).
III The use of FISH to explore the relationship between copy number changes
identified by array CGH and translocations identified by M-FISH (Chapter 5).
The study strategy (Figure 1.8) views cell lines and patient samples as separate 
model systems. Similar analytical techniques will be applied to both sets of samples and 
the findings compared.
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Figure 1.8 Strategy of the study
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Chapter Two 
Materials and Methods
2.1 Cell lines and Patient samples
Cell lines (CRL1620, CRL2020, CRL2365, CRL2366, CRL2610, CRL2611, 
Htbl38, U87, U118 and U251) derived from patients with high-grade (grade III and 
grade IV) astrocytic gliomas were obtained from the American Tissue Culture Collection 
(ATCC) and from Cancer Research UK London Research Institute Cell Production. Cell 
lines CRL1620, CRL2020, CRL2365, CRL2366, CRL2610, CRL2611, U87, U118 were 
derived from grade IV astrocytic gliomas. Htbl38 and U251 were reported as being 
derived from gliomas but the grade was not given. It is likely that these are also from 
astrocytic gliomas grade TV as it is difficult to generate cell lines from grade II and III 
tumours. Cell lines CRL2365 and CRL2366 were derived from a tumour from the same 
patient. The nine patients from whom cell lines were derived had an age range of 33-76 
with an average age of 57 years. The two patients from whom cell lines CRL2365/6 and 
U87 were derived were younger, being 33 and 44, respectively, while the older patients 
were 50-76 (Table 2.1).
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Cell line Sex Age Prior treatment
CRL1620 M 53 NA
CRL2020 F 59 Treated chemotherapy and radiotherapy
CRL2365 M 33 Untreated
CRL2366 M 33 Untreated
CRL2610 M 65 NA
CRL2611 F 60 NA
Htbl38 M 76 NA
U87 F 44 NA
U118 M 50 NA
U251 M 75 NA
Table 2.1 Cell lines used in the study
The patient samples were selected from a tissue bank in the Department of 
Pathology, University of Cambridge. The samples, T1-T10 were obtained from patients 
treated in Karolinska Hospital, Stockholm, Sweden. The samples were taken from the 
patients prior to treatment with radiotherapy or chemotherapy. DNA was obtained from 
Professor V.P. Collins, Department of Pathology, University of Cambridge. Professor 
Collins had previously worked in Sweden where the patients were treated. Ethics 
approval for use of the patient samples in this study were obtained from the Ethics 
Committee of Karolinska Hospital, Stockholm, Sweden (No. 91:16) and Cambridge 
Local Research Ethics Committee, Cambridge, UK (Ref. LREC 03/115). There were six 
males and four female patient samples. The age range was 55-78 with a mean age of 62.4 
years (Table 2.2).
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Patient ID Sex Age
T1 F 59
T2 F 78
T3 F 55
T4 M 71
T5 M 59
T6 M 60
T7 M 68
T8 F 56
T9 M 62
T10 M 56
Table 2.2 Demographics of patients whose astrocytic glioma grade IV samples were 
used in the study
Control DNA was extracted from blood samples volunteered from co-workers at 
Cancer Research UK London Research Institute.
2.2 DNA extraction
DNA extraction from blood and cells was performed using the QIAGEN QIAmp 
DNA blood maxi kit, with the protocol modified to extract DNA from cell lines. A 
medium-sized flask (T75) for cell culture contains approximately 0.6x107 cells. The cells 
were treated with trypsin, washed in phosphate-buffered saline (PBS) and suspended in 
10 mis of PBS. From this stage the same protocol was followed for 10 mis blood and for 
the cells in 10 mis of PBS. Cell lysis was achieved by the addition of 500 pi of proteinase 
K and 12 mis of buffer AL, followed by vortexing the sample 3 times for 5 seconds for
adequate mixing, and incubating at 70°C for 10 minutes. 10 mis of absolute ethanol was 
added, and the mixture vortexed to precipitate the DNA. Half the solution was then added 
to the QIAmp maxi column and centrifuged for 3 minutes at 1850 x g. The filtrate was 
discarded, and the remainder of the solution added to the QIAmp maxi column and 
centrifuged at 1850 x g for 3 minutes. As before, the filtrate was discarded. Five mis of 
buffer AW1 was then added to the QIAmp maxi column which was centrifuged at 4,500 
x g for 1 minute. Five mis of buffer AW2 was then added and centrifuged at 4,500 x g for 
15 minutes. The column was then placed inside a clean collecting tube, and 1ml of 
distilled water added and left to equilibrate for 5 minutes. The column was then 
centrifuged at 4,500 x g for 5 minutes. The filtrate was then re-loaded into the QIAmp 
column, again left for 5 minutes and centrifuged at 4,500 x g for 5 minutes. The 
concentration of the DNA in the filtrate was estimated using a spectrophotometer and 
stored at -20°C.
2.3 Metaphase CGH
CGH is a method for screening an entire genome for gains and losses of DNA. 
The CGH assay is based on the competitive hybridisation of fluorescently labelled test 
(tumour) and reference (normal) DNA onto human metaphase spreads and the subsequent 
measurement of the fluorescent signals along each chromosome. The relative values for 
normal and tumour DNA show the positions of the genomic losses and gains. 
Conventional CGH was performed using human metaphases from a normal male, broadly 
following standard methods (Kallioniemi etal., 1992).
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The probes were labelled directly by nick translation. One pg of each probe DNA 
was mixed on ice with 5 pi of nick translation buffer (lOx nick translation buffer: 0.2 mM 
dATP, 0.2 mM dCTP, 0.2 mM dGTP in 500 mM Tris-HCl pH 7.8, 50 mM MgC12, 100 
pM ME, 100 pi BSA) and distilled water to make up the total volume to 50 pi, with 1 pi 
of FITC-12-dUTP or Texas Red-5-dUTP, 10 pi of DNA polymerase/DNase mix and 1 pi 
of DNA polymerase I. The reaction mixture was incubated at 16°C for 2 hours (or until 
the labelled fragments were 500-2000 base-pairs). The mixture was stored on ice while 
5pl of the mixture was run on a 1% agarose gel to measure the size of the labelled 
fragments. When the fragments were the appropriate size, 2pl of EDTA was added and 
the mixture heated to 70°C for 5 minutes to denature the enzymes. The probes were then 
stored at -20°C until ready for hybridisation.
Labelled test (lpg) and control (lpg) DNA were mixed with 50pl of human Cotl 
DNA (1 mg/ml), 0.1 volume of 3M sodium acetate and two volumes of absolute alcohol. 
The Cotl DNA was added to inhibit the binding of labelled DNA to repetitive sequences 
in the target DNA (Kallioniemi et al., 1992). The mixture was then placed onto dry ice 
for 30 minutes to precipitate the DNA. The mixture was centrifuged at 13,000 rpm for 15 
minutes and the supernatant aspirated. The DNA pellet was air dried, re-suspended in 5pl 
of deionised formamide and incubated at 37°C for 30 minutes. 5pl of 2x hybridisation 
buffer (20% dextran sulphate, 4x SCC pH 7.0) was added and mixed. The DNA was then 
denatured at 75°C for 5 minutes and incubated for 1 hour at 37°C. During this incubation 
the target metaphases on the slide (Vysis) were denatured by placing the slide into 50mls 
of denaturation solution (70% deionised formamide, 2x SSC pH 7.0) heated to 73°C in a
66
water bath for 4 minutes. The slide was then placed in an ethanol series (70% ethanol 
(4°C), 95% ethanol and absolute ethanol, each for 2 minutes) to dehydrate the 
metaphases, and the slide then dried in air. Once the probe had incubated for an hour, the 
slide was placed on a hot plate (37°C) and lOpl of denatured probe applied to the area of 
the slide with the denatured metaphases. A 22 x 22 mm coverslip was placed over the 
target area, and rubber sealant applied to seal the edges. The slides were placed in a 
humidified chamber and incubated for 72 hours at 37°C.
Post-hybridisation, in low lighting conditions, the rubber cement and coverslip 
were removed and the slide was taken through a series of washes, 3 x 5  minutes in 50% 
formamide, 2 x SSC pH 7.0, then 3 x 5  minutes in 2 x SSC pH 7.0. These washes were 
performed in a Coplin jar placed in a shaking waterbath at 37°C. This was followed by a 
5 minute wash in SSCT (4 x SSC, 0.05 % Tween 20 pH 7.0). The metaphases on the slide 
were then dehydrated in a further ethanol series. The slides were air-dried, 30pl of 
mounting solution applied (DAPI, Citfluor and antifade), and covered with a 22 x 50 mm 
coverslip.
Images were captured using a Zeiss Axioplan epifluorescence microscope 
equipped with a Photometries KAF 14500-500 cooled charge-coupled device (CCD) 
camera and triple colour epifluorescence filter (selective for DAPI, FITC and rhodamine) 
connected to an Apple G3 computer. The image analysis was performed using software 
from QUIPS™. The automated karyotyping was checked manually.
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To define the fluorescence ratio levels for CGH, DNA from a normal male and 
female were used in control experiments. The fluorescence from each metaphase was 
captured (Figure 2.1). In these experiments, male DNA labelled with Texas Red and 
female DNA labelled with FITC were co-hybridised onto normal metaphases. The 
images were captured using different filters specific for DAPI, Texas Red and FITC. 
Panel A shows the DAPI counterstain. Panel B shows the inverted DAPI image with the 
classical G banding pattern. Panel C shows the Texas Red image. Panel D shows the 
FITC image. Panel E shows the composite CGH image in which the Y chromosome can 
be seen excessively red and the X chromosome is excessively green. The data in panel E 
are then collated to give the composite representation (Figure 2.2). The threshold was 
selected so that there were no changes detected on the autosomes. The threshold was set 
at gain if the ratio was greater than 1.1 and at loss if the ratio was less than 0.9.
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Figure 2.1 Composite images showing the same metaphase in a male versus female 
CGH control experiment
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Figure 2.2 CGH of male versus female control experiment.
The red line indicates a relative loss and the green line indicates a relative gain. In 
this case there is a relative loss of the Y chromosome and relative gain of the X 
chromosome. On the Y chromosome the pseudoautosomal region can be seen where the 
fluorescence ratio is nearer to the normal level.
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2.4 Array CGH
Array CGH is a modification of CGH and uses a similar method. The 
hybridisation platforms were obtained as part of a collaboration with The Wellcome Trust 
Sanger Institute (Fiegler et a l, 2003). Over three thousand BAC and PAC clones were 
selected from the Golden Path to give an average separation of 1 Mb. Human-specific 
DOP-PCR primers were used to amplify the clones. Following an amino-linking PCR 
reaction, the amplified DNA was then spotted onto glass slides. For control purposes, 
each clone was printed in duplicate, and Drosophila DNA was also used.
Random labelling o f DNA
DNA extracted from the patient samples and cell lines was labelled with Cy5 and 
normal male DNA was labelled with Cy3, using a Bioprime Labelling kit (Invitrogen). 
60pl of Random Primer Solution was added to 0.45pg of DNA and made up to 126pi 
with water. The solution was incubated at 100°C for ten minutes and then cooled on ice 
to denature the DNA. Fifteen pi of 10 x dNTP mix, 6pl of either Cy3 or Cy5 labelled 
dCTP and 3pl of Klenow Fragment were added to make a total volume of 150pl and the 
solution mixed gently. This solution was incubated at 37°C overnight and the reaction 
stopped by adding 15pl of EDTA.
Unincorporated labelled nucleotides were then removed from the labelled DNA 
using Micro-spin G50 columns. These columns were prepared by vortexing, with each 
placed in an Eppendorf tube and centrifuged in a microcentrifuge for one minute at 4,000 
rpm. The columns were then placed in new Eppendorf tubes and used to clean the
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labelled DNA. An aliquot (5}il) of each labelled DNA sample was then run on a 1% 
agarose gel to check the relative concentrations of test and reference DNA.
Preparations for hybridisation
Prior to hybridisation it is necessary to block repetitive sequences both in the 
clones on the hybridisation platform and in the labelled DNA. Repetitive sequences were 
blocked in the arrays with Cotl and Herring Sperm DNA and in the labelled DNA with 
Cotl DNA. The Pre-hybridisation Mixture (Herring sperm DNA, 135pl human Cotl 
DNA, 23pl 3M NaAc (pH 5.2) and 400pl of cold absolute ethanol) and Hybridisation 
Mixture (180pl Cy3 labelled DNA, 180pl Cy5 labelled DNA, 135jul human Cotl DNA, 
55pl 3M NaAc (pH 5.2) and 1ml cold absolute ethanol) were precipitated at -20°C 
overnight.
To prepare the slide for hybridisation, a wall of rubber cement was placed around 
the area of the slides with the clones to create a well for the Pre-Hybridisation and 
Hybridisation mixture.
The precipitated Pre-Hybridisation mixture DNA was then washed in ethanol, and 
dried and re-suspended in 160pl Hybridisation buffer (70°C). The Pre-hybridisation 
Mixture was then applied to the slide within the well created by the rubber cement wall. 
The slide was then placed in a humidity chamber (slide box containing a 2 x SSC/40% 
formamide mix on a Whatman paper strip), which was placed on a rocking table for 60 
minutes (5 rpm). Meanwhile, the precipitated Hybridisation Mixture DNA was then
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washed in ethanol and dried and re-suspended in 60 pi of Hybridisation Buffer and 6pl 
yeast tRNA (lOOpg/pl, dissolved in H2O at 70°C).
Hybridisation
The slide was removed from the humidity chamber and the Pre-Hybridisation 
Mixture removed with a pipette. The Hybridisation Mixture was then applied to the slide. 
It was important to ensure there were no bubbles and that there was even coverage of 
solution. The slide was then placed into a slide mailer humidified with 20% formamide/2 
x SSC, sealed with Parafilm and placed into a hybridisation oven at 37°C. The slide was 
incubated with gentle rocking (5 rpm) for 48 hours, with a turn of 90° after 24 hours.
Washing
The slide was then removed from the incubator, the rubber cement removed, and 
placed into a tall glass trough containing PBS/0.05% Tween 20 to wash off any excess 
hybridisation solution. It was then transferred to another glass trough and washed in 
PBS/0.05% Tween 20 for 10 minutes at room temperature (shaking). It was then 
transferred to a 50% formamide/2 x SSC solution and incubated for 30 minutes (rocking, 
maximum speed) at 42°C. The slide was then placed in fresh PBS/0.05% Tween 20 and 
washed for 10 minutes at room temperature. The slide was then removed and placed in a 
metal rack and centrifuged at 1000 rpm for 2 minutes to dry it. The slide was now ready 
to scan.
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Scanning
The fluorescent output from each fluorescent dye was measured in a confocal 
scanner ScanArray® 4000 (GSI Lumonics). This generated two images, one for the test 
and one for the reference. Figure 2.3 shows the output of one of the test samples (Cy 5 
fluorescence of experiment using cell line CRL1620). The colours of the spots are not 
actual but representative of intensity of the signal. The optimal signal range is blue, but as 
the signal intensity increases beyond blue there is a change in colour from green to red to 
white.
Data processing
The relative intensities of Cy5 and Cy3 were extracted from the array images 
using Spot (Jain et a l , 2002). This generated a text file containing the data and a TIFF 
image, which gave a graphical representation of the data and was used to check if the test 
and reference images have been correctly overlaid. At this stage the data are in a text file 
and are then processed in an Excel file. The first processing step checked the test and 
reference values against the Drosophila clones. If the test and reference clones were less 
than twice the median Drosophila clone then the clones were rejected. The raw log2 
ratios were normalised by dividing by the median raw ratio of the accepted values, and 
then the clones within each subarray were normalised using the median raw ratio of the 
subarray. There was then a check on the duplicate clone. The programme user could set 
an acceptable difference in these two values, and typically a value of 5-10% was used. If 
the difference was greater than this, the clone was excluded from further analysis. The 
clone ratios were then plotted against genomic location mapped against the July 2003
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Figure 2.3 Cy 5 fluorescence from an array
The clones were arranged into blocks of 18 by 18 (subarrays).
The blocks were arranged on the slide into 24 blocks, which were 6x4.
The clones were spotted onto the array in duplicate with one clone in one half 
of the array and its duplicate in the other half. Drosophila clones were inserted 
for control purposes into two of the subarrays.
freeze of the human genome sequence (NCBI133) within Ensembl 
(http://www.ensembl.org/Homo_sapiens/) to generate graphical representations of copy 
number for each chromosome (Figure 2.4).
2.5 Fluorescence in-situ hybridisation (FISH)
Standard FISH techniques were used (Senger et al., 1993). The Clones for FISH 
were selected from the Sanger Institute website (http://www.ensembl.org/Homo_sapiens) 
and requested from the Sanger Clone Library (http://www.sanger.ac.uk/cgi- 
bin/humace/CloneRequest) (Table 2.3). Additional probes for chromosomes 6, 7 and 9 
and 10 centromeres, chromosome paints for 6p, 6q, 7p and 7q and a dual probe to detect 
EGFR and chromosome 7 centromere were all obtained from Vysis.
Probe Cytogenetic location Position (Mb)
RP3-337H4 6p21.1 43.56 - 43.66
RP11-22124 6p21.1 43.66 - 43.71
RP1-261G23 6p21.1 43.70 - 43.88
RP11-344J7 6p21.1 43.88 - 43.96
RP11-227E22 6p21.1 43.96 - 44.05
RP11-346N8 6ql6.1 93.89 - 94.09
RP11-557H15 6q23.2 134.78 - 134.97
RP11-448D5 6q23.3 137.23 - 137.23
RP11-368P1 6q24.1 142.22 - 142.36
RP11-8604 6q24.2 143.50 - 143.62
RP11-13P5 6q25.3 159.46- 159.57
RP3-495O10 6q26 163.59 - 163.78
RP1-51J12 6q26 163.85 - 163.97
RP11-517H2 6q27 167.48 - 167.58
RP11-471L1 6q27 168.05- 168.11
RP11-513M16 9p22.1 19.31 -19.42
RP11-14912 9p21.3 21.89-22.00
RP11-495L19 9p21.3 23.37 - 23.55
Table 2.3 Probes obtained from Wellcome Trust Sanger Institute for FISH
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Figure 2.4 Whole genome array profile of a male versus female DNA control experiment.
The X axis shows the chromosome number and the Y axis is the fluorescence ratio on a log2 scale.
The male DNA was used as the control and the result shows relative gain of the X chromosome and 
loss of the Y chromosome.
The stabs of the clones could be stored for up to four weeks at 4°C until ready for 
use, but they were usually grown within a few days. The agar plates were prepared by 
heating liquid broth to 50°C in a water bath. The appropriate antibiotic was added (Table 
2.4). The liquid broth was poured into a plate, allowed to set and then turned upside 
down. The plates could be stored in a fridge at 4°C covered with tin foil. All procedures 
involving the clones or preparing the agar plates were performed using a blue flame from 
a Bunsen burner to prevent contamination.
To grow the clones, an aliquot was taken with a loop from the stab, and placed in 
10ml of LB with the appropriate antibiotic. The clones were then incubated in a shaking 
oven at 37°C for 8 hours. Using a loop, a sample from the culture was streaked onto an 
agar plate. Then a fresh loop was taken and streaked through the first streak, this time 
going around the plate. The plate was inverted and incubated at 37°C overnight.
Clone
Type
Library
Code
Sanger
Code
Agar Antibiotic Growth
Temperature
PAC RP-1,3,4,5 dJ LB Kanamycin 37°C
PAC RP-6 dA LB Kanamycin 37°C
PAC RP-21 dM LB Kanamycin 37°C
BAC RP-11 bA LB Chloramphenicol 37°C
BAC RP-13 bB LB Chloramphenicol 37°C
Table 2.4 Growth conditions for clones from the Sanger Clone Library. 
Kanamycin (25 pg/ml), Chloramphenicol (20 pg/ml), LB=liquid broth
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The following morning a single colony was selected and inoculated into lOmls of 
LB and appropriate antibiotic and placed into a shaking oven at 37°C overnight. Glycerol 
stocks were prepared by adding 800pl of the culture to 200pl of glycerol. These were 
stored at -80°C. The remainder of the culture was placed in a centrifuge at 1,500 rpm for 
5 minutes, the pellet was dried and a mini-preparation of plasmid DNA performed to 
extract the DNA. (The Equipment Park at Cancer Research UK performed the mini­
preparations using a Qiagen kit).
To generate larger quantities of DNA, a sample was taken from the glycerol stock 
of a particular clone and inoculated into 10ml of LB with antibiotic. Eight hours later, 20 
tubes containing 10ml of LB and antibiotic were prepared and inoculated with 200pl of 
culture. These were then incubated in a shaking oven at 37°C overnight. Each 10ml was 
centrifuged at 1,500 rpm for 5 minutes and the pellet dried prior to extraction of DNA.
Following DNA extraction, an estimation of the DNA concentration was made 
using a spectrophotometer. Digoxigenin labelling mixture (5pl) and 5pi of 10 x enzyme 
mixture were added to lpg of probe DNA and made up to 40pl with water. The mixture 
was placed at 16°C until the fragments were the appropriate size (500 bp), which 
typically took 85 minutes. Five pi of the mixture was run on a 1% agarose gel to check 
the fragment size. EDTA (5pl) was then added and the mixture heated to 60°C for 5 
minutes to inactivate the enzymes.
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Hybridisation
Prior to hybridisation, the chromosomes on the slide were firstly aged in a 
microwave for 2.5 minutes. Denaturation Mixture (70% Formamide, 2 x SSC) (90|nl) was 
then placed on the slide under a 22 x 50 mm coverslip, and the slide placed on a hot plate
at 73°C for 3 minutes to denature the chromosomes. The slide was then washed in cool 2 
x SSC and dehydrated in an ethanol series.
The probes were then prepared for hybridisation. Labelled DNA (300ng, 15pi) 
was precipitated with 5pl of human Cotl, 2pl salmon sperm DNA, 2pl of 3 M NaAc and 
300pl of absolute alcohol on dry ice for 30 minutes (or -20°C overnight). The tube was
then centrifuged at 15,000 rpm for 15 minutes at 4°C, dried in air and the DNA re­
suspended in 11 pi of Hybridisation Mixture (50% formamide (ultrapure), 2 x SSC, 10%
dextran sulphate). The probe was denatured on a heating block at 85°C for 5 minutes and
then incubated at 37°C for 30 minutes. Following this, the slide was pre-warmed on a
heating block at 37°C and the denatured probe applied to a selected area of the slide. The 
hybridisation area was then sealed under a cover slip with rubber cement and the slide
was placed in a moist chamber at 37°C overnight.
Post hybridisation washes & detection
The slide was washed in 50% formamide, 2 x SSC, pH 7.0 at 42°C three times for
5 minutes each with gentle shaking and then in 1 x SSC, pH 7.0 at 60°C three times for 
five minutes each. Then without allowing slides to dry, the hybridisation area was 
blocked in 90pl of SSCTM (4 x SSC, 0.1% Tween 20 (SSCT) + 5% Marvel) and
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incubated at 37°C for 25 minutes. The blocking solution was drained from the slide and 
9 0 jli1 of the detection antibody (diluted in SSCTM) applied and covered with a coverslip 
(22 x 50 mm). Antibodies avidin-FlTC 1:300 and anti-dig-rhodamine 1:100 were used
for detection by incubating at 37°C for 45 minutes, followed by washing for 3 x 5
minutes in 4 x SSC, 0.1% Tween 20 (SSCT) at 42°C. The chromosomes were then
counterstained with DAPI (0.3 pg/ml) in Citifluor and stored at 4°C in the dark. The 
images were captured with a Photometries KAF 1400-500 cooled CCD camera attatched 
to a Zeiss Axioskop epifluorescence microscope.
2.6 M-FISH
Pre-treatment o f slide with metaphase spreads
The slide with the metaphase spreads needed to be treated to remove cellular 
debris. RNase working solution (lOOpl) was applied to the slide under a 22 x 50 mm 
cover slip at 37°C for 30 minutes to remove RNA. The slide was then washed in 2 x SSC 
at room temperature ( 2 x 5  minutes). It was then placed in pepsin working solution (pre­
warmed to 37°C) for 5 minutes to remove proteins, cellular debris and cytoplasm. The 
slide was then washed in PBS at room temperature ( 2 x 5  minutes) and placed in 
formaldehyde fixation solution at room temperature for 2 minutes. The slide was again 
washed in PBS at room temperature ( 2 x 5  minutes), placed in an ethanol series to 
dehydrate the DNA and dried in air.
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Hybridisation
The slide was placed in denaturation solution (70% deionised formamide, 2 x 
SSC pH 7.0) at 72°C for 1 - 3 minutes and then in an ethanol series and dried in air. The 
probe (lOpl) was denatured in a 72°C water bath for 5 minutes and applied to the slide. A 
22 x 22 mm coverslip was applied and sealed with rubber cement. The slide was place in 
a warm chamber and incubated at 37°C overnight.
Post-hybridisation washes
The slide was placed in 0.4 x SSC, 0.3% NP-40 at 72°C for 5 minutes, washed in 
2 x SSC, 0.1% NP-40 at room temperature for 3 minutes, then air dried in the dark. DAPI 
III counterstain (40pl) was applied under a 22 x 50 mm coverslip. The slide was then 
ready for image acquisition with a CCD camera and fluorescence microscope.
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Chapter Three 
Development of analysis parameters for array CGH
3.1 Introduction
Conventional or metaphase comparative genomic hybridisation (CGH) is a 
hybridisation-based method of assessing DNA sequence copy number across the whole 
genome (Kallioniemi et a l,  1992). Differentially labelled test and control DNAs are 
competitively co-hybridised onto metaphase chromosome spreads. The relative 
intensities of the fluorochromes across each target chromosome show the positions of 
genomic loss and gain. Since hybridisation of repetitive DNA sequences gives 
inconsistent data for assessing copy number change, unlabelled repetitive DNA is 
included in the hybridisation to block out this effect. Hence, within an individual 
experiment there are three elements competing to hybridise to the target DNA: labelled 
test and control DNA, and unlabelled Cotl DNA containing repetitive sequence. 
Differences in experimental conditions cause variation in hybridisation efficiency, 
leading to variation around the true value of the hybridisation ratio of the two competing 
elements of labelled test and control DNA. To reduce the effects of variation across a 
slide, within an experiment, a composite CGH profile is derived from the averaging of at 
least five metaphase profiles.
Array CGH is a refinement of metaphase CGH, the main difference being the 
hybridisation platform. In metaphase CGH, the hybridisation platform consists of 
metaphase chromosomes, whereas in array CGH the chromosomes are replaced with
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mapped fragments of DNA sequence arrayed onto a glass slide (Pinkel et a l , 1998; 
Solinas-Toldo et al., 1997). There are two broad categories of hybridisation platform 
used in array CGH. The first has genomic sequence in bacterial artificial chromosome 
(BAC) and PI artificial chromosome (PAC) clones (Pinkel et a l , 1998) and the second 
has complementary DNAs (cDNA) clones (Pollack et a l , 1999). (BAC and PAC are 
vectors used for cloning relatively large fragments of DNA. cDNAs are generated by 
converting RNA to DNA before insertion into a cloning vector.) The advantages of using 
cDNAs are that they give gene specific information and are not subject to mapping 
errors, as are genomic arrays. In addition, the probes are smaller and the array platforms 
are less labour intensive to produce. However, since cDNA clones are produced from 
RNA, they may have differences in sequence as a result of alternative intron splicing. The 
advantages of using genomic sequences are that these arrays cover non-expressed regions 
of the genome and have better hybridisation characteristics, as the probe and the target 
sequence have greater homology.
The challenges faced in array CGH are similar to those encountered with 
metaphase CGH. Array CGH is prone to both inter- and intra-experimental variation. The 
aims of this chapter are to gain a better understanding of experimental variability in array 
CGH and to devise a method of formulating a threshold to define regions of gain and loss 
in experimental samples.
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3.1.1 Thresholds and experimental variation
In metaphase CGH two numerical thresholds are set. One threshold is used to 
define gain and the other to define loss. The convention in metaphase CGH is to set the 
thresholds based on control experiments, the ideal thresholds being values that optimise 
the balance between false positives and false negatives. The ratio of normal copy number 
is 1. The threshold for copy number change varies between users, but in general, 
thresholds of gain are set from to 1.1 to 1.15 and loss from 0.85 to 0.9. Array CGH is a 
more sensitive technique with a ratio being given for each datum point on the array. 
Array CGH is sufficiently sensitive to determine amplification, where the ratio will be 
very high. For this reason the ratios are expressed as log2 ratios (Table 3.1). Hence, 
regions of normal copy number in a diploid nucleus (2:2) and a tetraploid nucleus (4:4) 
have a ratio of 1 and a log2 value of 0. Aneuploidy makes CGH analysis more 
complicated as, for example, a single copy loss in a tetraploid cell line has a 3:4 ratio, 
which is a log2 ratio of -0.41.
Copy number Ratio Log2 ratio
Diploid Tetraploid
0:2 0:4 0 -Infinity
- 1:4 0.25 -2
1:2 2:4 0.5 -1
- 3:4 0.75 -0.41
2:2 4:4 1 0
- 5:4 1.25 0.32
3:2 6:4 1.5 0.58
- 7:4 1.75 0.81
4:2 8:4 2 1
10:2 20:4 5 2.32
20:2 40:4 10 3.32
Table 3.1 Ideal fluorescence ratios with corresponding log2 values.
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In conventional CGH there is averaging of results between metaphases, but 
variation is still apparent (Kallioniemi et al., 1992). Array CGH is a more sensitive 
technique than conventional CGH, and this generates its own challenges in interpreting 
results. While conventional CGH tests copy number of regions of a chromosome, array 
CGH tests copy number change of individual regions that are limited by the size of the 
probe.
In the control experiments where normal male and female DNA were used as the 
test and reference DNA, the autosomal clones should have a log2 ratio of zero. However 
deviation from zero is apparent (Figure 3.1). If thresholds of ±0.2 were selected then 
regions of the chromosome would be incorrectly called gain and regions incorrectly 
called loss (false positives).
In a female versus male DNA control experiment, the X chromosome ratio is 2:1, 
which should give a log2 ratio of 1. Again, variation from the expected value across the 
chromosome is apparent (Figure 3.2). If the threshold for gain is set at log2 of 1 (log2 
ratio of 2:1=1) then no region of the chromosome would be classed as gain (false 
negative). Even if the threshold were reduced to log2 0.5, although most of the 
chromosome would be called gain, there would still be regions classed as no copy 
number change.
The clone-to-clone variation within a region of change also contributes to the 
problem of defining thresholds between normal and change in copy number. However
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Figure 3.1 Array CGH profile of chromosome 19 in a female (test) versus male 
(control) experiment. Chromosome 19 consistently showed the greatest varaibility 
from the expected ratio in control experiments.
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Figure 3.2 Array CGH profile of the X chromosome in a female (test) versus male 
(control) experiment.
there are several limiting factors that need to be considered in an experiment on tumour 
cells, including the presence of contaminating normal DNA, tumour heterogeneity and 
incomplete suppression of repeat sequences in the probes (Snijders et al., 2001). As with 
all experimental methods, array CGH is limited by sensitivity and specificity and the 
balance between these is defined by the threshold that is used in the analysis. The 
optimum threshold is a value that maximises sensitivity without over-compromising 
specificity.
This intra-experimental variation makes it difficult to interpret all the data from an 
experiment. What is needed is a method of analysis that will compensate for this 
variation. Although in array CGH, each clone gives an independent log2 ratio, the results 
are linked in that all the clones in a region of change (for example the X chromosome in 
the female/male DNA control experiment) should show change. Thus, the likelihood of 
one clone having the same copy number ratio as its neighbours can be used in the 
analysis of array CGH experiments.
3.1.2 Analysis parameters used in other array CGH studies
One of the earliest studies with array CGH used lambda DNA in different test 
dosages to show that DNA copy number could be predicted using this technique (Pinkel 
et a l , 1998). However, as discussed above, it can be difficult to distinguish between 
‘signal’ (true copy number change) and ‘noise’ (region of no change where the deviation 
from zero is due to experimental variation). To overcome this problem some groups have 
used set thresholds in their analysis (Cai et al., 2002; Snijders et a l, 2001; Veltman et a l,
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2003), while others have used moving thresholds that change according to the value of 
the neighbouring clones (Clark et a l , 2003; Clark et a l , 2002; Pollack et a l, 2002).
One study using set thresholds for detecting copy number change in bladder 
tumours, selected log2 thresholds of 0.2 for gain and -0.2 for loss (Veltman et a l, 2003). 
It is not transparent how these figures were reached except that they were based on eight, 
sex-mismatched, control experiments. It is inferred that the thresholds, for what are 
described as homozygous deletion or amplification, were based on the numerical value of 
the log2 value of the 2:1 ratio. Hence, scores above 1 were considered amplification and 
those below -1 as homozygous deletion. Analysis of homozygous deletion of CDKN2A 
by quantitative real-time PCR showed that fourteen of the tumours had a homozygous 
deletion of this gene and these had a mean log2 ratio of -2.16. (However, 3 tumours had 
log2 ratios of -0.63, -0.68 and -0.74). Twenty tumours showed normal copy number of 
CDKN2A by PCR, but the array for one of these gave a log2 ratio of -0.21.
A different study using an array of 960 BACs from the mouse genome set the 
thresholds at 1.2 and -0.8. These thresholds were based on autosomal chromosome 
variation of 0.85-1.15 with a coefficient of variation of 8% (Cai et a l, 2002).
Snijders et al examined breast tumours with array CGH (Snijders et a l, 2001). 
Figure 3.3 is taken from this study and it demonstrates that a threshold of log2 ratio -0.5 
excludes some clones within regions of what appear to be loss. If the threshold is reduced
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to -0.25, still not all the clones are included and there is overlap with clones from other 
regions, which may be normal.
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Figure 3.3 Array profile from Snijders et al (Snijders et al ,  2001).
To address the problems in using set thresholds some groups have used moving 
thresholds, where the value of the surrounding clone is taken into account in interpreting 
the results (Clark et a l ,  2003; Clark et al ,  2002; Pollack et a l ,  2002).
3.1.3 Aims
As yet there is no firm consensus as to how the results from array CGH 
experiments should be analysed. The simplest approach is to present data from selected 
regions only, showing for example, homozygous deletions and amplifications, which are 
easy to identify. Although single copy changes are more difficult to distinguish from 
normal, especially within a tetraploid genome, they may be very relevant. The array CGH 
platform used here facilitates a genome-wide survey of copy number change and I wished 
to present all the data. Therefore, a pragmatic and objective approach was needed to 
allow rational comparisons to be made between data sets. The aims of this chapter are 
firstly, to examine both inter- and intra-experimental variation in control experiments of
genome order 1pter to Xqter
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array CGH. Secondly, to examine the effect of altering thresholds on the interpretation of 
results. And thirdly, to use these investigations to devise an objective analytical tool for 
genome-wide array CGH. The statistical analysis for the interpretation of array CGH 
results was performed in collaboration with Professor Peter Sasieni, Cancer Research UK 
Centre for Epidemiology, Wolfson Institute for Preventive Medicine, London.
3.2 Materials and Methods
Six control array CGH experiments were performed using DNA from normal 
males and females. The fluorescence ratio of each clone was plotted on an Excel graph 
against its position along the chromosome. These test hybridisations provide three models 
for interpreting genetic changes in cancer. The autosomal clones represent the behaviour 
of normal regions of DNA, in a male versus female experiment the Y chromosome clones 
represent homozygous deletions, and in a female versus male DNA experiment the X 
chromosome clones represent a single copy loss in a diploid nucleus.
3.2.1 Additional pre-processing
Each experiment had a different experimental quality depending on factors such 
as the batch the slides came from, the production batch of Cotl DNA and whether the 
slide dried out during hybridisation. A poor quality experiment gives fluorescence ratios 
that deviate from the true value more than for good experiments. In practice, it was 
straightforward to see when an experiment had not worked sufficiently well because there 
was variation in noise intensity across the slide and an increase in background signal. 
Methods of quantifying this variation were considered. For example, the spread of the
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data could be measured. The spread is the difference between the greatest value and the 
least. As the spread of data can give a skewed view of the data due to outlying values, the 
inter-quartile range of locally centred values was used to measure variation. The inter­
quartile range is the difference between the 75th percentile and the 25th percentile. If this 
value was greater than 0.275 then the experimental results were not used and the 
experiment was repeated.
The data in each included experiment were re-scaled so as to take account of the 
variable variability of the results. The effect of this is to use thresholds specific for each 
experiment. We determined the difference between each marker's log2 ratio and the local 
average (from the 5 down-stream and the 5 up-stream markers), and then scaled all log2 
ratios by the inter-quartile range of these differences for the 22 autosomal chromosomes. 
Each experiment was normalised to an inter-quartile range of 1.
A further re-scaling was made using a chromosome specific factor obtained from 
the six control experiments. The chromosome specific factors were derived from the 
inter-quartile range of each individual chromosome, after the control data were 
normalised.
3.2.2 Sensitivity and specificity
The sensitivity of a test is the proportion of actual gains and losses identified. The 
specificity is the proportion of actual nulls identified. In the six control experiments, the 
autosomes were the known null and the mismatched sex chromosomes were the known
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gain and the known loss. Table 3.2 shows the hypothetical results from known results and 
test results and how this can be quantified.
Test results
Loss Null Gain Totals
Actual Loss A=True positive B=False negative C=False positive A+B+C
Actual Null D=False positive E=True negative F=False positive D+E+F
Actual Gain G=False positive H=False negative I=True positive G+H+I
Table 3.2 Table of results from a hypothetical experiment 
Sensitivity = (A+I) /  (A+B+C+G+H+I)
Specificity = E / (D+E+F)
A receiver operating characteristic (ROC) curve plots the sensitivity against ‘one 
hundred minus the specificity (%)’ at different thresholds and this curve is then used to 
select the optimum threshold criteria.
3.3 Results
Three sets of results were obtained from this analysis of the control experiments. 
Firstly the list of clones that were discarded due to inconsistent or aberrant hybridisation 
characteristics, secondly the chromosome specific scaling factors and, thirdly, the ROC 
from which the threshold for the analysis can be selected.
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3.3.1 Discarded clones
The clones representing the autosomes in male versus female DNA experiments 
that do not show a log2 ratio of around 0 were excluded from the analysis, i.e. markers 
that consistently gave large positive or negative results, or both, in the control samples 
(Table 3.3).
Chr Clone position 
(Mb)
Clone name
1 0.2 CTB-14E10
2 190.0 CTC-444N24
4 3.5 RP11-492123
4 191.3 CTC-963K6
5 10.4 CTD-2274H20
5 14.5 RP1-29012
5 27.3 CTD-2219P12
5 162.2 RP11-505G12
6 33.4 RP11-175 A4
6 169.3 RP1-137D17
7 0.7 RP11-449P15
7 99.7 RP11-44M6
8 144.1 RP5-1118A7
8 144.2 RP11-472K18
9 132.5 RP11-83N9
10 135.0 RP11-122K13
11 64.1 RP11-424011
11 65.1 CTB-184C17
12 49.0 RP11-302B13
12 133.3 CTC-221K18
13 56.6 RP11-279F15
Chr Clone position 
(Mb)
Clone name
13 113.8 RP11-245B11
14 81.1 PR11-406A9
15 19.7 RP11-2F9
15 87.9 RP11-233C13
16 1.0 RP11-161M6
16 2.1 CTB-121I4
16 89.6 CTC-240G10
16 89.7 RP11-533D19
17 4.8 RP5-1050D4
17 37.2 RP5-906A24
17 80.7 GSI-50C4
17 81.2 RP11-567016
18 73.9 RP11-234N1
18 76.9 RP11-315M18
18 77.2 RP11-154H12
19 5.0 CTC-482H14
19 13.1 CTC-250I14
19 18.2 CTC-251H24
20 61.1 RP5-1107C24
21 43.6 RP11-351D2
22 39.4 RP3-355C18
Table 3.3 List of discarded clones
3.3.2 Chromosome scaling factors
The following figures were calculated from a measure of the inter-quartile range 
of the log2 ratios of each chromosome when collated from all six control experiments
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(Table 3.4). Chromosome 19 is the chromosome with greatest variability and therefore 
has the largest scaling factor. The inter-quartile range of chromosome 19 in the 
normalised samples was 2.2. These inter-quartile ranges were then used as scaling 
factors. For example, each normalised log2 ratio on chromosome 19 was divided by 2.2.
Chromosome Scaling factor
1 1.15807
2 1.034719
3 1.078727
4 1.175389
5 1.069797
6 1.032107
7 1.177455
8 1.091517
9 0.986733
10 1.108118
11 1.192114
Chromosome Scaling factor
12 1.108734
13 1.087662
14 1.190092
15 1.028538
16 1.209821
17 1.249908
18 1.157617
19 2.210811
20 1.23505
21 1.201608
22 1.414799
Table 3.4 Chromosome-specific scaling factors used in the statistical analysis
3.3.3 Identification of thresholds from the ROC
3.3.3.1 Dual thresholds
The first method for analysing copy number change used two separate thresholds 
for gain and two separate thresholds for loss based on control experiments (Figure 3.4, 
Algorithm A). The standard deviation of the autosomal clone log2 ratios was 0.09 in the 
control experiments. For loss the more stringent threshold was set at (-3SD -0.01) and a 
less stringent threshold was set as (-1SD -0.1). This translated into a more stringent 
threshold of log2 -0.28, [(-0.09 x 3) -0.01] and a less stringent threshold of log2 -0.1, 
(-0.09 -0.01). Hence, when defining a region of loss the value of -3 SD from the zero
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ROC curve
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Figure 3.4 ROC curve. Different thresholds were selected to test the effect on 
sensitivity and specificity.
Algorithm A
Algorithm B1
Algorithm B2
- N - Algorithm B3
Algorithm B4
— Algorithm B5
-0.1, needed to be achieved and the surrounding clones were also considered to be loss if 
the value was less than -0.1. The converse rules were applied for gain (Figure 3.4, 
Algorithm A). To assess how altering the more stringent threshold affected the sensitivity 
and specificity, the more stringent threshold was varied to ±0.25, ±0.28 and ±0.35 (Figure
3.4, Algorithm A). As the more stringent threshold was reduced the sensitivity increased 
but the specificity decreased. The less stringent threshold was altered from ±0.08 to ±0.1 
and ±0.14. There was very little change in the data with this variation (Data not shown), 
and hence for the example demonstrated, the less stringent threshold was left at ±0.1. It 
can be seen that by using Algorithm A, no threshold combinations would give a 
sensitivity approaching 100%. Hence, to improve the sensitivity of the analysis a more 
sophisticated analytical algorithm was developed (Algorithm B).
3.3.3.2 Single threshold based on multiple parameters (Algorithm B)
The threshold for a single marker was set so as to give a theoretical false positive 
rate of approximately 2 false gains and 2 false losses per 10,000 markers in control 
experiments. Because most regions of gain/loss detected by the array are longer than one 
mega-base, we used less stringent thresholds for consecutive markers. Thus we also used 
theoretical thresholds (using the Normal distribution and independence of consecutive 
marker values) for the minimum (maximum) of 2, 3, 4 or 5 consecutive markers 
exceeding a given positive (negative) value so as to detect a gained or lost region (Figure
3.4, Algorithm Bl). We also classified longer regions as being gained or lost if the 
average value of five consecutive markers consistently (over 25 clones) crossed an 
appropriate threshold (Figure 3.4, Algorithm B2). We defined all clones with log2 ratios
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close to zero as null. At this stage there are regions defined as loss, gain, null or other. 
The values of regions defined as other were then averaged and classified as either gain, 
loss or null depending on the mean value of the number of clones involved (Figure 3.4, 
Algorithm B3). All markers have now been assigned a value of loss, gain or null. The 
next stage then determined if these classifications were correct. An average value of null 
regions was taken to assess if they are similar to the surrounding regions and if they were 
similar then they were re-classified. Following this all regions of loss or gain were then 
assessed and at least one quarter of all the clones in a particular region had to cross one 
threshold value, and three quarters have to cross another threshold and if not they are 
classified as null (Figure 3.4, Algorithm B4). Finally, we merged regions if the log2-ratios 
of the markers between two markers showing gain or deletion were consistent with 
continued gain or loss across the extended region (Figure 3.4, Algorithm B5). Professor 
Sasieni automated this method of analysis using a programme written in ST AT A. The 
programme is currently being written in Excel format to facilitate wider use.
Using the full Algorithm B (including all steps B1 - B5), 229 (1.26%) of 18175 
control markers were falsely identified as losses and 288 (1.58%) as gains, with an 
overall specificity of 97.2% (three markers were on the boundary between regions of loss 
and gain and were included in both categories). The sensitivity in regions of known loss 
was 98.7% (for 624 markers). It was 99.7% for areas of known gain (309 markers).
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3.4 Discussion
This chapter has described the development of an automated method of analysis 
of array CGH that can be used to provide an objective assessment of results thus allowing 
comparisons between experimental sets. Examination of multiple tumour samples allows 
the frequency of genetic changes to be calculated and also minimal regions of deletion 
and gain to be defined. However, it should be remembered that a single genetic change in 
a single tumour might be significant in that tumour.
3.4.1 Errors
False positive results can be classified into two categories, statistical errors or 
errors relating to the characteristics of the reporter clone.
3.4.1.1 Statistical issues
Depending on the thresholds used, different levels of sensitivity and specificity 
are obtained. With 99% specificity, one null clone in a hundred will be a false positive. 
Hence, for a 3000-clone array (with little loss or gain) 30 clones will give false positive 
results. This may be an acceptable number of false positives, but if the array had 30,000 
clones and the specificity was 99% then there would be 300 false positive results. With 
any method of analysis there are invariably going to be some false positives due to the 
analytical methodology and it is up to the individual user to decide which thresholds 
should be set, depending on the aims of the experiment.
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3.4.1.2 Clone characteristics
In a control experiment, if a clone fails to give the expected log2 ratio, it may be 
that the clone is mis-labelled or mis-mapped, or contain a large proportion of repetitive 
sequence or sequence polymorphism. If a clone is mis-labelled or mis-mapped, as a clone 
in an autosomal region but is in fact a clone from the X chromosome, in a male versus 
female control experiment, the clone will consistently give a result indicating copy 
number change and therefore should be removed from the analysis. If a clone is mis­
labelled or mis-mapped and both the true and false clone positions are within the 
autosomes, then this will not be detected by the sex mismatch controls. FISH mapping 
clones showing copy number changes to normal human metaphases will confirm their 
genomic positions. Sequencing the clones and comparison with the sequence database 
could also be used as a check. Clones with a high content of repetitive sequence give 
unreliable hybridisation characteristics, as the effect of repetitive sequences may not be 
completely suppressed by the Cotl DNA
3.4.1.3 Genetic heterogeneity
Individuals show sequence variation between their genomes. Variation ranges 
from the level of the individual nucleotide where variation from single nucleotide 
polymorphisms (SNPs) is found, up to variation in copy number of hundreds of 
kilobases, termed large-scale copy number variation (LCV) (Iafrate et a/., 2004; Sebat et 
a l , 2004). The significance of LCV is not known, however it is conceivable that it may 
play a role in cancer susceptibility. The effects of variation such as LCV in genomes in
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array CGH could be overcome by using DNA derived from the blood of the test 
individual as the control.
In summary, this chapter has raised some of the difficulties in interpreting array 
CGH results and has described a method of analysis to objectify this interpretation. The 
next chapter uses this method of interpretation in the array CGH analysis of high-grade 
astrocytic glioma cell lines and patient samples.
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Chapter Four
DNA Copy Number Changes in High-Grade Astrocytic Gliomas
4.1 Introduction
Array CGH is a rapidly evolving method, and the utilisation of this technology is 
increasing. The first study published using array CGH had low resolution, but 
demonstrated the potential of the method (Solinas-Toldo et al., 1997). Array CGH was 
used again in 1998 in the analysis of four breast tumours, and showed gain on 
chromosome 20, which was confirmed by FISH (Pinkel et a l , 1998). A low resolution 
array CGH system developed by Vysis was used to examine seven cell lines and seven 
tumours from patients with astrocytic glioma grade IV with only 58 clones specific for 
known oncogenes (Hui etal., 2001). No novel findings were described.
This chapter describes the copy number changes detected by array CGH, with 
examples of confirmation of results by metaphase CGH in ten astrocytic glioma grade IV 
patient samples and ten high-grade astrocytic glioma cell lines. The array CGH platforms 
used in this study were developed as part of a collaboration between the Sanger Institute 
and Cancer Research UK. The resulting hybridisation platforms had 3000 BAC and PAC 
clones with an average separation of 1Mb (Fiegler et al., 2003).
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4.2 Results
Array CGH was performed on ten astrocytic glioma grade IV tumour samples and 
ten high-grade astrocytic glioma cell lines (Chapter 2.1.2). In addition, conventional 
CGH were performed on the cell lines. Multiple regions of copy number change across 
the genome were revealed by array CGH. Array CGH revealed, on average, 5.2% of the 
autosomal genome was deleted in the primary tumours and 14.9% in the cell lines. The 
corresponding figures for gain were 5.2% and 11.7%, respectively. By comparison, the 
percentages of deletions and gains (false positives) in control samples were 0.5% and 
0.1%, respectively.
Conventional CGH identifies regions on the chromosome by cytogenetic banding. 
Array CGH identifies regions by chromosome number and nucleotide position, which are 
given in megabases (Mb). To assist in the interpretation of the data, the size of each 
chromosome and the positions of the centromeres are set out in Table 4.1. However 
heterochromatic regions are refractory to array CGH analysis and are therefore excluded 
from the results. The sex chromosomes are excluded from the analysis, as the samples 
were not sex matched.
103
Chromosome Length
(Mb)
Centromere
(Mb)
1 245 123
2 243 93.4
3 199.3 91.4
4 191.6 50.9
5 190.0 47.7
6 170.7 60.4
7 158.4 58.5
8 145.9 44.8
9 134.5 46.5
10 135.4 40.3
11 135.0 53.6
Chromosome Length
(Mb)
Centromere
(Mb)
12 133.4 36.0
13 114.1 16.0
14 105.3 15.6
15 100.1 17.0
16 90.0 37.4
17 81.6 23.7
18 77.8 16.7
19 63.8 28.4
20 63.6 27.7
21 47.0 12.3
22 49.4 11.8
Table 4.1 Chromosome size and position of the centromere in megabases (Mb).
4.2.2 Copy num ber changes presented in numerical chromosome order
Selected findings are presented in chromosome order and, in particular, affected 
genes involved in neural development or in known pathways in cancer are highlighted. 
The genetic locations of the changes are also given. When delineating the region involved 
in a copy number change, the flanking normal clones are used as the boundaries and each 
breakpoint is therefore between an aberrant clone and the adjacent normal clone. In the 
composite figures for each chromosome, the positions of the flanking normal clones are 
given for each aberrant genomic region.
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Chromosome 1
Multiple gains and losses were found across the whole length of the chromosome 
(Figure 4.1). The distal short arm of chromosome 1 is a complex area of loss. The cell 
line U87 shows loss between 0.2 and 6 Mb. There is gain in chromosome lp  in seven 
patient tumour samples and seven cell lines. Tumour T1 shows a discrete loss between 5 
and 10 Mb and tumour T5 has a discrete loss between 5 and 11 Mb. This region is 
encompassed by larger deletions in tumour T6 and cell lines CRL1620 and CRL2611. 
Chromodomain Helicase DNA-binding Protein 5 (CHD5) (lp36.31; 5.9 Mb), which 
plays a role in neural development maps within these deletions (Thompson et al., 2003).
A discrete gain of RP5-1108M17 (lp21.1; 103 Mb), flanked by clones RP11- 
202K23 and RP1-118, was found in tumours T7 and T10 and cell line Htbl38. Larger 
deletions involving this region were found in tumour T3 and cell lines CRL2365 and 
U87. Genes in this minimal region are the Amylase genes AMY I A, AMY2A and AMY2B.
A  discrete gain was present in CRL2020 between 200 and 203 Mb, which 
contains the MDM4 and Phosphatidylinositol 3-kinase, class 2, beta (PIK3C2B) (lq32). 
A discrete amplification was present in tumour T5 between 238 and 240 Mb, which 
contains the v-akt murine thymoma viral oncogene homolog 3 (AKT3) (lq43-44). The 
distal long arm had deletions between 224 and 245 Mb in four cell lines. The Fumarate 
Hydratase (FH) tumour suppressor gene (lq42.1), which is mutated in multiple 
leiomyomatosis and in renal cancer, maps within this deletion (Alam et al., 2003).
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Figure 4.1 Composite array CGH profile of chromosome 1
U87 shows multiple regions of copy number change (Figure 4.2 and Table 4.2). 
There is a region of heterochromatin between 118 Mb and 140 Mb on the proximal part 
of the long arm of chromosome one, this causes a break in the data and splits the region 
of gain. A discrete region of gain in cell line U87 is flanked by RP11-428D12 and RP11- 
253A20. The clones showing copy number gain are RP5-1013G21 and RP1-86A18. This 
region includes Cyclin-Dependent Kinase Inhibitor 2C (CDKN2Q (lp32.3).
Copy no. 
change
Position
(Mb)
Cytogenetic
location
Flanking clones
Loss 0-6 Mb lp36 CTB-14E10 and RP3-438L4
Gain 48-51 Ip33-lp32.3 RP11-428D12 and RP11-253A20
Loss 77-104 Ip31.1-lp21.3 RP11-30614 and RP11-17C2
Gain 98-118 Ip31.1-lpl2 RP11-143H12 and RP11-418J17
Gain 140-161 Iql2-lq23.3 RP11-417J8 and RP11-180L13
Loss 160-217 Iq23.3-lq42.2 RP11-276J4 and CTB160H23
Loss 224-245 Iq42.13-lq44 RP11-276J4 and CTB160H23
Table 4.2 Array CGH results of chromosome 1 in cell line U87
Chromosome 2
Five cell lines showed loss of material on the short arm of chromosome 2 and five 
cell lines showed loss on the long arm (Figure 4.3). Tumour T5 had loss on the distal end 
of chromosome 2, form 233-245 Mb (2q37-tel) (Figure 4.4). The break point the terminal 
end of chromosome 2 is between clones RP11-52C8 (Mb) and RP11-91N19 (Mb) 
containing Neuronal Guanine Nucleotide Exchange Factor (NGEF) (2q37) and 
Natriuretic Peptide Precursor C gene (NPPC) (2q37.1).
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Figure 4.2 Array CGH profile of chromosome 1 in U87
Chromosome lp shows two regions of loss and a region of copy number gain, 
lq followed by a region of gain and two regions of loss. The heterochromatin 
on lq  gives a gap in the data.
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Figure 4.4 Array CGH profile of chromosome 2 in tumour T5 
Note the deletion at the distal end of the chromosome.
Chromosome 3
Many copy number gains and losses were detected on chromosome 3 (Figure 4.5). 
A single clone deletion, RP11-165B2 at 13 Mb (3p25.1), flanked by clones RP11-488M6 
and RP11-316A10, was deleted in cell line CRL1620 (Figure 4.6). This deletion contains 
Wingless-Type MMTV Integration site family member 7A gene (WNT7A) (3p25) 
(Kirikoshi and Katoh, 2002). There is a discrete deletion at 117 Mb in cell line CRL2611. 
The deleted clone is RP11-342J17 (3ql3.31) and is flanked by RP11-249J17 and RP11- 
165B13. Limbic System-Associated Membrane Protein (LSAMP) is within this deletion.
Chromosome 4
There is a region of discrete gain/amplification in tumours T3 and T4 and in cell 
lines CRL2020 and U118 at 54-55 Mb (4ql2) (Figure 4.7) (Table 4.3). T3 shows 
amplification of two clones RP11-12J3 and RP11-231C18 between flanking clones 
RP11-18M17 and RP11-148K14 (54.3-56.1 Mb) (Figure 4.8). Genes within this region 
are Cysteine-Rich Hydrophobic Domain 2 (CHIC2), Platelet Derived Growth Factor 
Receptor Alpha (PDGFRA), KIT oncogene (KIT) and Kinase Insert Domaine Receptor 
CKDR).
Sample RP11-157C8 RP11-18M17 RP11-12J3 RP11-231C18 RP11-148K14
T3 -0.04 0.03 1.48 1.9 0.09
T4 0.24 0.20 0.36 0.14 0.11
CRL2020 0.18 0.18 0.92 0.09 0.18
U118 -0.20 -0.09 0.47 0.04 0.00
Table 4.3 Log2 ratios of clones in tumour samples and cell lines showing gain or 
amplification at 4ql2.
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Figure 4.6 Array CGH profile of chromosome 3 in cell line CRL1620
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Figure 4.7 Composite array CGH profile of chromosome 4
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Chromosome 5
Gain of 82-86 Mb (5q21) was found in tumours T2, T3 and T4 and in cell lines 
CRL2611 and Htbl38 and this gain was encompassed by lager region of gain in cell line 
CRL2610 (Figure 4.9). Genes in this region of gain include Heparanase (HPSE), CPD- 
Diacylglycerol Synthase 1 (CDS1), Heterogeneous Nuclear Ribonucleoprotein D 
(HNRPD) and Protein Kinase CGMP-dependent, type II (PRKG2).
Chromosome 6
Chromosome 6 shows numerous regions of copy number change (Figure 4.10). 
The short arm of chromosome 6 had deletions in one tumour and four cell lines. The 
minimal region of deletion in tumour T2 was between 17 and 19 Mb (6p22.3) and 
contains the Spinocerebellar Ataxia 1/ataxin-l gene (SCA1). The long arm of 
chromosome 6 had numerous copy number aberrations, the majority of changes being 
loss. Two patient samples, T5 and T8 show loss of 6q. The cell lines have a more 
complex set of changes.
CRL2365 and CRL2366 are derived from the same patient sample and they have 
the same DNA copy number profile on chromosome 6. The array CGH shows gain at 6p 
and two areas of loss, 6ql4.3 (86 Mb) - 6ql6.3 (100 Mb) and 6q21 (114 Mb) - 6q22.31 
(122 Mb) (Figure 4.11). The flanking clones are bA30P6, bA117M4 and bA346K2, 
bA95G17. The deletion between 86 and 100 Mb, contains the Ephrin Receptor A7 gene 
(EPHA7) (6ql6.1, 93.9Mb). A further deletion between 99 and 104 Mb (6ql6.3), 
containing Cyclin C (CCNQ  and Single Minded (SIM1) was seen in U87.
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Figure 4.9 Composite array CGH profile of chromosome 5
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Figure 4.11 Metaphase CGH and array CGH profiles 
of chromosome 6 in cell line CRL2366
A discrete deletion was found between 117 and 118 Mb (6q22.1) in U118 (Figure 
4.10), which encompasses a previously described microdeletion. This microdeletion 
causes a fusion between two genes, Fused in Glioma (FIG) and v-ros avian UR2 sarcoma 
virus oncogene homolog (ROS1) (Charest et al., 2003a; Charest et al., 2003b). ROS1 is at 
6q22.1 (117.63-117.76 Mb). The array suggests a loss between 117 and 118 (Figure 
4.12). In fact, by chance this 0.24Mb microdeletion was detected because the clone RPI- 
94G16 is at 117.83-117.93 Mb was included in the array and the microdeletion is at 
117.90-117.94 Mb. A further discrete deletion was present in U87 between 135 and 143 
Mb (6q23.3-6q24.2), containing the Mitogen-Activated Protein Kinase-Kinase-Kinase 5 
(MAP3K5), Tumour Necrosis Factor Alpha Induced Protein 3 (TNFAIP3) and 
Microtubule Associated Protein 7 (MAP7) genes.
Four cell lines had loss of the distal end of 6q, and of these, CRL2020 and 
CRL1620 had pronounced discrete regions of loss between 160 and 167 Mb (6q26-27). 
This region contains the tumour suppressor gene Insulin-like Growth Factor Receptor 2 
(IGF2R), the Parkin (PARK2) gene, which is associated with autosomal recessive 
juvenile parkinsonism, Parkin Co-Regulated Gene (PACRG) and Quaking Isoform gene 
(QKI) (Figure 4.13).
Minimal regions of loss were seen at 75-77 Mb in tumour T10 and at 167-170 Mb 
in tumour T7. A discrete deletion was found in U251 between 96 and 97 Mb (6ql6.1).
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Figure 4.12 Array CGH profile of chromosome 6 in cell line U118
Clone RP1-94G16 shows a deletion at 117 Mb.
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Figure 4.13 Metaphase CGH and array CGH profiles 
of chromosome 6 in cell line CRL2610
Chromosome 7
Gain of genetic material from chromosome 7 was seen in all tumour samples and 
nine cell lines (Figure 4.14). The Epidermal Growth Factor Receptor (EGFR) gene, 
represented by clone RP5-1091E12 at 55 Mb (7pll.2) was gained or amplified in four 
tumours and seven cell lines. EGFR was found to have a normal copy number in cell 
lines CRL2365, CRL2366 and U87 (Table 4.4). When amplification was present at 
7pll.2 , other clones were amplified along with RP5-1091E12 (Table 4.5). U87 has gain 
between 121 Mb and 158 Mb (7q31.32-7qter). An example of amplification
demonstrated by array CGH, is shown of tumour T5 (Figure 4.15).
Sample RP5-1091E12 
(EGFR) log2 ratio
Copy
Number
Sample RP5-1091E12 
(EGFR) log2 ratio
Copy
Number
T1 3.68 Amp CRL1620 0.8 Gain
T2 4.4 Amp CRL2020 0.37 Gain
T3 0.37 Gain CRL2365 0.13 Normal
T4 1.47 Amp CRL2366 0.27 Normal
T5 3.75 Amp CRL2610 0.34 Gain
T6 0.22 Gain CRL2611 0.58 Gain
T7 2.8 Amp Htbl38 0.45 Gain
T8 2.2 Amp U87 0.00 Normal
T9 2.3 Amp U118 0.42 Gain
T10 0.26 Gain U251 0.47 Gain
Table 4.4 Log2 value of clone RP5-1091E12 representing EGFR in all the tumour 
samples and cell lines
In the literature, gain is more than two copies in a diploid state and amplification 
is four-five extra copies. Numerically it is possible to state how many copies a certain 
log2 value represents, however in practice this is not so straightforward. In this study a
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Figure 4.14 Composite array CGH profile of chromosome 7
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Figure 4.15 Array CGH profile of chromosome 7 in tumour T5
There is amplification of clones RP5-1091E12 (54.63 Mb) and RP11-339F13 (54.78 Mb).
log2 value of greater than 1 has been called amplification. Table 4.5 shows the log2 values 
of the surrounding clones where there is amplification of EGFR. Log2 values are rounded 
to 2 decimal places.
Sample
RP11-
95E2
(50.2 Mb)
RP4-
718N17
(51.4 Mb)
RP11-
324M21
(52.5 Mb)
RP11-
449G3
(54.4 Mb)
RP5-
1091E12
(54.8 Mb)
RP11-
339F13
(55.0 Mb)
RP4-
725G10
(55.9 Mb)
T1 0.38 0.2 0.23 3.85 3.69 3.2 0.28
T2 0.04 0.02 0.07 NA 4.5 4.23 0.35
T4 0.6 0.63 0.88 1.25 1.48 0.88 0.32
T5 0.36 0.24 0.32 0.38 3.76 3.45 0.3
T7 0.43 0.13 0.3 0.8 NA 2.18 0.19
T8 0.37 0.25 0.2 2.27 2.27 1.28 0.28
T9 0.47 0.18 0.14 NA 2.3 1.55 0.23
Table 4.5 Log2 values of surrounding clones where there is amplification of EGFR 
(NA = Not applicable)
Chromosome 8
There were deletions in chromosome 8, in eight cell lines but not in any tumour 
samples (Figure 4.16). There was a discrete gain of RP1-144M5 at 34 Mb (8pl2) in 
tumour T3 and cell line CRL1620. This region, flanked by clones RP11-75P13 and RP1- 
155L11, contains no genes. Cell line U87 has two discrete deletions on the long arm. The 
first is from 87-90 Mb and is flanked by clones RP11-2F15 and RP5-1098020. Included 
in this region of loss is the Matrix Metalloproteinase 16 gene (MMP16) (8q21.3). The 
second deletion from 141-145 Mb involves loss of clone RP11-370K2 (8q24.3) and is 
flanked by RP11-65A5 and RP5-118A7. Protein-Tyrosine Phosphatase type 4 A3 gene 
(PTP4A3) (8q24.3) is included in this deletion.
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Figure 4.16 Composite array CGH profile of chromosome 8
Chromosome 9
Loss of 9p material was seen in nine tumour samples and six cell lines (Figure 
4.17). Homozygous deletions were found on the short arm between 21 and 24 Mb (9p21) 
in tumour T2 and in cell lines CRL2020, CRL2610, U87 and U118 (Figure 4.18) (Table 
4.6). This region includes the Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) and 
Cyclin-Dependent Kinase Inhibitor 2B (CDKN2A) genes, as well as the Interferon Apha 
and Beta gene cluster, Methylthioadenosine Phosphorylase (MTAP), Doublesex and 
Mab-3 Related Transcription-like family A1 (DMRTA1) and Embryonic Lethal, 
Abnormal Vision, Drosophila-like 2 (Hu antigen B) (ELAV2).
Sample
RP11-
513M16
(19.4)
RP11-
15P13
(20.2)
RP11-
113D19
(21.0)
RP11-
495L19
(23.4)
RP11-
33K8
(24.1)
RP11-
468C2
(24.9)
RP11-
33G16
(25.7)
RP11-
5P15
(26.5)
T1 NA -1.0 -0.37 NA NA NA -1.3 -0.2
T2 2.37 -1.23 -1.35 NA -0.85 -0.82 -0.95 -0.57
T7 -0.48 -1.15 -0.5 NA -0.24 -0.46 -0.21 -0.38
CRL2020 -0.24 -0.26 -0.1 -1.39 -0.28 -0.24 -0.79 -0.42
CRL2610 -0.2 -3.03 -2.93 -3.77 -1.9 -1.85 -1.66 -0.39
U87 -0.72 -3.49 -3.08 -2.29 -0.12 -0.76 -0.8 -0.76
U118 -0.47 -1.84 -1.09 -1.29 -0.92 -0.84 -1.05 -1.45
Table 4.6 Log2 ratios of clones in tumours and cell lines showing homozygous 
deletion involving 9p21. A nominal log2 value of -1 has been assigned to describe a 
homozygous deletion.
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Figure 4.17 Composite array CGH profile of chromosome 9
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Figure 4.18 Array CGH profile of chromosome 9 in cell line U118 
The heterochromatin on 9q gives a gap in the data.
The copy number data in the cell lines in the region involving CDKN2A was 
correlated with LOH status and mutation status of CDKN2A (Table 4.7).
Cell line Copy num ber LOH CDKN2A
CRL1620 Loss Loss Mut
CRL2020 Loss NA NA
CRL2365 Gain NA NA
CRL2366 Gain None NA
CRL2610 Loss NA Mut
CRL2611 Gain NA Mut
Htbl38 Null NA Mut
U87 Loss LOH Mut
U118 Loss LOH Mut
U251 Gain LOH Mut
Table 4.7 Comparison of copy number change, LOH and mutation status of 
CDKN2A (Ishii eta l., 1999).
DN=de novo
Cell line CRL1620 shows a probable homozygous deletion from 125-128 Mb 
(9q34). This deletion is flanked by clones RP11-373J8 and RP11-5N16 and includes the 
gene Abelson Murine Leukemia Viral Oncogene Homologue 1 (ABL1) (Figure 4.19).
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Figure 4.19 Array CGH profile of chromosome 9 in cell line CRL1620
Chromosome 10
All but one of the tumour samples and all the cell lines had some loss of 
chromosome 10 material (Figure 4.20), involving either the short (Figure 4.21) or long 
arm or both. The entire chromosome 10 was lost in three patient samples and four cell 
lines. A discrete deletion was found between 48 and 49 Mb (10qll.22-qll.23), 
containing the Mitogen Associated Protein Kinase 8 gene (MAPK8), in CRL2020 and 
U87. A second discrete deletion was found between 75 and 77 Mb (10q22.2), containing 
the Adenosine Kinase gene (ADK), in U251. A third discrete deletion was found at 89 
Mb (10q23.31), containing the PTEN gene in CRL1620 (Figure 4.22) (Table 4.8). A 
homozygous deletion in a coding sequence of the Phosphatase and Tensin Homologue 
gene (PTEN) has previously been identified in CRL1620 (Fan et a l , 2002). A fourth 
deletion was present from 122 Mb to lOqter in CRL1620 (Figure 4.21). The WD Repeat- 
containing protein 11 gene (WDR11), which is disrupted by a t(10;19) translocation in 
this cell line, maps at the junction of this deletion at 122 Mb (Chernova et al., 2001). 
Also contained within this region of loss is the Methylguanine-DNA Methyltransferase 
gene (MGMT) (Esteller et al., 2000).
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Figure 4.21 Metaphase and array CGH profiles of chromosome 10 
in cell line CRL2366
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Figure 4.22 Array CGH profile o f chromosome 10 in CRL1620
The red arrow indicates the position of clone representing PTEN
Sample Copy num ber RP11- 
380G5 {PTEN)
LOH PTEN
M utation
CRL1620 Loss NA Mutant
CRL2020 Null NA NA
CRL2365 Null LOH NA
CRL2366 Null NA NA
CRL2610 Null NA Wild-type
CRL2611 Loss NA Wild-type
Htbl38 Loss NA Wild-type
U87 Null NA Mutant
U118 Loss LOH Mutant
U251 Null LOH Mutant
Table 4.8 Comparison of copy number change, LOH and mutation of PTEN (Cox et 
al., 2005; Huang et a l , 2004; Ishii et a l , 1999).
Chromosome 11
Loss of 1 lq  material was seen in four cell lines and two tumours (Figure 4.23). 
Tumour T3 has a terminal deletion from 114-134 Mb (Figure 4.24). Tumour T5 has loss 
from 110-119 Mb and includes the genes Myeloid/Lymphoid or Mixed Lineage 
Leukaemia (AfLL), Melanoma Cell Adhesion Molecule (MCAM) and Immunoglobulin 
Superfamily Member 4 (IGSF4). Htbl38 has a discrete gain from 129-132 Mb (llq24- 
q25). This gain involves RP11-567M21 and PAC1064E20 and is flanked by clones 
RP11-264E20 and RP11-340L13. Friend Leukaemia Virus Integration 1 gene {FLI1) is 
included in this region.
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Figure 4.24 Array CGH profile of chromosome 11 in tumour T3
Chromosome 12
No regions of gain were seen in the tumour samples. However, there was gain in 
five cell lines (Figure 4.25). A discrete region of gain from 50-59 Mb (12ql3-ql4) was 
seen in cell line CRL2020 and was involved in larger regions of gain in three other cell 
lines. Clones RP11-112N23 and RP11-150C16 flank this region. This is a gene rich 
region that includes Insulin-like Growth Factor Binding Protein 6 gene (IGFBP6), 
Homeo box C (HOXC) gene cluster, Cyclin-Dependent Kinase 2 gene (CDK2) (12ql3), 
Cyclin-Dependent Kinase 4 gene (CDK4)( 12ql4) and the glioma-associated oncogene 
homologue 1 gene (GLI) (12ql3). A discrete deletion in tumour T2 from 119-122 Mb 
(12q24.13) was included in larger regions of loss in cell lines CRL1620, CRL2366 and 
CRL2611. RP11-322N7 and RP11-87C12 are the clones with normal copy number ratio 
flanking this region. The gene B-cell CLL/Lymphoma 7A (BCL7A) is included in this 
deletion.
Chromosome 13
Nine cell lines and four tumours have loss on chromosome 13, and three cell lines 
show gain (Figure 4.26). Cell fine U87 has two regions of loss at 19-32 Mb and 47-62 
Mb, demonstrated on conventional CGH and array CGH (Figure 4.27). The flanking 
clones of the deletion 47-62 Mb are RP11-408L13 and RP11-234023. The gene 
Retinoblastoma (RBI) is encompassed by this deletion. A minimal region of deletion 87- 
91 Mb (13q31.1) was defined by cell line U251 (Figure 4.28). The clones flanking this 
loss are RP11-478H12 and RP1-267D11. This region has low gene density but contains
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Figure 4.25 Composite array CGH profile of chromosome 12
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Figure 4.26 Composite array CGH profile of chromosome 13
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Figure 4.27 Array CGH profile of chromosome 13 in cell line U87
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Figure 4.28 Array CGH profile of chromosome 13 in cell line U251 
Red arrow indicates deletion from 87-91 Mb
the gene SLIT and Neutrotrophic Tyrosine Kinase Receptor-like family member 5 
CSLITRK5).
Chromosome 14
Four cell lines, but no tumour samples show gain of chromosome 14 (Figure 
4.29). Eight cell lines and three tumour samples show loss. The entire chromosome is lost 
in four cell lines and one tumour sample. A minimal region of deletion, 18-23 Mb 
(14qll.2) was seen in tumour T3. The telomere and RP11-89K22 flank this deletion. 
Genes included in this region are Telomerase Protein Component 1 (TEP1), Poly(ADP- 
Ribose) Polymerase 2 (PARP2), Cyclin B1 Interacting Protein 1 (CCNB1IP1), 
Phosphatidylinositol-3-phosphate 5-Kinase Type 3 (PIP5K3), Myosin Heavy Chain 6 
(MYH6), Myosin Heavy Chain 7 (MYH7) and Receptor-Interacting Serine/Threonine 
Kinase 3 (RIPK3).
Chromosome 15
Loss was seen from chromosome 15 in six cell lines and one tumour sample 
(Figure 4.30). Gain was seen in four cell lines, but no tumour samples. There are two 
discrete regions of deletion on chromosome 15 in two cell lines U251 and Htbl38. U251 
has a discrete deletion between 25 and 27 Mb (15ql3). The deleted clone is RP11- 
408F10 and is flanked by PR11-322N14 and RP11-164K24. Genes included in this 
deletion are hect domain and RLD 2 (HERC2), Amyloid Beta (A4) Precursor Protein- 
Binding Family A Member 2 (APBA2), Melanoma-Associated Antigen G1 (MAGG1), 
Kruppel-Like Factor 13 (KLF13) and Transient Receptor Potential Cation Channel
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Figure 4.29 Composite array CGH profile of chromosome 14
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Figure 4.30 Composite array CGH profile of chromosome 15
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Subfamily M Member 1 (TRPM1). Htbl38 has a discrete deletion between 29 and 30 Mb 
(15ql3.3). The deleted clone is RP11-E12 and is flanked by RP11-164K24 and RP11- 
250G15. Genes included in this deletion are cholinergic receptor, nicotinic, alpha 
polypeptide 7 (CHRNA7), Rho GTPase Activating Protein 11A (ARHGAP11A), 
Secretory Granule Neuroendocrine Protein 1 (SGNE1) and Gremlin 1 Homologue 
Cysteine Knot Superfamily (GREM1).
Chromosome 16
The entire chromosome is lost in two tumour samples, and the entire long arm is 
lost in one cell line and gained in one cell line (Figure 4.31). Smaller regions of loss and 
gain were also detected. Cell line U87 has a deletion between the telomere and 8 Mb. 
This deletion is flanked by the telomere and RP11-152P23. Cell line CRL1620 has a 
discrete deletion between 63 and 64 Mb (16q21-q22.1). The deleted clones are RP11- 
370P15 and RP11-467C24 and are flanked by RP11-148F12 and RP11-298C15. The only 
gene in this region is Cadherin 11 Type 2 (CDH11). A second discrete deletion on 
chromosome 16 was detected in cell line U251 between 77 and 78 Mb (16q23.1-q23.2). 
The deleted clone is RP11-556H2 and is flanked by RP11-281J9 and RP11-303E16. The 
gene WW Domain Containing Oxidoreductase (WWOX) is included in this deletion.
Chromosome 17
Three cell lines had loss of material on the short arm of chromosome 17, and five 
tumour samples and three cell lines had loss of material from the long arm (Figure 4.32). 
Cell line Htbl38 has a discrete deletion between 6 and 7 Mb (17pl3.2-pl3.1) (Figure
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Figure 4.31 Composite array CGH profile of chromosome 16
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Figure 4.32 Composite array CGH profile of chromosome 17
4.33). The clones flanking this deletion are RP11-243K12 and RP11-404G1. The gene 
p53 is included in this deletion. Eleven exons of p53 were screened by SSCP for 
mutations in the cell lines by the Cancer Research UK Mutation Detection Facility. Those 
exons showing an abnormal result were then sequenced (Table 4.9).
Cell line Copy
number
LOH p53
CRL1620 Null Null WT
CRL2020 Null NA Exon 10: 17708 A>T (mutation not reported)
CRL2365 Loss NA Exon 8: 856 G>A -  missense mutation 
and exon 10: 17708 A>T (mutation not reported)
CRL2366 Null LOH Exon 8: 856 G>A -  missense mutation 
and exon 10: 17708 A>T (mutation not reported)
CRL2610 Null NA Exon 7: 14040: G>C homozygote
CRL2611 Loss NA Exon 4: 12217: C>T homozygote
Htbl38 Loss NA Exon 7: 14070: G>A homozygote
U87 Null Null WT
U118 Null Null Exon 6: 13398 G>A homozygote
U251 Null LOH Exon 8: 818 G>A -  missense mutation.
Table 4.9 Detection of p53 mutations in astrocytic gliomas
p53 mutations were detected in eight out of ten cell lines. CRL2365 and CRL2366 
were derived from the same tumour and had the same p53 mutations. The two cell lines 
with no p53 mutation had no copy number loss of 17pl3. Of the eight cell lines with p53 
mutation, five had no loss of 17pl3. Three cell lines CRL2365, CRL2611 and U87 
showed copy number loss involving 17pl3.1 andp53 mutation.
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Figure 4.33 Array CGH profile of chromosome 17 in cell line Htbl38 
The red arrow indicates the clones representing p53
Tumour T3 has a discrete deletion between 41 and 42 Mb (17q21). The deleted 
clone is RP11-39201 and is flanked by RP11-948G15 and RP5-905N1. The gene Breast 
Cancer 1 (BRCA1) is included within this deletion. Cell line U87 has a discrete deletion 
between 42 and 43 Mb (17q21.31).
Chromosome 18
Four cell lines showed gain of chromosome 18 material but no tumour samples 
showed gain (Figure 4.34). Loss was seen in six cell lines and in one tumour sample. 
Loss of the distal long arm was demonstrated by conventional CGH and array CGH in 
cell line CRL1620 (Figure 4.35).
Chromosome 19
There were few genetic changes on chromosome 19 (Figure 4.36). Cell line U87 
has a discrete deletion between 52 and 55 Mb (19ql3.32-19ql3.33) (Figure 4.37). This 
region is encompassed by larger deletions in three cell lines and one patient sample. 
Clones CTC-483I11 and CTD-2545M3 flank this deletion. The gene Meisl Myeloid 
Ecotropic Viral Integration Site 1 Homologue 3 (MEIS3) is included within this deletion.
Chromosome 20
The entire chromosome 20 was gained in four patient samples and seven cell 
lines. In addition, there is loss of 20q in two cell lines, and gain of 20p and the proximal 
part of 20q in one patient sample (Figures 4.38 and 4.39). The only region of loss on this 
chromosome is of the short arm of chromosome 20 in cell line U87 in which there is also
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Figure 4.39 Metaphase and array CGH profiles of chromosome 20 in cell line CRL2020
gain of the long arm (Figure 4.40). 20ql2-13 is a region often amplified in ovarian 
cancer. (Tanner et al., 2000) Genes in this region include v-myb myeloblastosis viral 
oncogene homolog (avian)-like 2 (MYBL2) and Aurora Kinase A (AURKA).
Chromosome 21
Gain of material on chromosome 21 was seen in four cell lines and one patient 
sample (Figure 4.41). Loss of material was seen in one cell line and three patient samples.
Chromosome 22
Loss of the entire chromosome 22 was seen in one patient sample and two cell lines 
(Figure 4.42). Gain of the whole chromosome was seen in one cell line. Cell line 
CRL2610 has two discrete regions of loss on this chromosome (Figure 4.43). The first 
deletion is from the telomere and 24 Mb. This deletion is flanked by the telomere and 
CTA-125H2 (tel-22ql2.1). The gene Breakpoint Cluster Region (BCR) is included in this 
deletion. The second region of loss is between 39 and 42 Mb (22ql2.3-ql3.2). The clones 
flanking this deletion are RP1-215F16 and RP3-388M5. This is a gene rich area, and 
genes of interest include Minichromosome Maintenance Deficient 5 (MCM5), E l A 
binding protein p300 (EP300), Myosin Heavy Polypeptide 9 (MYH9), SRY (sex 
Determining Region Y)-Box 10 (SOX 10), GTP Binding Protein 1 (GTPBP1) and 
Mitogen-Activated Protein Kinase Kinase Kinase 7 Interacting Protein 1 (MAP3K7IP1).
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Figure 4.40 Metaphase and array CGH profiles of chromosome 20 in cell line U87
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Figure 4.43 Array CGH profile of chromosome 22 in cell line CRL2610
4.3 Discussion
This chapter has catalogued the copy number changes in ten cell lines and ten 
patient samples as identified by array CGH with a resolution of 1 Mb. The method of 
analysis described in Chapter 3 was used in the assessment of these data. The principal 
overall observation is that although many copy number changes are present, there are 
consistent patterns in these changes. In common with previous studies using conventional 
CGH, this study has demonstrated aneuploidy in high-grade astrocytic glioma cell lines 
and tumour samples. There are whole chromosome losses especially of chromosome 10, 
and whole chromosome gains, most notably of chromosomes 7 and 20. However, there 
are three very significant characteristics of these data that distinguish them from previous 
CGH data. Firstly, the greatly increased sensitivity, which facilitates the detection of 
small, novel copy number changes, secondly the increased precision in mapping the 
breakpoints of discrete regions of copy number changes, and thirdly the ability to 
estimate copy number.
Conventional CGH cannot detect deletions that are less than 5-10 Mb. The greatly 
increased sensitivity with array CGH of detecting copy number changes is seen in 
discrete small regions of copy number change. Examples of regions with copy number 
changes detected by a single clone include clone RP11-165B2 on chromosome 3 in cell 
line CRL1620 (Figure 4.6) and RP1-94G16 on chromosome 6 in cell line U118 (Figure 
4.12). Examples with copy number changes detected by two clones are amplification of 
the clones RP11-12J3 and RP11-231C18 on chromosome 4 in tumour T3 (Figure 4.8), 
and RP5-1091E12 and RP11-339F13 in tumour T5, chromosome 7 (Figure 4.15).
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Examples where two clones show a deletion are RP11-165M8 and RP11-380G5 on 
chromosome 10 in cell line CRL1620 (Figure 4.22), and RP11-275J18 and RP11-388D4 
on chromosome 13 in cell line U251 (Figure 4.28).
The precision in mapping breakpoints is also greatly enhanced. The breakpoints 
are defined between two clones with an average separation of approximately 1 Mb. 
Previous CGH studies would have defined the breakpoint only within the cytogenetic 
band. This is demonstrated in comparisons of conventional CGH and array CGH. 
Examples include chromosome 6 in CRL2366 (Figure 4.11), chromosome 6 in CRL2610 
(Figure 4.13), chromosome 13 in U87 (Figure 4.27) and chromosome 18 in CRL1620 
(Figure 4.35). Other examples demonstrating the increased precision in breakpoint 
mapping will be discussed further in Chapter 5, and include a deletion on the short arm of 
chromosome 6, from the telomere to 43 Mb in cell line U87. The actual breakpoint is 
between RP11-501118 (42.9 Mb) and RP11-227E22 (44.0 Mb). Genes within this region 
include Vascular Endothelial Growth Factor (VEGF), Polymerase DNA ETA (POLH) 
and GTP Binding Protein 2 (GTPBP2). Another example is seen in an interstitial deletion 
between 135 and 143 Mb, on the long arm of chromosome 6 in U87. The proximal 
breakpoint is between RP11-323N12 (135.6 Mb) and RP11-448D5 (137.2 Mb) and the 
distal part of the deletion is between RP11-368P1 (142.3 Mb) and RP11-8604 (143.5 
Mb).
In addition to the additional sensitivity and precision in array CGH, the log2 ratios 
of the individual clones enable an estimate of relative levels of gain or loss to be made,
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i.e. regions of amplification (Tables 4.4 and 4.5) and homozygous deletion (Table 4.6). 
The data from these tables will be further discussed in Chapter 6. On chromosome 6 in 
cell line CRL2020, the increased sensitivity of detection and increased precision, together 
with the knowledge of relative changes in copy number high-lighted a region of interest 
at 6q26. In this example, there is relative loss of the whole of chromosome 6, but in 
addition there appears to be an interstitial deletion at the distal end of the chromosome. 
This is discussed further in Chapter 5.
Array CGH is a new method of analysis and therefore the full significance of the 
data generated using this method needs to be explored. Knowledge of what a region of 
copy number change detected by array CGH indicates, will determine how these data are 
used to further understand these tumours. However, observations of how known genetic 
changes are represented by this method will facilitate a greater understanding of the 
method, which may be applied to novel regions of change. Particular regions where there 
are copy number changes that are known to be associated with gene mutations include 
PTEN, CDKN2A, FIG-ROS, EGFR and PDGFR. Gain or amplification on chromosome 4 
between 54 and 55 Mb (4ql2) was detected in cell lines U118 and U251 and in tumours 
T3 and T4 (Figure 4.7 and Table 4.3). PDGFR is contained within this region. As with 
amplification of EGFR, there is co-amplification of surrounding genes. Activating 
mutations in PDGFR have not been described in astocytic glioma, however mutations in 
PDGFR have been detected in another tumour type, gastrointestinal stromal tumours 
(Heinrich et al., 2003). The 0.24 Mb interstial deletion in cell line U118 on chromosome 
6 leads to the fusion of two genes, FIG and ROS1, to produce a novel oncogene (Charest
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et al.y 2003a; Charest et a l, 2003b) (Figure 4.12). Therefore, this deletion detected by 
array CGH does not indicate the presence of a tumour suppressor gene, but the presence 
on an oncogene. The region demonstrating the most extreme loss in terms of log2 ratio 
and in the number of samples involved is the short arm of chromosome 9. Table 4.6 
shows the log2 values for the clones in this region in those samples showing a deletion. 
The lowest values for log2 ratios are centred in the region of the tumour suppressor gene 
CDKN2A. The tumour suppressor gene PTEN is at 89 Mb on chromosome 10. Cell line 
CRL1620 has a homozygous deletion in this region. The log2 ratio of the clone 
representing this homozygous deletion is RP11-380G5 is -0.46. As with the case of the 
FIG-ROS microdeletion in cell line U118, the homozygous deletion does not cover the 
entire clone and hence this is reflected in the log2 ratio.
One consideration in assessing the significance of a region of copy number 
change is that of genetic heterogeneity (Section 3.4.1.3). LCVs in the genome have 
recently been mapped (Iafrate et al., 2004). Areas identified in this study which 
correspond to areas of LCV as identified by Iafrate et al are shown in Table 4.10
Region of copy number change Genes
lp21.1 Amylase gene cluster
lq43-44 AKT3
10qll.22 MAPK8
12q24.13 BCL7A
13q31.1 SLITRK5
Table 4.10 Regions of copy number change identified by array CGH, which are LCVs
168
Genes encompassed by a region of copy number change and those genes at the 
breakpoints are all candidate tumour suppressor genes or oncogenes. Apart from the 
expected findings involving EGFR and PDGFR other growth factors or genes affecting 
growth factor signalling were identified including KIT (4ql2), KDR (4ql2), ROS1 
(6q22.1), IGF2R (6q25-26) and IGFBP6 (12ql3). Regions of copy number change 
encompassed many signalling molecules including PTEN (10q23.31), PIK3C2B (lq32), 
MAP3K5 (6q23) and MAP3K7IP1 (22ql3.1). Candidate genes with a more direct role in 
cell cycle control and apoptosis include CDKN2A, CDKN2B (9p22), MDM4 (lq32), 
CDKN2C (lp32.3), CCNC (6q21), CDK2 (12ql3), CDK4 (12ql4) and MCM5 (22ql3.1). 
Involved genes with a role in maintenance of genome integrity include p53 (17pl3), RBI 
(13ql4) and EP300 (22ql3).
In conclusion, this chapter has identified regions of copy number change, 
containing many candidate tumour suppressor genes and oncogenes, in high-grade 
astrocytic glioma cell lines and tumour samples. The frequency of each genetic change is 
scored, as theoretically it could be considered that the most frequently occurring changes 
are the most significant. This argument follows from the concept that if a genetic change 
gives a growth advantage to the cell then the cells with these changes will be selected for 
and so will predominate in the cell population. Also, the more frequent a genetic change 
then the more likely this change is intrinsic to the original tumour from which the cell 
line was derived. The relationship between selected copy number changes and 
translocation breakpoints are investigated in Chapter 5. A wider view of the significance 
of copy number changes in tumours is discussed in Chapter 6.
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Chapter Five 
Molecular Cytogenetic Analysis of 
High-Grade Astrocytic Glioma Cell Lines
5.1 Introduction
Having assessed the astocytic glioma tumour samples and cell lines for regions of 
copy number change, the next step was to confirm selected regions of copy number 
change by FISH. Following this, I investigated the relationship between the copy number 
data obtained by array CGH and the positional data as identified by FISH. Comparing the 
array data from this study and data from a paper published in 2001 about a translocation 
breakpoint in cell line CRL1620, indicated that array CGH might be used to map 
translocation breakpoints (Chernova et al., 2001). Chernova et al detected a reciprocal 
translocation t(10;19) in cell line CRL1620, which resulted in the formation of a chimeric 
fusion protein between WDR11 and ZNF320. The function of WDR11 is not known, but 
it is a member of the WD-repeat protein family and these are involved in cell functions 
such as signal transduction, cell cycle progression and apoptosis. Examination of the 
array profile of chromosome 10 in cell line CRL1620 (Figure 4.20 and 4.22) shows a 
breakpoint between 122 and 123 Mb, with a loss of the distal region of chromosome 10. 
The breakpoint is between clones RP11-323P17 (122.6 Mb) and RP11-62L18 (123.4 Mb) 
and contains WDR11. Hence, this suggests that regions of copy number change identified 
by array CGH may be used to map translocation breakpoints.
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When interpreting FISH data the ploidy of the cell should be considered. Hence, 
the first step was to determine the ploidy of each cell line using karyotyping and M-FISH. 
In array CGH the control is normal human DNA, which has a 2n ploidy. The same 
quantity of DNA is used for the test and reference. Therefore, if a sample with a 4n 
ploidy was used with the control of 2n, there would be no changes detected by array 
CGH. Secondly, the array CGH data is considered from the perspective of three model 
situations of copy number change. These are DNA gain or amplification, homozygous 
deletion and reduced copy number. Using FISH to confirm copy number change requires 
that two probes are used, one from within the region of interest and one from a region of 
normal copy number.
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5.2 Results
The M-FISH experiments described in this section were performed in 
collaboration with Radost Vatcheva and the FISH experiments were obtained in 
collaboration with Tania Jones, Pat Gorman and Chrysanthos Poullikas.
5.2.1 M-FISH karyotypes of the cell lines
All the cell lines in the study were karyotyped by M-FISH, except for Htbl38 and 
U118, which have previously been described. A summary of the ploidy is shown in Table 
5.1, and following this there is a full description of each karyoype with representative 
images (Figures 5.1-5.8). Chromosomal translocations are specified in the M-FISH 
karyotypes.
Cell Line Chromosome Range Mode
CRL 1620 75 -  82 Hypotetraploid 82
CRL 2020 7 5 -1 0 1  Near-tetraploid 93
CRL 2365 68 -  99 Near-tetraploid Bimodal 88 or 92
CRL 2366 76 -  96 Near-tetraploid 
149-196  Near-octaploid
93
CRL 2610 5 0 -7 1  Hypotriploid 61
CRL 2611 69 -  99 Hypertriploid - hypertetraploid 86
U87 4 1 -4 7  Near-diploid 
85 -  87 Near-tetraploid
44-47
U251 47 -  54 Hyperdiploid 49
Table 5.1 Chromosome range and modal number of chromosomes in cell lines
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Figure 5.1 M-FISH karyotype of CRL 1620
A range of 71 - 83 chromosomes, with a mode of 82, was found in 30 cells counted.
M-FISH analysis showed a male karyotype with the following aberrations: 
der(l)t(l;14)[6], dic(l)t(l;X)[8], der( 1 )t( 1; 18)(q32;?)[8], der(2)(2;5)[8], 
der(3)t(3;9)(q27;?)[6], del(5)(ql3) x 2[6], del(6)(?)[8], del(6)(-p)[l], 
der(7)t(6;7)(ql4;ql 1)[8], del(8)(q?)[8], del(9)(pll.2)[8], dic(9)x 2[6], del(10)(q?)[l], 
der( 11 )t( 1; 11)[8], -13[8], -14 x 3[8], del(16)[8], der(18)t(l;18) x 3[8], der(21)t(13;21)[8], 
-22 [8], der(?)t(14;22) [1] [cp 8]
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Figure 5.2 M-FISH karyotype of CRL2020
A range of 75-101 chromosomes, with a mode of 93, was found in thirty cells counted.
M-FISH analysis showed a female karyotype with the following aberrations:
-1 x 2[9], der(l)t( 1 ;4)t( 1 ;9)t(9; 11)[3], t(l;4)x 2[6], -2[6], der(3)(3;13)(ql3;ql2)[3], 
der(4)t(4;5)(p 14;?)x2[6], der(5)t(5;16;17)(pl3;?;?)[5], der(5)t(4;5;19)[6], +7[4], 
der(7) t(6;7)(?; p22)[5], t(8;13)[l]6 ins(9) (6;9)(?;pl3)[6], der(10)t(X;10)t(?;pll.2)[6], 
der (11 )t( 1; 11 )t(?;q23)[5], der(13)t(13;14)[2], del(13) [1], der(16)t(5;16)x2[6], -18[5], 
der(19)t(19;5;16)(ql2;?;?)[6], +20[6] +21 x 2[6], -22[2] [cp6]
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Figure 5.3 M-FISH karyotype of CRL2365
A range of 68 -  184 chromosomes, with a mode of 88-92, was found in thirty cells 
counted.
M-FISH analysis showed a male karyotype with the following aberrations: 
t(l;14)[l], t(l;7)[l], t(7;6;l;7)[l], der(l)t(l;5)(p36;?)[l], der(l)t(l;17)t(p36;?)[5], 
der( 1 )t( 1 ;7)[ 1 ], +3[4], der(3)t(3;4)(ql3;?)[l], -4[6], der(4)t(4;5)[2], del(5)(q32)[5], 
der(6)t(6;19)(p24;?) x 2-3[6], dic(6)[l],-7[3], del(9)[l], -10 x 2[4], del(10)(q?)[l], -13[4], 
i(14)(ql0)[l], der( 16)t(6; 16) x 2 [6], der(19)t(13;19)(ql2;ql3)[6], del(19)[l], +20[4], 
+21[4],-22[6] [cp 6]
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Figure 5.4 M-FISH karyotype of CRL2366
A range of 76-196 chromosomes, with a mode of 93, was found in thirty cells counted.
M-FISH analysis showed a male karyotype with the following aberrations: 
der( 1 )t( 1; 10)[2], der(l)t(l;7)[l], t(l;21)[l], der(2)t(2;6)(q33;?)[4], del(3) x 2 [2], 
der(4)t(4;5)[2], +5[5], del(5) [5], del(7)[2], der(8)t(X;8)[4], del(9)[4], der(ll)t(ll;17)[4], 
der(14)t(14;21)[l], der (15)t(15;18)(pl2;?)[2], der(18)t(18;21)[l], -19[4], +21[2], -Y [1] 
[cp5]
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Figure 5.5 M-FISH karyotype of CRL2610
A range of 50 -  71 chromosomes, with a mode of 61, was found in thirty cells counted.
M-FISH analysis of showed a male karyotype with the following aberrations: 
del(l)[4], t(2;5)[l], der(2)t(l;2)[2], der(3)t(l;3)[l], der(3)(3;16)[2], del(4)[4], 
der(5)t(l;5)[6], del(6)[2], der(6)t(6;16)[l], del(8)[3], der(8)t(3;8)[l], 
der( 10)t(4; 10)(?;p 11 )[7], der( 10)t(X; 10)(?;q 10)[ 1 ], der( 11 )t( 11; 14)(q25;?)[7], 
der( 11)(1; 11)[5] der(12)t(12;18)[7], der(13)t(8;13)[2], der(19)t(20;19;6)[3] [cp8]
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Figure 5.6 M-FISH karyotype of CRL2611
A range of 7 5 -1 6 7  chromosomes, with a mode of 86, was found in thirty cells counted.
M-FISH analysis showed a female karyotype with the following aberrations:
der( 1 )t( 1; 17)[5], der(l)t(l;18)[2], del(l)[5], der(2)t(2;ll)[2], der(2)t(X;2), t(3;20)[l],
der(4)t(4;6)(pl6;6?)[5], der(5)t(3;5)(?;pl2)[2], der(5)t(5;8)[2], del(6)[4], t(6;7)[3],
der(7)t(5;7)x2[2], der(8)t(6;8)(6;q24)[4], der(8)t(8;17)[3], del(8)[2], del(9)[2],
der( 10)t( 10; 17) [ 1 ], der( 11 )t( 11; 17)(q21;?)[3], der(12)t(5;12)t(5;X)[4], der(12)t(5;12)[2],
der(14)t(14;18)(q32;?)[4], del(16)[2], der(17)t(17;19)[l], der(19)t(X;19)(?;ql3)[4],
+20[5], del(20)x2[l], der(20)t(16;20)[l], der(22)t(15;22)[2], der(X)t(X;2)[4],
der(X)t(X;10)(X;10)[5], t(X;7),[2] [cp 5]
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Figure 5.7 M-FISH karyotype of U87
A range of 41-87 chromosomes, with a mode of 44-47, was found in thirty cells counted.
M-FISH analysis showed a female karyotype with the following aberrations: 
der( 1 )del(l)t( 1; 13)[6], der(6)t(6;7)(p21;q31)[6], der(6)t(6; 12)t(q23-24;?)[7], 
der(9)ins(9; 13)(?;?;?)[6], del(10)(qll)[5], del(ll)[6], der(12)t(6;12)[2], 
der( 12)del( 12)t(6; 12)(q23-24;q23)[4], der(13)t(10;13)[l], der(16)t(l;16)(?;pl3)[7], 
del(20)(pl0)[5], der(20)t( 1; 14)t( 1 ;20) [7], i(21)(ql0)[l], der(22)t(10;22)(?;ql3)[4]; 
der(21)t(17;21)[l] [cp7]
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Figure 5.8 M-FISH karyotype of U251
A range of 47 -  54 chromosomes, with a mode of 49, was found in thirty cells counted.
M-FISH analysis showed a male karyotype with the following aberrations:
-X,[5], der(5)t(5;8)(q31;?)[3], del(5)(q?)[l], +7[4], der(8)t(5;8)(?;q22)[5], 
der(9)t(3;9)(?;q21)[5], -10[5], der( 11 )t( 11; 10)t( 10; 15)[5] or 
der(ll,10,15)(ll?::10?::15?::)[5], der(17)t(5;17)[5],der(ll)t(ll;15)(ql2; ql2)[5], 
del(ll)(?)[5], del(18)(qll)[5] [cp5]
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5.2.2 Confirmation of copy num ber change
5.2.2.1 Amplification
Gene amplification was detected by array CGH predominantly in the patient 
tumour samples. However, I wished to confirm amplification in a cell line with FISH. 
The best model for an amplified gene in the cell lines was EGFR in CRL1620. This cell 
line shows a region of amplification on chromosome 7 between clones RP11-449G3 (54 
Mb) and RP4-725G10 (55 Mb), which contains EGFR (Figure 5.9 a). A dual probe for 
the centromere of chromosome 7 and EGFR confirmed EGFR copy number gain in cell 
line CRL1620. This hypotetraploid cell line was found to have 4-5 centromeres of 
chromosome 7, each associated with EGFR. However, copies of EGFR were also 
integrated into 1-2 copies of chromosome 11 (Figure 5.9 b).
5.2.2.2 Homozygous deletion
A discrete deletion was detected in cell line CRL2610 between 21 and 24 Mb 
(9p21), containing CDKN2A/CDKN2B (Figure 5.10). This region was included in larger 
deletions in six cell lines and all patient samples. Array CGH log2 ratios suggested 
homozygous loss at 21-22 Mb (9p21-p22) in tumour T2 and cell lines CRL2020, 
CRL2610, U87 and U118. FISH was used to investigate the homozygous deletion in 
CRL2610. The control probe RP11-513M16 (19.3 Mb; 9p22.1), labelled with Texas Red 
was co-hybridised with each of the test probes, RP11-14912 (21.9Mb; 9p21.3) and RP11- 
495L19 at (22.3 Mb; 9p21.3), both labelled with F1TC.
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Figure 5.9 a Array CGH profile of chromosome 7 in CRL1620. 
Red arrow indicates the clone containing EGFR.
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Figure 5.9 b FISH analysis of CRL1620 with a dual probe for EGFR (red) and 
the centromere of chromosome 7 (green).
Red arrows show EGFR inserted into chromsome 11.
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Figure 5.10 Array CGH profile of chromosome 9 in cell line CRL2610 
Reduced copy number of chromosome 9 is seen, with a homozygous deletion 
involving clones RP11-113D19 (21.0 Mb), RP11-15P13 (20.2 Mb) and 
RP11-495119 (23.4 Mb). These clones are indicated with red arrows.
Most cells analysed had two copies of chromosome 9. The control probe was 
found to be present on each copy of chromosome 9, but no signal is present on either 
chromosome 9 for either of the test probes, indicating a homozygous deletion of these 
probes (Figures 5.11 and 5.12).
Figure 5.11 FISH analysis of CRL2610 with probes RP11-513M16 (red) and RP11- 
14912 (green). Only the control probe (RP11-513M16) is seen.
Figure 5.12 FISH analysis of CRL2610 with probes RP11-513M16 (red) and RP11- 
495L19 (green). Only the control probe (RP11-513M16) is seen).
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5.2.23 Reduced copy number
The array CGH results from CRL2356 and CRL2366 suggested that there were 
two discrete deletions on chromosome 6, one between 89 and 94 Mb and the other 
between 115 and 120 Mb (Figure 5.13 a). The deletion between 89 and 94 Mb was 
confirmed by FISH using a test probe RP11-346N8 (93 Mb, 6ql6) containing the gene 
EPHA7, together with a control probe RP11-517H2 (167 Mb, 6q27) (Figure 5.13 b).
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Figure 5.13 a Array CGH profile of chromosome arm 6q in cell line CRL2365. 
Two deletions are demonstrated. The positions of two probes are shown with 
arrows RP11-346N8 (red) and RP11-517H2 (green).
Figure 5.13 b FISH analysis of the chromosome 6 deletion between 89 
and 94 Mb in CRL2365. Loss of the EPHA7 gene was shown using 
RP11-346N8 (red) and RP11-517H2 (green). In this tetraploid cell line four 
copies of RP11-517H2 are present, but only two copies of RP11-346N8.
5.2.3 Translocations associated with deletions involving chromosome 6
I wished to test whether regions of copy number change were associated with 
translocation breakpoints. As demonstrated in Chapter 4, chromosomes 6 (Figure 4.10) 
and 10 (Figure 4.20) have recurrent deletions in astrocytic gliomas and could be 
considered for further investigation. However, it can be seen that the whole of the 
chromosome 10 is often lost whereas there are discrete regions of loss in chromosome 6. 
Hence, chromosome 6 was chosen as the model chromosome to examine the relationship 
between regions of copy number change and translocation breakpoints. The array CGH 
and M-FISH profiles for chromosome 6 (Figures 5.1-5.8) were then used to choose three 
cell lines for further analysis by FISH, U87, CRL2020 and CRL2610.
5.2.3.1 Cell line U87
In U87, the array CGH profile shows four regions of copy number loss on 
chromosome 6 (Table 5.2). The M-FTSH profile of U87 (Figure 5.7) shows three aberrant 
chromosomes with chromosome 6 material. These were derived from one chromosome 6 
translocated to chromosome 7, der(6)t(6;7)(p21;q31), and a reciprocal translocation 
between chromosomes 6 and 12, der(6)t(6;12)(q23-24;q?) and der(12)t(6;12)(q23-24;q?). 
The FISH experiments are shown first, followed by a diagrammatic representation of the 
findings.
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Genetic change Clones flanking deletion Position (Mb) Cytogenetic location
Loss RP11-227E22 0-43 6pter - 6p21.1
Loss RP3-422B11, RP11-30P6 5 7-86 6 p ll.2 -6 q l4 .3
Loss RP11-9819, RP1-244F1 99 -104 6ql6.2 - 6ql6.3
Loss RP1-32B1, RP11-8604 135 - 143 6q23.3 - 6q24.2
Table 5.2 Deletions of chromosome 6 in U87
5.2.3.1.1 Characterisation of der(6)t(6;7)(p21 ;q31)
The array CGH profiles for chromosomes 6 and 7 in cell line U87 and the 
proposed translocation breakpoints, marked with red arrows, are shown in Figure 5.14. 
FISH, using five probes (Table 5.3), was used to investigate the proposed breakpoint at
6p21.1.
Clone Position (Mb) Test or Control
RP3-337H4 43.5 Test
RP11-22124 43.6 Test
RP1-261G23 43.7 Test (VEGF)
RP11-344J7 43.8 Test (VEGF)
RP11-227E22 43.9 Control
Table 5.3 Probes used to test the 6p21.1 breakpoint in U87
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Figure 5.14 Characterisation of der(6)t(6;7) in cell line U87 
AM-FISH of der(6)t(6;7) (p21;q31)
B Array CGH profile of chromosome 7 in U87 
The red arrow indicates the breakpoint at 6p21 
C Array CGH profile of chromosome 6 in U87 
The red arrow indicates the breakpoint at 7q31
FISH analysis with probes RP11-227E22 and RP11-344J7 showed both probes to 
be present on the der(6)t(6;12) and on the der(6)t(6;7). The breakpoint is therefore 
telomeric to RP11-344J7 (Figure 5.15).
der(6)t(6;12) 
der(6)t(6;7)
Figure 5.15 FISH analysis of U87 with probes RP11-227E22 (red) & RP11-344J7
(green).
FISH analysis with probes RP11-227E22 and RP1-261G23 showed both probes to 
be present on the der(6)t(6;12) and the der(6)t(6;7). The breakpoint is therefore telomeric 
to RP1-261G23 (Figure 5.16).
der(6)t(6;7)
der(6)t(6;12)
Figure 5.16 FISH analysis of U87 with probes RP11-227E22 (red) and RP1-261G23 
(green).
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 der(6)t(6;12)
der(6)t(6;7)
Figure 5.18 FISH analysis of U87 with probes RP11-227E22 (green) & RP3-337H4 
(red)
FISH using a chromosome 7q arm specific paint was performed on U87 to 
determine whether the translocation involved the long or short arm of this chromosome. 
There was signal on two copies of chromosome 7 as well as the der(6)t(6;7) (Figure 5.19) 
indicating that the translocation breakpoint is on the long arm of chromosome 7. The 
array profile of U87 shows a gain from 7q31 to 7qter, with a breakpoint between 120.2 
and 122.4 Mb (Figure 5.14). Further FISH studies with probes from 7q31 are needed to 
confirm the location of the translocation breakpoint.
192
Figure 5.19 FISH analysis of U87 with a paint for chromosome arm 7q
5.2.3.1.2 Characterisation of the der(6)t(6;12) and the der(12)t(6;12)
The array CGH profiles for chromosomes 6 and 12 in cell line U87 are shown in 
Figure 5.20. The proposed translocation breakpoint at chromosome 6q23-q24 is marked 
with a red arrow. FISH, using the probes in Table 5.4 was used to investigate the 
breakpoint at 6q23-q24.
Clone Position (Mb) Test or Control
RP11-557H15 134.8 Control
RP11-448D5 137.2 Test
RP11-368P1 142.2 Test
RP11-8604 143.5 Test
Table 5.4 Probes used to test the chromosome 6 breakpoints in t(6;12) in U87
FISH analysis with probes RP11-557H15 and RP11-448D5 showed RP11- 
557H15 to be present on both the der(6)t(6;12) and the der(6)t(6;7), indicating that it is 
centromeric to the deletion (Figure 5.21). RP11-448D5 is present on the der(6)t(6;7), but 
not on the der(12)t(6;12) or the der(6)t(6;12), indicating that the probe is deleted in the 
t(6;12).
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Figure 5.20 Characterisation of der(6)t(6;12) and der(12)t(6;12) in cell line U87 
A M-FISH der(6)t(6;12) and der(12)t(6;12)
B Array CGH profile of chromosome 6 in U87 
The red arrow indicates the translocation breakpoint 
at 6q23-q24
C Array CGH profile of chromosome 12 in U87
der(6)t(6;7)
der(6)t(6;12)
Figure 5.21 FISH analysis of U87 with probes RP11-557H15 (red) and RP11-448D5
(green).
FISH analysis with probe RP11-368P1 showed the probe to be present only on the 
der(6)t(6;7) indicating that it is deleted in the t(6; 12) (Figure 5.22).
der(6)t(6;7)
Figure 5.22 FISH analysis of U87 with probe RP11-368P1 (red).
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FISH analysis with probes RP11-448D5 and RP11-8604 showed RP11-8604 to 
be present on both the der(12)t(6;12) and the der(6)t(6;7), indicating that this probe is 
telomeric to the deletion and has been translocated to chromosome 12. RP11-448D5 is 
present on the der(6)t(6;7), but not on the der(12)t(6;12) or the der(6)t(6;12), confirming 
that this probe is deleted (Figure 5.23).
der(12)t(6;12) ^  
der(6)t(6;7) —
Figure 5.23 FISH analysis of U87 with probes RP11-448D5 (red) and RP11-8604
(green).
In summary, in U87 I characterised the chromosome 6 breakpoints in the 
der(6)t(6;7) and the reciprocal t(6;12) translocation (Figure 5.24). Probe RP11-22124, 
which contains the POLH  and GTPBP2 genes, gave a very small signal on the 
der(6)t(6;7), indicating that it is intersected by the translocation. These experiments 
confirm the presence of a deletion of chromosome 6 within and distal to probe RP11- 
22124, and show that it is associated with a translocation between chromosomes 6 and 7. 
In addition, FISH analysis of the t(6;12), confirms a deletion between RP11-557H15 and 
RP11-8604, and shows that it is associated with a translocation between chromosomes 6 
and 12.
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Figure 5.24
Summary of FISH analysis of chromosome 6 aberrations in U87. 
Chromosome 6 is shown in green, chromosome 7 in red, and 
chromosome 12 in yellow. RP 11-22124* signifies a smaller signal 
for this probe on the der(6)t(6;7) than on the der(6)t(6;12) suggesting 
that the breakpoint intersects this probe.
5,23.2 Cell line CRL2020
M-FISH shows that cell line CRL2020 is near-tetraploid with three copies of 
chromosome 6, in most cells, and a translocation of a fragment of chromosome 6 to 
chromosome 7. In the karyotype shown, three apparently normal copies of chromosome 7 
are present, and two copies of the der(7)t(6:7) (6?:p22) (Figure 5.2). The array CGH 
profile confirms the gain of the whole of chromosome 7 and a deletion at 6q26-q27 
(Figure 5.25). In order to determine whether the deletion at 6q26-q27 was the 
translocation breakpoint FISH analysis was performed using the probes in Table 5.5. The 
FISH experiments are shown first, followed by a diagrammatic representation of the 
findings.
Clone Position (Mb) Test or Control
RP11-13P5 159.5 Test
RP3-495O10 163.6 Test
RP1-51J12 163.9 Test
RP11-517H2 167.5 Test
RP11-471L1 168.0 Control
Table 5.5 Probes used to test the 6q26-q27 breakpoint in CRL2020
FISH analysis with probes RP11-13P5 and RP3-495O10 showed RP11-13P5 to 
be present on 2-3 copies of chromosome 6, while RP3-495O10 is present on only one of 
these, confirming a deletion of this probe (Figure 5.26).
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Figure 5.25
Deletion associated with a translocation, involving chromosome 6 
in cell line CRL2020.
(a) M-FISH of der(7)t(6;7)
(b) Array CGH profile of chromsome 6 in CRL2020 
(b) Array CGH profile of chromosome 7 in CRL2020
Figure 5.26 FISH analysis of CRL2020 with probes RP11-13P5 (red) and RP3-495O10
(green).
FISH analysis with probes RP11-13P5 and RP1-51J12 showed RP11-13P5 to be 
present on 2-3 copies of chromosome 6, while RP1-51J12 is present on only one of these, 
confirming a deletion of this probe. (Figure 5.27)
Figure 5.27 FISH analysis of CRL2020 with probes RP11-13P5 (red) and RP1-51J12 
(green). Only 2 copies of chromosome 6 are present on this partial metaphase spread.
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FISH analysis with probe RP1-51J12 and 6q paint showed three copies of 6q to be 
present, only one of which has RP1-51J12, confirming the deletion of this probe from 6q 
(Figure 5.28).
Figure 5.28 FISH analysis of CRL2020 with probe RP1-51J12 (green) and 6q paint 
(red).
FISH analysis of CRL2020 with probe RP11-471L1 showed this distal 6q probe 
to be present on the long arm of one chromosome 6 and on the terminal short arm of each 
of the der(7)t(6;7) (Figure 5.29).
6q26
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Figure 5.29 FISH analysis of CRL2020 with probe RP11-471L1 (green).
In summary, in CRL2020, chromosome 6 is translocated to chromosome 7 to give 
a der(7)t(6;7)(p?; q26-27) and del(6)(q26-27) x2 (Figure 5.30). An apparently normal 
copy of chromosome 6 is also present. A discrete deletion detected by array CGH 
between 160 and 167 Mb was investigated by FISH using probes RP11-13P5 (159.4 Mb), 
RP3-495O10 (163.6 Mb), RP1-51J12 (163.8 Mb) and RP11-471L1 (168 Mb). All four 
probes were present on the normal chromosome 6. Of the other chromosome 6 
derivatives, RP11-13P5 was present on the del(6)(q26-27) while RP11-471L1 was 
present on the der(7)t(6;7). Therefore, it appears that the segment of chromosome 6 distal 
to RP11-13P5 became translocated to the short arm of chromosome 7, but sequences 
including RP3-495O10 (PACRG) and RP1-51J12 (QKI) became deleted so that only the 
terminal probe from 6qter, RP11-471L1, is present on the der(7)t(6;7). The chromosome 
6 from which the segment translocated became duplicated after the translocation. These 
experiments confirm the presence of a deletion between 160 and 168 Mb, including the
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Figure 5.30
Summary of FISH analysis of the chromosome 6 deletion in CRL2020. 
Chromosome 6 is shown in green and chromosome 7 in red.
PARK2, PACRG and QKI genes, and show that it is associated with a translocation 
between chromosomes 6 and 7.
5.2.3.3 Cell line CRL2610
M-FISH shows that cell line CRL2610 is a hypo-tetraploid cell line. There were 
complicated rearrangements of chromosome 6 with one to two apparently normal copies, 
and one to three abnormal copies in which either or both 6p or 6q were deleted. The array 
CGH profile of chromosome 6 in this cell line shows rearrangements of 6q (Figure 5.31). 
FISH paints for 6q and two probes RP1-51J12 (163.9 Mb, 6q26) and RP11-471L1 (168.0 
Mb, 6q27) were used to investigate these rearrangements. Once again, the FISH 
experiments are shown first, followed by a diagrammatic representation of the findings.
FISH analysis of the distal chromosome 6 deletion in CRL2610 using probe RP1- 
51J12 and 6q paint showed RP1-51J12 to be present on the distal end of one 6q, but not 
on the other (Figure 5.32). Instead, the probe is on a small and as yet unidentified 
chromosome.
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Figure 5.31 Array CGH profile of chromosome 6 in cell line CRL2610.
The green lines indicate the position of the probes used in the FISH experiments. 
The probe names are also indicated.
Figure 5.32 FISH analysis of the distal chromosome 6 deletion in CRL2610, using 
probe RP1-51J12 (green) and a 6q paint (red).
FISH analysis of CRL2610 with probe RP11-471L1 showed RP11-471L1 to be 
present on the distal end of one chromosome 6, and also on a small, unidentified 
chromosome (Figure 5.33).
Figure 5.33 FISH analysis of CRL2610 with probe RP11-471L1 (green).
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In summary, in cell line CRL2610, a distal deletion was identified using probes 
RP1-51J12 and RP11-471L1 (Figure 5.34). These probes were both found to be at the 
distal end of 6q on one chromosome and on a very small chromosome, but missing from 
a second 6q segment. These findings indicate a translocation at the distal end of 
chromosome 6 with the breakpoint centromeric to these two probes.
Figure 5.34 Summary of FISH analysis of the distal chromosome 6q deletion in CRL 
2610. Chromosome 6 is shown in green.
RP1-51J12 
RP11-471 LI
RP1-51J12 
RP11-471 LI
6 de!6q
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5.3 Discussion
This chapter showed the M-FISH analysis of eight of the cell lines used in this 
study. The cell lines were found to have complex karyotypes, with duplication of the 
genome and many genetic changes. On reviewing the whole chromosome changes, taking 
the cell lines as tetraploid, it can be seen that there is relative loss of chromosomes 6, 9 
and 10 and gain of chromosomes 7 and 20. Although the constituent cells in each cell line 
are clonal, cell-to-cell variation is observed using M-FISH, and hence there is a range in 
the number of chromosomes and the types of genetic changes. Therefore, the images 
shown in Figures 5.1-5.8 are only representative of the M-FISH karyotype of each cell 
line.
In these aneuploid cell lines, it is interesting to compare data from the array CGH 
and the M-FISH. Both methods are genome-wide and both give copy number data, 
however with M-FISH the copy number data can only be realistically assessed to the 
level of a chromosome band. The superiority of precision of the array CGH data in giving 
copy number data is evident, however the M-FISH gives valuable information for 
karyotyping. In regard of positional data, when interpreting array CGH it is assumed each 
clone is in the position of the normal karyotype, it is M-FISH that gives information 
regarding aberrant genomic position such as in relation to a translocation.
The initial FISH experiments were performed to confirm selected regions of copy 
number change detected by array CGH. Examples selected were of amplification, 
homozygous deletion and a clone with reduced copy number. There is no precise
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definition of amplification. However, if there is greater than a five-fold increase in copy 
number it is generally interpreted as amplification, rather than just gain of DNA. The 
example that was selected for amplification was that of EGFR (Figure 5.9). From the 
FISH analysis, it was possible to state that there was an increase in EGFR copy number, 
as the number of signals of EGFR was detected in excess of the control centromere 
probe. Also the strength of the signal was greater for EGFR than in the control 
experiments. However, quantification of copy number using FISH signal intensity can 
only be described as an estimate, as signal intensity varies with probe hybridisation and 
detection efficiency.
FISH proved to be more effective in assessing deletions than in quantifying copy 
number gain. Incorporating a control probe for comparison, FISH was used to confirm a 
homozygous deletion of the probe containing CDKN2A in cell line CRL2610. Here, the 
number of signals was important rather than strength of signal. In patient samples, there 
will be a mixture of normal and tumour cells. Therefore, dual-probe interphase FISH may 
be a more reliable method of detecting a homozygous deletion than PCR.
FISH was also used to assess relative copy number loss. The region assessed is an 
interstitial deletion in cell lines CRL2365 and CRL2366. A probe containing EPHA7 was 
selected for confirmation. EPHA7 is part of the EPH family of protein tyrosine kinase 
receptors. The EPH family are involved in neurulation, control of axon guidance and in 
blood vessel development (Holder and Klein, 1999; Holmberg et al., 2000). Further 
studies have suggested that EPHA7 is an effecter of HOXA13 (Stadler et al., 2001). The
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probe representing this gene was co-hybridised with a probe from a region on the same 
chromosome with normal copy number as assessed by array CGH. The relative loss of 
this DNA was confirmed.
Following a comparison of the array CGH data and the M-FISH data, three 
translocations were selected for further analysis. Translocations involving chromosome 6 
were considered particularly interesting, as this chromosome has previously been 
reported to have frequent LOH and reduced copy number in these tumours. Also the 
deletions of 6 were discrete deletions as opposed to the deletions of chromsome 10, 
which tended to involve the whole chromosome. These selected translocations were 
der(6)t(6;7) in cell line U87, a reciprocal translocation der(6)t(6;12) and der(12)t(6;12) 
again in cell line U87, and translocations in two cell lines CRL2020 and CRL2610 
involving a deletion in band 6q26. These translocations were characterised for the 
chromosome 6 components. Work is ongoing to characterise the chromosome 7 
component of der(6)t(6;7) and the chromosome 12 breakpoints in the reciprocal 
translocation der(6)t(6;12) and der(12)t(6;12), and the translocation partners of 
chromosome 6 in cell lines CRL2020 and CRL2610.
Having characterised these translocations with array CGH and M-FISH and then 
further defined them with FISH, the next question is what is the significance of these 
translocations. From the view of gene theory, if these translocations engender a growth or 
survival advantage to the cell, then the presumption is that the translocation results in an 
alteration in the function of a gene or genes in the region. The classical view of a
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functional translocation is that of BCR-ABL, which results in a fusion oncoprotein. This 
may well be the case in at least some of the translocations described in this thesis. 
Namely, the translocation breakpoints are within two genes and result in the fusion of 
their coding sequences, changing their activity. However, the array CGH data gives a 
wider perspective in that it shows that these translocations are associated with regions of 
copy number change. It may be that genomic aberrations within these regions of copy 
number change are giving the growth advantage to the cell and the translocations are 
merely a by-product of the mechanism of genetic change that has effected this copy 
number change. How the data from this thesis may give information about mechanisms 
of genetic change are discussed in Chapter 6.
Examination of the copy number changes associated with each of the 
characterised translocations shows that there are both deletions and gains and that some 
of the copy number changes are discrete, interstitial changes. The der(6)t(6;7) in cell line 
U87 has a deletion from the telomere of the short arm of chromosome 6 to the breakpoint 
at 43.6 Mb. The question raised here is whether the critical event is deletion of one or 
more tumour suppressor genes on 6p? Alternatively, or possibly in addition, the 
translocation itself is important, with a fusion gene being generated at the breakpoint. It 
remains to be established whether the key gene in this translocation is DNA polymerase 
eta (POLH) or GTPBP2 on chromosome 6 or it could be that the aberrant gene is on 
chromosome 7. Genes in the region of the breakpoint on chromosome 7 include Protein 
tyrosine phosphatase receptor type 2 (PTPZR1) (121.2 Mb) and Alpha aminoadipic 
semialdehyde synthase (AASS) (121.3 Mb). POLH is a low fidelity polymerase and is
212
involved in post-replicative DNA repair (Kusumoto et al., 2004; Matsuda et a l , 2000). 
Defects in this gene are responsible for the Xeroderma Pigmentosum Variant (Broughton 
et al., 2002; Masutani et a l , 1999). GTP binding proteins, also termed G proteins are 
activated by binding GTP and inactivated by the hydrolysis of GTP to GDP. This “on” 
and “o ff’ switch mechanism enables these varied proteins perform a wide range of 
biological activities (Bourne et a l , 1990). GTPBP2 is a novel member of the G protein 
family, at 6p21, its function is yet to be characterised (Watanabe et a l , 2000). PTPRZ1 is 
involved in oligodendrocyte differentiation (Canoll et a l , 1996; canRanjan and Hudson,
1996). Using a mouse model of multiple sclerosis, Harroch et al suggested that PTPRZ1 
has a role in oligodendrocyte survival and recovery (Harroch et a l , 2002). AASS is an 
enzyme which catalyses the first steps of the degradation of the essential amino acid, 
lysine. Inactivating mutations of AASS have been found in patients with hyperlysinaemia 
(Sacksteder et a l , 2000).
The other translocations characterised here are associated with discrete, interstitial 
deletions on the long arm of chromosome 6. The first interstitial deletion between 137.2 
Mb and 143.5 Mb contains a large number of genes. What can be considered here is 
whether a translocation breakpoint is the critical change in the tumour or if it is the 
deletion of a tumour suppressor gene? The same consideration can be applied to the 
translocations involving 6q25-26. Does the deletion at 6q25-26 harbour a tumour 
suppressor gene?
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Genes involved in the deletion associated with translocation at 6q26 include 
IGF2R, PARK2, PACRG and QKI. Insulin-like growth factor II receptor (.IGF2R) 
activates the potent growth inhibitor, transforming growth factor beta, and is involved in 
the degradation of the mitogen insulin-like growth factor 2 (IGF2). Mutation in IGF2R, 
in association with LOH, has been identified in hepatocellular carcinoma and non-small 
cell lung cancer (De Souza et a l , 1995; Kong et al., 2000). Parkinson’s disease is a 
neurodegenerative illness where there is loss of a cell population in the mid-brain, the 
substantia nigra. Mutations in PARK2 (Parkin) are associated with autosomal recessive 
juvenile parkinsonism, especially in exons 2, 3, 4 and 7 (Giasson and Lee, 2001; Hedrich 
et al., 2004). PARK2 is involved in protein degradation as an E3 ubiquitin ligase (Zhang 
et al., 2000). Inactivating mutations have been identified in PARK2 in other tumour types 
including ovarian cancer, hepatocellular carcinoma and non-small cell lung cancer 
(Cesari et a l , 2003; Denison et a l , 2003; Picchio et a l , 2004; Wang et al., 2004). Parkin 
coregulated gene (PACRG) shares the same promoter as PARK2 (West et a l , 2003). 
PACRG is also thought to be involved in protein degradation (Imai et a l, 2003). Mutant 
mice, called Quaking have an abnormal gait and defects in myelination (Sidman et a l, 
1964). The mice with this deficit were found to have mutation in QKI (Cox et a l, 1994; 
Ebersole et a l,  1992; Justice and Bode, 1988). This assumption has recently been 
complicated, by the finding that mice with Quaking phenotype, have both mutation of 
QKI and absent PARK2 expression (Lorenzetti et a l, 2004).
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w5.3.1 F u rther work
Having characterised the chromosome 6 components of the selected 
translocations, the translocation partners should now be characterised. In respect of 
der(6)t(6;7) in cell line U87, the array CGH profile of chromosome 7 shows a region of 
gain from 121 Mb (7q31.32) to the telomere of the long arm (Figure 5.14c). Probes from 
7q31.32 can be used in FISH to investigate this proposed translocation breakpoint (Table 
5.6).
Clone Cytogenetic location Position (Mb)
RP11-384A20 7q31.32 121.2
RP5-1049N15 7q31.32 121.3
RP11-560119 7q31.32 121.4
RP5-1101C3 7q31.32 121.6
RP5-850I1 7q31.32 121.7
RP11-350G10 7q31.32 121.8
RP11-395G17 7q31.32 121.9
RP5-1166A24 7q31.32 122.0
RP4-589D8 7q31.32 122.1
RP11-61D3 7q31.32 122.2
RP11-85N14 7q31.32 122.3
RP11-560119 7q31.32 122.4
Table 5.6 Tiling path probes which can be used to investigate chromosome 7 
breakpoint of der(6)t(6;7) in cell line U87
Regarding the reciprocal translocation der(6)t(6;12) and der(12)t(6;12) in cell line 
U87, the array CGH profile of chromosome 12 shows an interstitial deletion on the long 
arm (Figure 5.20c). Probes from the breakpoints around this interstitial deletion can now
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be selected and these should lead to the identification of the translocation breakpoint 
(Table 5.7).
Clone Cytogenetic
location
Position
(Mb)
RP11-11G4 12ql5 68.8
RP11-320P7 12ql5 68.8
RP11-396J13 12ql5 68.9
RP11-566H23 12ql5 69.0
RP11-785D18 12ql5 69.2
RP11-130E17 12ql5 69.3
RP11-654D6 12ql5 69.4
RP11-158011 12ql5 69.5
CTD-2021H9 12ql5 69.6
RP11-934P3 12ql5 69.7
RP11-101K2 12ql5 69.8
Clone Cytogenetic
location
Position
(Mb)
RP11-575G13 12q23.1 99.4
RP11-427C3 12q23.1 99.5
RP11-252G12 12q23.1 99.6
RP11-263E1 12q23.1 99.7
RP11-447N23 12q23.1 99.7
RP11-350G24 12q23.1 99.8
RP11-426H24 12q23.1 99.9
Table 5.7 Tiling path probes which can be used to investigate the chromosome 12 
breakpoints of the reciprocal translocation der(6)t(6;12) and der(12)t(6;12) in cell line 
U87
The breakpoint on the short arm of chromosome 7 from the der(7)t(6;7) in cell 
line CRL2020 has not been identified. On examining the array CGH profile of 
chromosome 7, it can be seen there is gain of the whole chromosome but no obvious 
deletion. It could be that the material from chromosome 6 has translocated to the 
telomere of the short arm of chromosome 7. FISH using a telomeric probe from 7 would 
confirm this supposition. The translocation partner of chromosome 6q material in cell 
line CRL2610 has not yet been identified, M-FTSH being unsuccessful in this respect.
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Undoubtedly, one of the contributing factors for this is that the material from 
chromosome 6 is small. Individual chromosome-specific FISH paints in conjunction with 
a probe from the long arm of chromosome 6 (labelled in a different fluorescence probe) 
could solve the problem.
Genes affected by the translocations, or close to the breakpoints have been 
selected for further investigation, based on their involvement in other tumours, in cell 
growth control or their specific role in neural cells (Table 5.8). Firstly I propose that the 
expression of the genes is assessed with real-time PCR and then selected genes are 
sequenced.
5.3.2 Conclusion
This chapter has demonstrated that genomic positional changes demonstrated by 
M-FISH are associated with copy number changes as detected by array CGH. FISH was 
used to confirm and further refine the breakpoints of selected translocations associated 
with deletions on chromosome 6. A detailed description on how to continue in the 
investigation of the genes at selected translocations was also given. Chapter 6 gives a 
wider view of this body of work and places it into the broader field of genetics. It also 
discusses its potential impact on medical therapies.
217
Gene
symbol
Gene name Cytogenetic
location
Position
(Mb)
GTPBP2 GTP-Binding protein 2 6p21.1 43.7
POLH Polymerase 6p21.1 43.7
PTPRZ1 Protein-tyrosine phosphatase receptor- 
type zeta-1
7q31.32 121.1
AASS Alpha-aminoadipic semialdehyde 
synthase
7q31.32 121.3
MAP3K5 Mitogen-activated protein kinase 
kinase kinase 5
6q23.3 136.9
MAP7 Microtubule-associated protein 7 6q23.3 136.7
CITED2 CBP/p300-interacting transactivator, 
with glu/asp-rich c-terminal domain 2
6q24.1 139.7
IGF2R Insulin-like growth factor receptor 2 6q25.1 160.4
PARK2 Parkin 6q26 161.7
PACRG Parkin co-regulated gene 6q26 163.1
QKI Quaking 6q26 163.8
Table 5.8 Selected genes from translocations
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Chapter Six 
Final Discussion
6.1 Review of the aims
This thesis focused on changes in DNA in high-grade astrocytic gliomas and in 
particular on copy number and positional changes and their inter-relationship. There were 
three main aims in this thesis. The first aim of this thesis was to gain a better 
understanding of the advantages of array CGH and to develop a method of analysis. The 
second aim was to assess copy number changes in high-grade astrocytic glioma cell lines 
and patient samples. And the third aim was to investigate the relationship between 
changes in copy number as detected by array CGH and positional changes in DNA, 
namely translocations detected by M-FISH.
6.2 Project methodology and results
6.2.1 Overview
The initial part of this thesis addressed the problem of variation in the assessment 
of array CGH results, and described the development of an automated analytical 
programme. This programme was then used to assess the array CGH results of ten high- 
grade astrocytic glioma cell lines and ten tumour samples. Each data point in each 
experiment was then designated gain, null or loss in relation to copy number. The method 
of analysis did not discriminate between levels of gain and levels of loss. For instance, 
using only this method it would not be possible to differentiate between a region of 
simple gain or high-level amplification. Likewise a homozygous deletion could not be
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distinguished from reduced copy number. In this thesis, I overcame this problem by 
selecting the regions with the greatest copy number change and presented these data as 
individual profiles. An alternative method would be to use an Excel file to present the 
clones listed in order of their log2 values.
Chapter 4 displayed the results of the array CGH with examples of individual 
chromosome profiles. At the time of inception of the study, array CGH was a new 
technique with metaphase CGH being the conventional method. It was important to 
compare the results from these techniques in order to assess the greater sensitivity and 
precision of the array CGH. In particular, this thesis demonstrated the advantage of 
assessing each individual data point independently in each experiment. This facilitated 
the ability to define breakpoints in chromosomes precisely and in Chapter 5 these were 
then used to map translocation breakpoints.
6.2.2 Evolution of array technology
There was great inter-experimental variation arising from batch differences of 
printed slides and Cotl DNA. As there are more users of this technology, sharing 
information on the performance of the printed slides and Cotl DNA and can iron out 
these issues. In my experience, keeping inter-experimental variation to a minimum was 
key to having reliable results. This is why I rejected experiments with an inter-quartile 
range of greater than log2 of 0.275. Greater confidence in the data would come from 
experimental replicates and combining data. Also, inter-experimental replicates would 
give a greater confidence in the data. In the arrays that were available, there were two
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copies of each clone in different regions of the slide. It would be preferable to have more 
replicates for analysis of the data. This is becoming feasible as the technology is evolving 
and more data points are being printed onto the slides. Currently this increase in capacity 
is being used to increase the resolution of the arrays (Ishkanian et al., 2004). This thesis 
has highlighted the problem of analysing large data sets and the issues relating to 
variation. My experience suggests that when designing the array CGH slides, these issues 
should be addressed and adequate controls and replicates included. For instance, if there 
were the same control probe in each sub-array then this would enable an assessment of 
experimental variation across the slide. Also, when designing experiments adequate 
slides should be allowed for sample repeats.
6.2.3 Advantages and disadvantages of using cell lines and patient samples
Cell lines were used in this study as they are a renewable resource and can be 
used as a model system for experiments. Metaphase spreads can be prepared from cell 
lines and so can be studied more easily by FISH than the primary tumours. The main 
disadvantages are cross contamination and artefact genetic changes. Cell lines are clonal, 
however in a genetically unstable cell there is evolution in the karyotype and the new 
genetic changes will not represent the original tumour. The primary tumour samples 
avoid the artefact of multiple passages and the accumulation of the subsequent cell line 
artefact genetic changes. The disadvantage of primary tumour samples is that they are 
infiltrated with normal cells, either from normal brain cells or white cells, which enter the 
area as part of an inflammatory response. Also there are different populations of tumour 
cells in the patient samples. These cells may be of different grades of tumour and even if
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the same grade there may be sub-populations with different genetic aberrations. Cell lines 
have the advantage of having no contaminating normal cells and are clonal, although the 
genetic profile differs from cell to cell. Therefore, a homozygous deletion will remain a 
homozygous deletion, and there is no dilution. With the advent of laser capture micro­
dissection it is now possible to select as little as one cell for analysis (Bonner et a l ,
1997). Hence, the cell lines and tumour samples are different model systems each with 
their own advantages.
A further disadvantage in using cell lines is the problem of cross contamination. 
This problem was addressed in the research community when certain cell lines were 
shown by DNA fingerprinting to be cross-contaminated with HeLa cells. It was 
suggested that new cell lines should have a source sample kept for later verification and 
there should be more accurate and complete documentation (Drexler and Matsuo, 1999; 
MacLeod et a l , 2002; Stacey, 2000). Cross contamination in astrocytic glioma cell lines 
has occurred between Htbl6 and U118. There has also been cross contamination between 
astrocytic glioma cell lines U251, SNB-19 and U373, which was detected in a study 
identifying mutations in p53, CDKN2A, p i 4 ^  and PTEN in 34 glioma cell lines. Cell 
lines were found to display different results when sourced from different laboratories 
(Ishii eta l., 1999).
It is clear the cell lines have many more copy number changes than the patient 
samples. It is assumed that this is due to changes that have arisen in cell culture of the 
lines. From this point of view, the copy number changes present in both the tumour
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samples and the cell lines are considered the most relevant. Of the expected changes the 
tumour samples the tumour samples demonstrated amplification of EGFR and PDGFR, 
whereas the log2 values of the clone representing EGFR tended to suggest gain rather 
than amplification in the cell lines. Mutations in EGFR have not been found in non­
amplified DNA (Ekstrand et al., 1992; Frederick et a l , 2000). However, it may be that 
there may be activating mutations of EGFR in the cell lines that were associated with 
amplification of EGFR, however the amplification of EGFR has been lost with repeated 
passages. Conversely, the homozygous deletion of CDKN2A is detected with greater 
deviation of log2 value by the cell lines. This may be because the cell lines are clonal and 
not contaminated by normal tissue. In detecting changes at PTEN and p53 again the cell 
lines proved to be more powerful. In the case of PTEN, the deletion was defined to 1 Mb 
in cell line CRL1620 as opposed to the minimum region of deletion of 4 Mb in T9, in the 
tumour samples. The tumour samples did not demonstrate copy number change involving 
p53 (17pl3), however three cell lines showed loss, involving p53. The minimal region of 
deletion was defined to 1 Mb in cell line Htbl38. The cell lines were important for the 
molecular cytogenetic studies as metaphase spreads could be obtained. Interphase 
cytogenetic studies could be performed on the tumour samples, however the results 
would be more difficult to interpret and many more nuclei are needed for examination. 
By using the cell lines and patient samples, the advantages of each can be selected and 
the disadvantages recognised and given due consideration in reaching conclusions
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6.3 Significance of thesis
Various questions are raised when considering the significance of regions of copy 
number change in high-grade astrocytic gliomas. The thesis focused on one aspect of the 
copy number change, the relationship to translocations. This forms only part of a wider 
view of what a region of copy number change may signify. Does a region of copy 
number change indicate the presence of an underlying mutation? Is the copy number 
change itself contributing to the tumour? Is it possible that the change contributed to the 
tumour at one time but is now redundant? How can the patterns of change seen be related 
to mechanisms of genetic change? And why are there so many and varied genetic 
changes in these tumours?
6.3.1 Copy number change and underlying mutation
The identification of a tumour suppressor gene or oncogene within a region of 
change is supportive evidence that the particular genetic change is pertinent to the 
tumour. However, the identification of a tumour suppressor gene or oncogene is in itself a 
process which builds upon numerous and independent lines of evidence. For example, in 
a region of deletion, all the genes in that particular region can be considered candidate 
tumour suppressor genes. Further evidence as to which is a tumour suppressor gene is if 
there is functional loss of the gene. Functional studies, such as replacing the lost gene 
product in a tumour and monitoring its effect on tumour growth build on the evidence 
that a particular gene is a tumour suppressor gene. Through independent studies, a gene 
will gain a body of evidence as to whether it is a tumour suppressor gene, as each stage 
and method has its own merit and inherent problems of interpretation.
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For the model of tumour suppressor genes proposed by Knudson, the presence of 
a region of deletion may indicate the presence of a mutation in the remaining allele. 
Subsequent studies have supported this model and have added complexity, in that along 
with a mutation in the remaining allele, loss of function of the remaining allele can occur 
through alternative mechanisms such as homozygous deletion and gene silencing. One 
effect is that it can alter gene expression (Fodde and Smits, 2002)
An amplification of a region of DNA containing an oncogene is a straightforward 
example of how identifying a genetic change can help in the search for genes involved in 
cancer development. To identify a single base-pair change in the 3000,000,000 base pairs 
of code, in the human genome is a mammoth task. At present it is not feasible to 
sequence the whole genome of each individual and compare it to the whole sequence 
within their tumour, so we need to identify hot spots. Our current understanding leads us 
toward coding sequences. The presence of a genetic change does not mean that it will be 
causal to the formation of the tumour. Indeed the genetic change may have contributed to 
the development of the tumour and now be present and no longer required, so it is 
conceivable that returning its function to normal at this stage will not be useful.
Undoubtedly astrocytic glioma genetics are complex, and amongst the genetic 
changes that are present some will be not be relevant to the tumour or may not be 
relevant at that time or in the cellular environment. Of the relevant changes three points 
should be considered. Firstly that multiple genetic changes are required for each tumour,
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Secondly at a genetic level, a gene can have loss of function through a number of 
mechanisms including homozygous deletion, loss of heterozygosity and mutation. Gain 
of function can be through mutation, deletion of regulatory regions, and translocation of 
regulatory regions. Finally locus heterogeneity describes the situation where the same 
disease can be caused by defects in different genes. This can be understood at a molecular 
level as different genes co-operating or acting in the same cellular pathway, where a 
defect in any one of the genes leads to the same end-point.
6.3.2 Temporal relationship between development of copy number change and 
underlying mutation
Certain copy number changes are associated with underlying gene mutations. 
Loss of the short arm of chromosome 17 is associated with p53 mutation in the remaining 
allele, as is deletion of chromosome 10 and PTEN mutation. A deletion of a chromosome 
will not be detected by copy number studies if there is duplication of the remaining allele, 
however this will be detected by LOH studies. One question that remains unanswered is 
what comes first, the mutation or the change in copy number?
In this thesis the relationship between copy number change, LOH and p53 
mutation is examined (Table 4.8). In eight cell lines, there are mutations of p53 and one 
of these cell lines, U118, is not associated with copy number change or LOH at 17pl3. 
Of the two samples with wild-type p53, neither demonstrated a deletion at 17pl3. Further 
to this, when examining CRL2365 and CRL2366, which are both derived from the same 
tumour, it can be seen that CRL2366 has no copy number loss but CRL2365 has a
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deletion involving 17pl3. Both cell lines had the samep53 mutations. It is interesting that 
none of the tumour samples show a copy number loss at 17pl3. Three of the cell lines 
show a loss at this region. This raises the possibility that cell lines lose material in regions 
of LOH following culture. On examining the relationship between PTEN mutation and 
deletion (Table 4.7), two samples with wild-type PTEN were found to have a deletion 
involving lO qll.
These examples in this study provide conflicting results on which comes first, the 
mutation or chromosome deletion. Explanations for these results include that both 
processes are going on in parallel, in that there is not a linear relationship between 
mutation and copy number change/LOH. The other explanation is that different 
mechanisms are operating for different genes. Further larger studies are required to gain a 
clearer picture.
6.3.3 Patterns of genetic change
The arrays demonstrate interstitial copy number changes; these may be discrete 
regions of gain or loss. The example of chromosome 6 in cell line CRL2020 is interesting 
because the array CGH suggested deletion of the whole chromosome. However, in 
addition to this there was a more marked loss seen at 6q26. Molecular cytogenetic studies 
showed loss of a whole chromosome 6 in this tetraploid cell line and that there was also a 
deletion at 6q26 of one of the chromosomes.
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Interstitial deletions may be better tolerated than, for instance, losing the whole 
chromosome arm, as along with the tumour suppressor gene there may be other genes 
necessary for the survival of the tumour. Hence, following the double strand break and 
loss of the region containing the tumour suppressor gene, the remaining fragment 
containing essential genes can be either rejoined causing an interstitial deletion or may be 
joined to another region of DNA, which has either been broken or joined to the end of a 
chromosome with telomere attrition. If this shuffling of the genome gives the cell a 
growth advantage then this cell will survive and divide, i.e. it is selected.
In considering mechanisms of genetic change, some insights can be gained from 
the patterns of change and the sites of change. Interesting regions are 7pl2 (EGFR) and 
9p21 (CDKN2A). Amplification of EGFR tends to be found only with gain of 
chromosome 7 (Figure 4.14 and Table 4.5). However, the log2 values of the gain and 
amplification in the region suggest that there are populations of differently sized 
amplicons containing EGFR. If these amplicons were generated by BFB cycles then it 
would suggest that there were not defined breakpoints in this cycle, or if there were 
defined breakpoints there has been attrition of the borders of the amplicons. The 
amplification of EGFR was seen in the patient samples but not in the cell lines. This 
suggests that the cell lines may lose the amplicons containing EGFR, which tend to be 
found as double minutes. Cell line CRL1620 maintained amplification of EGFR through 
stable integration of amplicons containing EGFR into chromosomes (Figure 5.9 b). The 
story of EGFR as an oncogene is further complicated by the presence of mutations in 
EGFR (Discussed later).
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In this study, the most striking region of gain or amplification was seen on the 
short arm of chromosome 7. The highest log2 ratios were for the clone RP5-1091E12, 
which represents EGFR (Table 4.4), it can be seen that the tumour samples showed much 
higher values than the cell lines. It is known that EGFR is amplified in astrocytic 
gliomas, but here it is shown that not just the clone representing EGFR is amplified but 
also the surrounding clones. From Table 4.5 it could be suggested that three clones, 
RP11-449G3, RP5-1091E12 and RP11-339F13, are co-amplified. The flanking clones are 
RP11-324M21 and RP4-725G10. Apart from EGFR, the genes encompassed by these 
flanking clones include Sec61 Gamma Subunit (SC61G), LanC Antibiotic Synthetase 
Component C-Like 2 (LANCL2), Mitochondrial Ribosomal Protein S17 (MRPS17), 
Glioblastoma Amplified Sequence (GBAS), Sulfatase-Modifying Factor 2 (SUMF2), 
Chaperonin Containing T-Complex Polypeptide 1 Subunit 6A (CCT6A), Phosphorylase 
Kinase Muscle Gamma-1 (PHKG1), Coiled-coil-Helix-Coiled-coil-Helix Domain 
Containing 2 (CHCHD2) and some novel proteins. The co-amplification of one or more 
of these genes may be necessary for tumour development.
Amplification of the clone representing EGFR is seen in the patient samples but 
not in the cell lines, although the entire chromosome 7 is gained in four cell lines and the 
short arm of chromosome 7 is gained in a further three cell lines. It is possible that there 
is amplification DNA, containing EGFR and as the cell line undergoes more passages it 
losses this additional material. Different patterns of amplification are seen (Section 
1.2.5). Inverted tandem repeats of the gene, the proposed mechanism for this being the
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BFB cycle. The second is that multiple copies of the gene can be inserted into the 
genome at alternative sites, not the normal gene locus. The third is that sections of DNA 
can be amplified as double minutes, which do not have a centromere. Hence, at cell 
division there is unequal division of the double minutes and perhaps following selection 
there is loss of the amplified gene.
Homozygous deletion at 9p21 was found in the presence of loss of the short arm 
of chromosome 9. The patterns of loss are variable. For instance, in cell line CRL2610 
there appears to be a distinct change in log2 values demarcating the homozygous deletion, 
but in U87 the change is more gradual. Again this is a reflection of sub-populations of 
cells with varying deletions.
The pattern of interstitial loss is interesting as current understanding of these 
regions is that there is likely to be a tumour suppressor gene in this region. In this study 
the smaller the deletion, the more likely the gene of interest will be identified. Hence, 
from this perspective the most interesting changes will be single copy deletions with a 
log2 value suggestive of a homozygous deletion. This is corroborated by the examples of 
PTEN in cell line CRL2610 and the FIG-ROS deletion in cell line U118. However, it may 
be the region that is retained that is equally as interesting. For example, in the 
translocations associated with deletion at 6q26, it may be that there are important genes 
for survival of the cell of the material distal to the deletion.
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6.3.4 Fragile sites
This study demonstrated regions of deletion at fragile sites including 6q26, lp36, 
9p22 and 16q23. Fragile sites are chromosomal regions that are prone to breaks when 
cells are grown in medium that inhibits DNA replication. There are 89 common fragile 
sites and these are present in the majority of the population. Chromosome breaks at 
common fragile sites can be induced by aphidicolin, 5-azacytidine or bromodeoxyuridine 
(BrdU). There are 28 rare fragile sites. These occur in less than 5% of the population and 
display Mendelian inheritance. Chromosome breaks at rare fragile sites can be induced 
by low folate and/or thymidine, or distamycin A or BrdU (Smith et al., 1998).
Four regions of deletion associated with fragile sites were demonstrated in this 
study. These regions contain several candidate tumour suppressor genes (Table 6.1). This 
study has demonstrated translocations associated with 6q26 deletions. On examining the 
array CGH and M-FISH data on the cell lines, it is possible that translocations are also 
associated with deletions at lp36 (cell line CRL2365) and 9p22 (cell line U87). This 
raises the question, are translocations at fragile sites part of the mechanism of deletion of 
certain tumour suppressor genes?
Genomic location Fragile site Candidate tumour suppressor genes
lp36 PRAIA p73
6q26 FRA6E IGF2R, QKl, PARK2, PACRG
9p22 FRA9A CDKN2A, CDKN2B
16q23 FRA16D WWOX
Table 6.1 Genomic regions associated with fragile sites in high-grade astrocytic 
gliomas. Candidate tumour suppressor genes from the regions are also suggested.
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6.4 Clinical perspective of this thesis
The potential diagnostic application of array CGH has been demonstrated in renal 
cancer using an array with 235 clones (Wilhelm et al., 2002). 33 out of 34 renal 
carcinomas were correctly identified through characterised genetic changes and 8 
samples were correctly identified as being either normal or benign tumour (Wilhelm et 
al., 2002). If a clinical decision is to be made using information based on array 
technology there has to be uniformity in analysing results. The analytical methods 
described in Chapter 3 of this thesis would contribute to this process. Expression arrays 
have been used in the classification of different histological subtypes of brain tumours 
and been able to predict prognosis in children with medulloblastoma (Pomeroy et al., 
2002). In the clinical setting, DNA is more convenient than RNA based-methods as DNA 
is more stable, and is more practical as formalin-fixed tissue can be used.
In breast cancer management molecular markers for predicting treatment response 
are already included in Pathology reports. Oestrogen receptor, progesterone receptor and 
c-erb B2 status are reported. Oestrogen receptor positive patients can be given endocrine- 
based therapies such as Tamoxifen. Trastuzumab is an antibody against the c-erb B2 
receptor. The Pathology report of the next decade will include an increasing amount of 
pertinent genetic data. The development of biological markers for astrocytic gliomas 
needs to develop in parallel with targeted therapies.
This study suggested candidate tumour suppressor genes and oncogenes in a 
number of key cellular pathways, such as p53, Rb, and the receptor tyrosine kinases,
232
EGFR, PDGFR. One approach of controlling cancer that is under development is that of 
designing therapeutic agents to specifically target and reverse the effect of key molecular 
aberrations. There are many molecularly targeted agents in development and in clinical 
trials (http://www.cancer.gov/tri2ds). These molecularly targeted agents need to be 
introduced into clinical use in parallel with better genetic characterisation of tumours.
There have been some successes in the treatment of cancer with molecularly 
targeted agents. One example is the use of small molecule inhibitors of receptor tyrosine 
kinases. In astrocytic gliomas, the receptor tyrosine kinase, EGFR is an attractive target 
for therapy as it is commonly has a gain of function in these tumours through, copy 
number changes or mutation. Gefitinib (4 - (3-chloro-4-fluoroanilino) - 7 - methoxy - 6 - 
(3-morpholinopropoxy) quinazoline) (also known as ZD1839 and Iressa) is a small 
molecule inhibitor of EGFR that has had demonstrable effect in non-small cell carcinoma 
of the lung (adenocarcinoma) (Fujiwara et a l , 2003).
Unfortunately, the success with Gefitinib was not repeated in high-grade 
astrocytic glioma patients (Rich et al., 2004). One explanation for this could simply be 
that Gefitinib does not cross the blood-tumour barrier. However, a more complex 
explanation may be emerging from studies on the coding sequence of EGFR. Oncogenic 
activation of EGFR can occur by a number of different mechanisms, including DNA 
amplification and activating mutations. These two mechanisms are interrelated, as 
evidence suggest that rearrangements occur following amplification. Two independent 
studies demonstrated the relationship between response to Gefitinib in non-small cell
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lung cancer and mutations in the EGFR of the patient’s tumour (Lynch et a l, 2004; Paez 
et a l,  2004). The presence of EGFR mutations may be a predictive marker for response 
to Gefitinib therapy in adenocarcinoma of the lung. Hence, along with copy number 
studies to determine response to therapies, other methods of analysis can be combined 
including sequence analysis
6.5 Conclusions
This thesis has contributed to the understanding of the application of a new 
technology, array CGH, and has used this technique to catalogue copy number changes in 
high-grade astrocytic glioma cell lines and patient samples. This thesis will therefore also 
contribute to neuro-oncology research, in the identification of tumour suppressor genes 
and oncogenes. In addition, the relationship between copy number changes and positional 
changes was examined and translocations associated with deletions were detected. 
Therefore, this thesis has also raised interesting questions about mechanisms of genetic 
changes in cancer.
Array CGH examines a single modality of cell structure and function, copy 
number changes. There other changes which may be inter-related and inter-dependent 
such as changes in RNA and protein. The value of the copy number data will be greatly 
strengthened by combining the data with other genome-wide assessments of cellular 
physiology such as parental origin of DNA strands, DNA sequence data, RNA expression 
and functional protein (tissue arrays). This thesis has described the beginning of what can 
now become a larger study as described in the original aim (Figure 1.8).
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Appendix A Reagents
QiampDNA Blood Maxi Kit (Qiagen, 51192)
Fluoroscein isothiocyanate-12-dUTP (FTTC) (NEN Life Science, NEL-413) 
Texas Red-5-dUTP (TR) (NEN Life Science, NEL-417)
2-mercaptoethanol (2-ME) (Sigma, M-3148)
Bioprime Labelling kit (Invitrogen 18094-011)
lOx dNTP mix (0.5 mM dCTP, 2 mM dATP, 2 mM dGTP, 2 mM dTTP in TE 
ImM Cy3-dCTP (NEN Life Science, NEL 576)
ImM Cy5-dCTP (NEN Life Science, NEL 577)
Micro-spin G50 columns (Pharmacia Amersham, 275330-01)
Dextran sulphate 
Tween 20 
SSC
Sodium acetate (Na Ac)
Human Cotl DNA (Invitrogen or Roche)
Herring sperm DNA (Sigma D7290)
Ethanol (100% and 80%)
Yeast tRNA (Invitrogen 15401-029)
Bionick kit (Invitrogen 18247 015)
Digoxigenin-ll-dUTP (Roche Diagnostics 1093 088). 
dATP (Amersham pharmacia biotech 27-2050-01) 
dCTP (Amersham pharmacia biotech 27-2060-01) 
dGTP (Amersham pharmacia biotech 27-2070-01) 
dTTP (Amersham pharmacia biotech 27-2080-01)
Fluorescein-avidin DCS (Vector labs A2011) 
anti-digoxigenin-rhodamine (Roche Diagnostics 1207 750)
Formamide (International Biotechnologies INC 72024)
Tween 20 (Pierce 28320)
Citifluor (Glycerol/PBS) (Citifluor Ltd)
RNase (Sigma R-5000)
Pepsin (Vysis MK262957)
NP-40 (CALBIOCHEM)
DAPIEI
Appendix B Cytogenetic nomenclature
p Short arm of the chromosome
q long arm of the chromosome
del Deletion
der Derivative chromosome
dup Duplication
I Isochromosome
Ins Insertion
Inv Inversion
t Translocation
ter Terminal (can also be written pter or qter)
+ If placed before a chromosome it indicates gain of the chromosome, if placed
after the chromosome it indicates gain of part of the chromosome 
If placed before a chromosome it indicates loss of the chromosome, if placed after 
the chromosome it indicates loss of part of the chromosome
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